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Introduction 
 1 
1 Introduction 204 
Diabetes mellitus (DM) is one of the most prominent public health threats in 205 
modern societies with a rapidly rising prevalence. In 2000, the World Health 206 
Organization (WHO) reported that there were 177 million people living with DM and 207 
predicted that this number will increase to at least 300 million by 2025 287. This is 208 
further supported by a report from Wild et al., which predicts an increase in individuals 209 
affected by DM of 37 % by the year 2030 289. This increase will not only affect the older 210 
population, but also an increasing number of individuals, especially men, in their 211 
reproductive age, since there is a rise in the number of childhood and adolescent males 212 
with type 1 (T1D) and type 2 (T2D) diabetes mellitus 246. Moreover, the great majority 213 
of T1D patients are diagnosed before the age of 30 years 3. 214 
To date, several clinical studies have reported a negative impact of DM on male 215 
reproductive function leading to erectile dysfunction and ejaculation dysfunction, as 216 
well as a reduction in semen volume, sperm counts, sperm motility, and abnormal 217 
sperm morphology 12. Furthermore, the unique characteristics of glucose metabolism 218 
within testicular cells make them prone to changes under diabetic conditions. It is likely 219 
that the glucose sensing machinery as well as the hormonal control within these cells to 220 
counteract hyper- und hypoglycaemia play a crucial role in the subfertility and/or 221 
infertility associated with DM 12,141,248. 222 
Focusing on the molecular mechanism responsible for DM-induced changes in 223 
male fertility numerous clinical and animal studies have been conducted to address this 224 
issue, yet still little is known and much remains to be evaluated further. 225 
Activins are members of the transforming growth factor-β (TGF-β) superfamily 226 
and have recently been reported to play an important role in glucose metabolism by 227 
regulating the differentiation and activity of the insulin-producing pancreatic β-cells, as 228 
well as the response of insulin on target cells 49. Additionally, these mechanisms have 229 
been proposed to modulate events involved in insulin sensitivity in a tissue dependent 230 
manner and therefore regulate whole-body insulin responsiveness 104. Therefore, the 231 
involvement of the activins in the development and onset of diabetes related male 232 
subfertility and/or infertility seems likely. 233 
In the studies described in this thesis, the mev-1 (methyl viologen sensitive) 234 
mutant of the nematode Caenorhabditis elegans (C. elegans), the Ins2Akita+/- mouse 235 
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model, as well as cultured Sertoli cells were used to investigate the effects of 236 
hyperglycaemia and insulin deficiency on the biological actions of the activins, 237 
specifically in male reproduction. The mev-1 mutant of the nematode C. elegans was 238 
shown to be a valuable model organism in the study of glucose-induced cell toxicity, 239 
and thus the study of hyperglycaemic effects of DM 71,84. It carries a mutation within the 240 
cytochrome b subunit of succinate dehydrogenase resulting in excessive mitochondrial 241 
superoxide production and premature death 121. This in turn closely resembles the 242 
metabolic situation of diabetic patients who exhibit a deficiency in the signalling of 243 
reactive oxygen species (ROS) leading to the initiation of autoimmune diabetes as well 244 
as diabetes induced morphological changes in mitochondria, which are closely linked to 245 
the presence of superoxide anion 159,266.  246 
The Akita mouse is a model of T1D that results from a mutation in the Ins2 247 
gene. This mutation leads to a misfolded protein product, which accumulates in the 248 
endoplasmic reticulum (ER), causing ER stress and, ultimately, death of the insulin 249 
producing β-cells of the pancreas 282. The diabetic Akita mouse is thus similar to 250 
humans with T1D, which is caused by an autoimmune destruction of the β-cells of the 251 
pancreas 1,12. Akita mice are a unique model to study infertility as they display a sudden 252 
and severe onset of diabetes at 4-6 weeks of age similar to untreated diabetes in human 253 
adolescents and without concern of drug-induced toxicity to both pancreas and testis125. 254 
My hypothesis is that hyperglycaemia will induce local low-grade inflammation 255 
regulated by activins and their binding protein follistatin. Therefore, the aim of this 256 
thesis is to investigate the impact of T1D on male reproductive function in the context 257 
of low-grade inflammation using mev-1 mutant nematodes, heterozygous Ins2Akita 258 
(Ins2Akita+/-) mice, and cultured Sertoli cells. I will give an overview about diabetes, the 259 
male reproductive tract, and a detailed description of the actions of the activins as 260 
members of the TGF-β superfamily. This is followed by material and methods, results 261 
and discussion. 262 
1.1 Diabetes mellitus 263 
Diabetes is a group of chronic, metabolic diseases characterized by 264 
hyperglycaemia resulting from defects in insulin secretion and/or insulin action 1. First 265 
described in ancient times, the name diabetes mellitus was coined by the Greek/Roman 266 
doctor Araetus of Cappodocia (ca. 81-133 A.D.) deriving from the Greek word 267 
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“diabenein” meaning “straddling” and the Latin word “mellitus” for honey sweet. Both 268 
words marked the most pronounced symptoms of the disease, namely the urge to pass 269 
urine frequently and a sweet taste of the urine, the latter being one of the earliest 270 
diagnostic methods 4. 271 
Left untreated, diabetes leads to chronic hyperglycaemia, which is associated 272 
with long-term damage, dysfunction, and failure of different organs, especially the eyes, 273 
kidneys, nerves, heart, and blood vessels 1,12,61,115,154,232,273. 274 
The development of DM involves several pathogenic processes, including 275 
autoimmune destruction of pancreatic β-cells with consequent insulin deficiency 276 
together with abnormalities that result in insulin resistance. The latter in turn leads to 277 
inadequate insulin secretion and/or diminished tissue responses to insulin at one or more 278 
points in the complex pathways of hormone action, affecting not only carbohydrate, but 279 
also fat, and protein metabolism 1,22. 280 
Symptoms of severe hyperglycaemia include polyuria, polydipsia, weight loss, 281 
and in some cases also polyphagia, blurred vision, growth impairment, and 282 
susceptibility to certain infections. Furthermore, uncontrolled DM can lead to acute, 283 
life-threatening consequences with ketoacidosis or the non-ketotic hyperosmolar 284 
syndrome. Additionally, DM is complicated by retinopathy with potential loss of vision, 285 
nephropathy leading to renal failure, peripheral neuropathy with risk of foot ulcers, 286 
amputations, Charcot joints, autonomic neuropathy causing gastrointestinal, 287 
genitourinary, cardiovascular symptoms, and sexual dysfunction. Moreover, patients 288 
with DM have an increased incidence of atherosclerotic cardiovascular, peripheral 289 
arterial, and cerebrovascular disease, accompanied by hypertension and abnormalities of 290 
lipoprotein metabolism 1,22. 291 
The great majority of diagnosed cases of DM are classified as T1D (discussed in 292 
greater detail below) or T2D. Patients suffering from T1D, caused by an absolute 293 
deficiency of insulin secretion, can often be identified by measuring circulating 294 
antibodies against pancreatic islets, as well as by genetic markers 1,178,196. 295 
T2D is much more prevalent than T1D and is caused by a combination of insulin 296 
resistance and inadequate compensatory insulin secretion. A marked feature of this 297 
condition is its presence for a long period of time before it is detected. This is due to 298 
varying degrees of hyperglycaemia sufficient to cause pathologic and functional 299 
changes in various target tissues, without clinical symptoms. However, measurement of 300 
plasma glucose in the fasting state or after a challenge with an oral glucose load can 301 
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demonstrate an abnormality in carbohydrate metabolism during this asymptomatic 302 
period 1,135. 303 
Further classifications of DM include neonatal diabetes mellitus, genetic defects 304 
of the β-cell, also referred to as maturity onset diabetes of the young (MODY), genetic 305 
defects in insulin action, diseases of the exocrine pancreas, endocrinopathies, drug- or 306 
chemical-induced diabetes, and gestational diabetes mellitus. Furthermore, it is known 307 
that certain infections, such as congenital rubella, adenovirus, and mumps are associated 308 
with β-cell destruction and can therefore lead to the development of DM. Besides these 309 
classifications, there are also uncommon forms of immune-mediated diabetes, including 310 
the stiff-man syndrome or diseases that lead to the production of anti-insulin receptor 311 
antibodies. Other genetic syndromes that are sometimes associated with diabetes 312 
include the chromosomal abnormalities of Down syndrome, Turner syndrome, and 313 
Klinefelter syndrome 1,29,83,147,158,212,257. 314 
To date, there is no simple cure for DM. Thus, disease management concentrates 315 
on the regulation of blood glucose levels using insulin as the main therapeutic agent. 316 
However, especially in T2D patients, adequate glycaemic control can also be achieved 317 
by weight reduction, exercise, and/or oral glucose lowering agents. Hence, these 318 
patients do not require insulin in the early stages of their diabetes but may require it as 319 
they age. The degree of hyperglycaemia reflects the probability of future complications. 320 
Hence, monitoring and targeted treatment of the glycaemic status of each patient is 321 
crucial 1,147. 322 
1.1.1 Prevalence and incidence of diabetes mellitus  323 
Worldwide the number of people with diabetes is increasing due to a variety of 324 
factors such as population growth, aging, urbanization, and increasing prevalence of 325 
obesity and physical inactivity. Unfortunately, the epidemiological data regarding 326 
diabetes mellitus and its associated diseases are often underreported and most data 327 
sources do not distinguish between T1D and T2D in adults. Therefore it is not possible 328 
to present data for certain countries, such as Germany, as well as for the subtypes of 329 
diabetes separately 289. 330 
The World Health Organizations Global Burden of Disease Study provided 331 
estimates for the global prevalence of DM in the year 2000, including projections for 332 
the year 2030. Prevalence is defined as the proportion of individuals in a population 333 
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having a disease or characteristic. According to WHO, there were 171,228 million 334 
people in the year 2000 suffering from diabetes 287. This number will rise by 37 % until 335 
the year 2030 with up to 363,212 million diabetic people in the world. The prevalence 336 
of diabetes is similar in men and women. However, since age is an important impact 337 
factor, prevalence is slightly higher in men over 60 years of age and in women at older 338 
ages. Furthermore, a report from Wild et al. found that even though the prevalence of 339 
diabetes is higher in men, there are more women with diabetes. Besides age, ethnicity is 340 
an important impact factor 289. Hence, in developing countries, the majority of people 341 
with diabetes are in the 45- to 64-year age range, whereas, the majority of people with 342 
diabetes in developed countries are over 64 years of age. According to Wild et al. and 343 
based on the WHO estimates the number of people with diabetes over 64 years of age 344 
will be more than 82 million in developing countries and more than 48 million in 345 
developed countries 287,289.  346 
This increase in individuals affected by diabetes is predicted to be mainly due to 347 
an increase in cases of T2D. However, since about 10 % of all cases suffer from T1D, 348 
by the year 2030 about 36 million people will be affected worldwide. Since the great 349 
majority of T1D patients is diagnosed before the age of 30 and there is a rise in the 350 
number of children and adolescents with T1D, not only the older population will be 351 
affected, but also an increasing number of individuals, especially men, in their 352 
reproductive age 3,246. Therefore, this study will focus on T1D and will include a general 353 
description of T1D, including its etiology, diagnosis, and pathogenesis. Furthermore, 354 
T1D as an inflammatory disease and the impact of T1D on male reproductive function 355 
will be discussed. 356 
1.1.2 Type 1 diabetes mellitus 357 
Type 1 diabetes mellitus can be further differentiated into immune-mediated 358 
T1D and idiopathic T1D.  359 
Immune-mediated T1D accounts for 5-10 % of all diabetes cases and was 360 
previously known as insulin dependent, or juvenile-onset diabetes. It commonly occurs 361 
in childhood and adolescence, but can also develop at later ages. It results from a T-cell 362 
mediated autoimmune destruction of the pancreatic β-cells and can be detected by 363 
measurement of immunological markers, such as islet cell autoantibodies, 364 
autoantibodies to insulin, autoantibodies to glutamic acid decarboxylase (GAD65), and 365 
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autoantibodies to the tyrosine phosphatases IA-2 and IA-2b, as well as autoantibodies to 366 
the zinc transporter 8 (ZnT8). In patients, if all classes of antibodies are present, this 367 
results in a nearly 100 % progression to clinical T1D given enough time. These markers 368 
are present in 85-90 % of the patients 1,178. 369 
Although the causes for T1D remain unknown, certain risk factors have been 370 
identified. Amongst these, certain variants of genes belonging to the human leukocyte 371 
antigen (HLA) complex, such as HLA-DQA1, HLA-DQB1, and HLA-DRB1, were 372 
found to be either predisposing or protective. The HLA complex is part of the immune 373 
system and involved in the recognition of proteins on the surface of cells 1,178. 374 
The onset of this form of diabetes differs between individuals, since the rate of 375 
β-cell decay varies from being rapid in some patients (mainly infants and children) and 376 
slow in others (mainly adults). Moreover, some individuals develop ketoacidosis as 377 
their first manifestation of the disease, whereas in others, the disease begins with 378 
modest fasting hyperglycaemia that can rapidly change to severe hyperglycaemia and/or 379 
ketoacidosis in the presence of infection or other stress. Furthermore, it is not unusual 380 
that some individuals retain residual β-cell function, which is sufficient to prevent 381 
ketoacidosis for many years. Nevertheless, at a latter stage eventually, when little or no 382 
insulin secretion remains, these individuals become dependent on insulin for survival 383 
and are at risk of ketoacidosis 1,22,120. 384 
Immune-mediated destruction of the pancreatic β-cell is known to have multiple 385 
genetic predispositions and is also related to environmental factors that are still poorly 386 
defined. While patients with this form of T1D are rarely obese, the presence of obesity 387 
is not incompatible with the diagnosis. Due to the autoimmune origin of the disease, 388 
these patients are also prone to other autoimmune disorders such as Graves’ disease, 389 
Hashimoto’s thyroiditis, Addison’s disease, vitiligo, celiac sprue, autoimmune hepatitis, 390 
myasthenia gravis, and pernicious anaemia 1,22,120. 391 
While immune-mediated T1D accounts for most T1D cases, in some cases of 392 
T1D no antibodies directed against β-cells can be found. This is known as idiopathic 393 
T1D, which is strongly inherited, lacks immunological evidence for β-cell 394 
autoimmunity, and is not HLA associated. In some patients there is manifestation of 395 
permanent deficient insulin secretion by pancreatic β-cells (insulinopenia) with a 396 
predisposition for ketoacidosis, whereas others suffer from episodic ketoacidosis with 397 
varying degrees of insulin deficiency between episodes. Hence, permanent monitoring 398 
for optimal disease treatment is crucial and an absolute requirement for insulin 399 
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replacement therapy in affected patients may be intermittent 1,152,271. 400 
1.1.3 Treatment of diabetes mellitus 401 
To date, there is no cure for DM, therefore therapeutic strategies concentrate on 402 
the regulation of glucose metabolism in order to retain normal blood glucose levels and 403 
avoid diabetic complications and long-term damage. Treatment strategies involve either 404 
medical or transplantation therapy 201. 405 
Medical therapy can be treatment with oral anti-diabetica (OAD), such as 406 
biguanide, glitazone, or sulphonylureas and can be used in about 40 % of all patients 87. 407 
Another form of medical treatment is insulin therapy, which is vital in most individuals 408 
with T1D. Insulin was first isolated in 1921 by Frederic Banting and Charles Best and 409 
resulted in a revolution in the treatment of diabetes 31. Clinical studies have shown that 410 
treatment of DM by intensive insulin therapy lowers glycated hemoglobin (HbA1c) 411 
levels, a long-term blood glucose marker, and subsequently reduces the incidence of 412 
strictly glucose-dependent complications such as diabetic retinopathy, nephropathy, and 413 
neuropathy 46,139. Intensive insulin therapy (IT) only became feasible through self- 414 
management trainings for patients and has increased their life span significantly. In 415 
contrast to conventional insulin therapy, IT comes with increased insulin blood levels 416 
and higher incidence for hypoglycaemia. At present, most caregivers and patients 417 
acknowledge that the benefits of IT outweigh its adverse events 46. Insulin treatment 418 
varies from additive substitution of basal insulin to full insulin substitution to insulin 419 
pump therapy 142. Since insulin plays a central role in the development and onset of 420 
diabetes, biosynthesis as well as mutations of the gene encoding insulin will be 421 
described in greater detail below. 422 
However, the therapeutic goal of the normalisation of blood glucose cannot be 423 
attained in a significant number of patients due to individual restrictions and risk of 424 
adverse events, such as hypoglycaemic incidents. Pancreas or pancreatic islet 425 
transplantation was demonstrated to reduce the burden of multiple glucose 426 
measurements and daily insulin injections, but these interventions are invasive and 427 
subject the patient to many risks, such as the need to use continuous 428 
immunosuppressive medication 201,210. Hence, treatment for DM is far away from a 429 
definitive cure and can still be optimized. 430 
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1.1.4 Type 1 Diabetes as an autoimmune disease 431 
As described in section 1.1.2 immune mediated T1D is the most common form 432 
of T1D resulting from a T-cell mediated autoimmune destruction of the pancreatic β- 433 
cells. For a better understanding of this interaction, this section will give a brief 434 
description of the immune system and its endocrine control, as well as of the special 435 
role of T-lymphocytes in the development of T1D. 436 
1.1.4.1 Immune system - general principles 437 
The immune system provides protection from invading organisms within 438 
complex animal species and is comprised of a complex series of cells that identify and 439 
eliminate invading pathogens. In vertebrates the immune system consists of an innate 440 
and an adaptive immune system, which overlap in many of their cellular and molecular 441 
mechanisms. The main cellular components of the immune system are the leukocytes, 442 
or white blood cells. These cells, as well as their products, circulate continuously 443 
through the blood, lymph, and tissues in both surveillance and effector mode 109. 444 
The innate immune system generally recognizes uniquely conserved patterns 445 
expressed by various pathogens. It comprises mainly of mononuclear phagocytes 446 
(monocytes and macrophages) and granulocytes or polymorphonuclear leucocytes such 447 
as neutrophils, eosinophils, basophils, and mast cells. Furthermore, it also involves 448 
natural killer (NK-) cells and dendritic cells, which themselves are closely aligned to the 449 
adaptive immune system. The innate immune system provides the first line of defence 450 
against external threats through an inherent ability to recognize and rapidly respond to a 451 
broad range of pathogens and other immunogens, and by initiating inflammation 6,109. 452 
The activation of the immune response involves the so-called pattern recognition 453 
receptors, which recognize specific motifs produced by bacterial, viral, fungal, and 454 
protozoan pathogens. These receptors belong to a family of transmembrane receptors, 455 
known as Toll-like receptors (TLR), which are expressed on cell surfaces and 456 
intracellular endosomes, especially in macrophages, monocytes, and dendritic cells. 457 
Upon activation of pattern recognition receptors, corresponding immune cells are 458 
activated leading to inflammation 52,109,281. Besides the activation of immune cells, this 459 
inflammatory response involves further major changes such as fever, increased blood 460 
flow at the site of inflammation, as well as enhanced pain sensitivity. Apart from 461 
specific pathogens, the inflammatory process can also be triggered by tissue injury, 462 
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insoluble particles, activation of the plasma complement and clotting protease 463 
pathways, immune complexes, and intracellular components released by tissue damage. 464 
While monocytes and macrophages are involved in the initial inflammatory response, 465 
mast cells regulate vascular permeability, vasodilation, and leukocyte recruitment 466 
thereafter, followed by a neutrophil response in which extracellular pathogens are being 467 
removed 52,109,222,281. During this process, a targeted expression of pro-inflammatory 468 
cytokines, pro-inflammatory prostaglandins and leukotrienes, neuropeptides, 469 
chemokines, and adhesion molecules, allows circulating neutrophils, monocytes, and 470 
lymphocytes to specifically target and enter the affected tissue. After the initial pro- 471 
inflammatory response, anti-inflammatory cytokines, prostaglandins, late-acute-phase 472 
proteins, and anti-inflammatory corticosteroids from the hypothalamic-pituitary- 473 
gonadal (HPG) axis resolve the inflammatory response. The long-term effects of 474 
inflammation include increased tissue fibrosis and persistent alterations in the number, 475 
type, and activity of leukocytes in the target tissue. Furthermore, the activation of the 476 
innate immune response leads, in turn, to the activation of the adaptive immune 477 
response 52,109,161. 478 
The adaptive immune system recognizes molecular patterns that are foreign to 479 
the host and involves lymphocytes, such as T-cells, B-cells and NK-cells, as well as 480 
antigen presenting cells (dendritic cells and macrophages). Through complex cellular 481 
interactions the adaptive immune system requires more time to become active than the 482 
innate immune system. These interactions, however, also provide efficacy, specificity, 483 
and memory to the immune response 109. It is activated by the recognition of antigens, 484 
usually associated with proteins, which are foreign to the host and indicate an external 485 
threat. This recognition process relies on the unique ability of lymphocytes to generate a 486 
wide range of cell-surface receptors that are able to bind almost any foreign molecule, 487 
without having encountered it before. B-cells display surface bound immunglobulins, 488 
whereas the receptor on T-cells (TCR) is structurally related to immunglobulins and is a 489 
complex of interacting surface proteins itself. B-cells interact directly with the antigen, 490 
whereas immune responses involving T-cells are more precise and determined by 491 
proteins of the highly polymorphic major histocompatibility complex (MHC). This 492 
complex is expressed on the surface of antigen-presenting cells and binds to the TCR 493 
leading to the activation and proliferation of the T-cell. Recognition of the MHC is 494 
facilitated by co-expression of the receptor proteins CD4 or CD8 as part of the TCR. 495 
Furthermore, activation of the T-cell requires the physical interaction between co- 496 
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stimulatory ligand pairs, such as CD40/CD40LG and CD80/CD86, and the production 497 
of either type 1 or type 2 cytokines. Type 1 cytokines enhance cellular immune 498 
responses and include the interleukins (IL) IL-2, IL-12, and interferon γ (IFN γ), 499 
whereas type 2 cytokines augment antibody responses and include IL-4, IL-5, IL-10, 500 
and IL-13. Due to this complex interaction and depending on the molecules that are 501 
involved, there is a great variety of outcomes of the T-cell activation, leading to the 502 
production of either type 1 helper cells (Th1) or type 2 helper cells (Th2) 64,107,109,251. 503 
The absence of the appropriate co-stimulatory molecule and/ or the presence of 504 
anti-inflammatory or immunosuppressive cytokines can lead to the inactivation of T- 505 
cells as well as to the deletion or the production of regulatory T-cells (T-reg), which are 506 
responsible for regulating antigen-specific immunity and maintaining peripheral 507 
immune tolerance 109,298. 508 
Reactions of the adaptive immune system are also responsible for an 509 
autoimmune reaction, which can lead to chronic inflammation and, dependent on the 510 
target tissue, the development of diseases such as T1D 109,176,178. The autoimmune 511 
process leading to T1D is described in greater detail in section 1.1.4.2. 512 
1.1.4.2 Autoimmunity in type 1 diabetes 513 
Autoimmune diseases generally represent a failure of tolerance or a disruption in 514 
the recognition of host antigens 109. In T1D the clinical onset is preceded by the 515 
appearance of autoantibodies against β-cell antigens, which leads to the specific 516 
destruction of the pancreatic islet β-cells and eventually results in a complete 517 
dependency on exogenous insulin. This specific destruction is initiated by the activation 518 
of T-cells through autoantibodies leading to either a Th1 or a Th2 response. The Th1 519 
response is initiated through activation of CD4 positive T-cells by β-cell antigens and 520 
antigen-presenting cells (APCs), such as dendritic cells, B-cells, and macrophages. This 521 
interaction leads to the production of pro-inflammatory cytokines and free radicals, 522 
which are toxic to the β-cell. Furthermore, the production of cytokines attracts T- and 523 
B-cells, which in turn proliferate in the islet of Langerhans leading to insulitis. 524 
Moreover B-cells mediate further damage to β-cells by producing antibodies against 525 
released β-cell antigens. As a consequence of the activation of CD8 positive T-cells, β- 526 
cells carrying the target auto-antigens are attacked directly 1,107,178. 527 
As discussed in section 1.1.2, T-cell activating autoantibodies include antibodies 528 
directed against insulin (IA), GAD65, insulinoma antigen-2 (IA-2) or ZnT8 1,80,178. 529 
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As a trigger for the development of autoimmunity in T1D, genetic 530 
polymorphisms in the HLA complex, as well as non-HLA polymorphisms have been 531 
considered 80. 532 
Polymorphisms in the HLA complex are thought to explain more than half of the 533 
genetic influence in T1D. Located on chromosome 6p21 the HLA complex contains a 534 
variety of genes related to the immune system. It can be divided into three classes, of 535 
which class II is the major genetic susceptibility determinant for T1D. This class 536 
includes heterodimeric proteins coded for at the DP, DQ, and DR loci. Interestingly, 537 
specific alleles at the DRB1, DQA1 and DQB1 loci are particularly associated with 538 
T1D. These proteins were shown to be expressed on APCs and to have a strong peptide- 539 
binding activity by which they bind to T-cells after recognition. Depending on the 540 
haplotype, these proteins were found to be either predisposing or protective. Besides 541 
class II proteins, HLA class I proteins, such as HLA-A and HLA-B, also contribute to 542 
the development of T1D, although to a lesser extent. These proteins act by directing 543 
CD8 positive T-cells towards cells that have been infected with a virus, as virus 544 
peptides are presented on class I heterodimers 80,187. 545 
Besides HLA genes, a number of non-HLA genes have been associated with 546 
autoimmunity and disease risk in T1D. These genes contribute either to the risk of islet 547 
autoimmunity or to the progression to clinical onset in subjects who had developed islet 548 
autoimmunity. One of the strongest non-HLA genes is protein tyrosine phosphatase 549 
non-receptor type 22 (PTPN22), which inhibits the T-cell receptor signalling and 550 
therefore downregulates the immune response. Single-nucleotide polymorphisms (SNP) 551 
within this gene are believed to promote progression to diabetes 44,80. A further non- 552 
HLA gene is the interleukin-2 receptor-α (IL2RA). This receptor is expressed on T- 553 
cells, which require IL-2 for their growth and survival. Genetic variants of this receptor 554 
were shown to impair T-cell function and therefore lead to autoimmunity 300. Moreover, 555 
recent studies on the interferon-induced with helicase C domain 1 (IFIH1), also known 556 
as MDA5 (melanoma differentiation-associated protein 5), have been linked to a 557 
reduced expression of this domain with T1D. IFIH1 recognises viral RNA and mediates 558 
the innate immune response. IFIH1 variants were shown to be either protective or 559 
predisposing for T1D 77,183.  560 
Furthermore, insulin is a key β-cell autoantigen in T1D. Hence it is not 561 
surprising that polymorphisms of the insulin gene (Ins) contribute to disease 562 
susceptibility. The Ins gene is located on chromosome 11 and shows polymorphism in 563 
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its promoter region. Predisposition to T1D is dependent on a variable number of tandem 564 
repeat polymorphisms, with shorter repeats conferring risk and longer repeats providing 565 
protection 80,176. 566 
Since insulin plays a central role in the development and onset of T1D, insulin 567 
biosynthesis and insulin gene mutations, as well as the role of insulin as an autoantigen 568 
will be discussed below. 569 
1.1.5 Insulin biosynthesis and insulin gene mutations 570 
Insulin is mainly synthesized within the pancreatic β-cells of Langerhans, but is 571 
also produced in other organs, such as the brain or the testis 92,253. The first translational 572 
product from the insulin gene is preproinsulin (shown in Fig. 1-1), which is a 110 amino 573 
acid polypeptide with the 24 amino acid signal peptide. 574 
During further synthesis, the signal peptide is bound by the signal-recognition 575 
particle (SRP), which then interacts with its receptor in the membrane of the 576 
endoplasmatic reticulum. The ER is a membrane-bound organelle that supports the 577 
biosynthesis of approximately one-third of the cellular proteins 185. Binding of the signal 578 
peptide to the ER membrane activates the penetration of preproinsulin into the ER 579 
lumen, where the proteolytic cleavage of the signal peptide from preproinsulin yields 580 
proinsulin. This process was first discovered by Steiner et al. 185,254,255. Subsequently, 581 
proinsulin undergoes protein folding as well as formation of disulphide bonds. After 582 
appropriate folding, proinsulin is transferred into the Golgi apparatus where it is sorted 583 
into constitutive or regulatory pathways 185,254,255. 584 
Thereafter, the transformation of proinsulin into insulin and C-peptide occurs 585 
within secretory granules by enzymatic removal of C-peptide at the sites of dibasic 586 
amino acids. This is achieved by two prohormone convertases (PC1/3 and PC2) that 587 
cleave proinsulin either at the connecting site between the insulin beta-chain (PC1/3) or 588 
at the insulin alpha-chain (PC2) and the connecting peptide (C-peptide). Finally, the 589 
remaining basic amino acids are removed by carboxypeptidase E 182,185,254,255. 590 
Humans carry a single insulin gene consisting of three exons of which exon 1 591 
(42 bp) contains only the 5’-untranslated region, exon 2 (204 bp) encodes the signal 592 
peptide, the B-chain and part of the C-peptide, and exon 3 (219 bp) encodes the rest of 593 
the C-peptide as well as the A-chain 74,185. 594 
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 595 
Fig. 1-1. The human preproinsulin molecule. 596 
Diagram representing the human preproinsulin molecule showing locations of 597 
mutations causing neonatal DM 257 with permission. 598 
 599 
So far, three distinct mutant insulins have been identified in humans, however, 600 
not all individuals with mutant insulin develop diabetes due to the presence of normal 601 
alleles. In those cases, an overproduction of normal insulin will compensate for the 602 
deleterious effect of the mutant insulin. This effect can, however, in turn be influenced 603 
by several factors that are likely to cause insulin resistance or pancreatic β-cell secretory 604 
dysfunction (i.e. aging) 102,179,185,261. Besides insulin gene mutations that lead to structural 605 
abnormalities within the insulin molecule itself, there are four known gene mutations 606 
that effect the conversion of proinsulin to insulin 56,185,302. 607 
In contrast to humans, insulin in rodents is derived from a two-gene system 608 
consisting of preproinsulin 2 (Ins2), which is orthologous to the insulin gene in humans 609 
and other mammals, and preproinsulin 1 (Ins1), which is a rodent specific retrogene. 610 
Both Ins2 and Ins1 are expressed in the pancreas and encode proinsulin peptides built of 611 
a signal peptide, a B-chain, a C-peptide, and an A-chain 241. 612 
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 613 
Fig. 1-2. Gene structure of Ins2 and Ins1 in the house mouse (mus musculus). 614 
Gene structure of Ins2 and Ins1 in the house mouse (mus musculus) 241 with permission. 615 
 616 
Ins1 was found to originate from a reverse-transcribed, partially processed 617 
mRNA of Ins2 and therefore retains only one of the two introns, which is homologous 618 
to the first intron of Ins2 (Fig. 1-2). Further, Ins1 carries homologous regulatory regions 619 
with Ins2 from aberrant transcription. This is partially due to processes where the 620 
mRNA was transcribed from the upstream region of Ins2 and hence contains not only 621 
the gene itself, but also the regulatory regions. Within the mouse genome Ins1 is located 622 
on chromosome 7 and Ins2 is located on chromosome 19, whereas in other rodents, 623 
such as the rat, both genes are located on the same chromosome 241. 624 
Murine insulin knockout models have revealed that both genes exert functional 625 
differences. This is supported by findings from Babaya et al. who showed that the two 626 
insulin genes have different null phenotypes related to the etiology of diabetes. Hence, 627 
without the presence of Ins2 alleles, Ins1-carrying mice were affected by the resultant 628 
insulin deficiency that accelerated the onset of T1D. Whereas, in mice carrying Ins2 629 
alleles, no decrease in insulin content was detected 27. This suggests that Ins1, which 630 
evolved after the Ins2 gene, might exert some negative effects on glucose metabolism, 631 
some of which could worsen the diabetic syndrome 27,241. 632 
1.1.6 Mouse models of type 1 diabetes 633 
To date several rodent models of T1D have been established and especially the 634 
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mouse models are widely used. These include genetic models such as the NOD, the 635 
Ins2Akita, or the Munich mouse, and toxin-induced mouse models such as the 636 
Streptozocin (STZ) treatment model 137,146,153,185. 637 
The NOD mouse, descriptive for non-obese diabetic mouse, is the premiere 638 
model for T1D and was first described by Makino et al. 160. The NOD mouse is an 639 
inbred mouse strain developed in the course of a breeding program to establish a 640 
cataract-prone sub line (CTS) from non-inbred ICR mice 145. These mice show an 641 
autoimmune destruction of the pancreatic β-cells accompanied by several organ specific 642 
pathologies. Showing an abrupt onset of diabetes, as indicated by leukocyte infiltration 643 
into the pancreatic islets (insulitis), between 90 and 120 days (equivalent to early 644 
adolescence period in humans), hyperglycaemia, glycosuria, hypercholesterolemia, 645 
ketonuria, polydipsia, polyuria, and polyphagia, the clinical features of the diabetes 646 
syndrome in NOD mice are quite similar to human T1D 146,160. These mice require daily 647 
insulin injections in order to survive, once diabetes is established. Hence, it is difficult 648 
to maintain aging colonies of this strain to further investigate the development of 649 
diabetic complications 146. 650 
The Ins2Akita mouse, a monogenic diabetic model, was first established by 651 
Yoshioka and colleagues in a colony of C57Bl/6N mice 146,282. Since this mouse model 652 
was used in this study, it will be described in greater detail below. 653 
A further genetic model for T1D is the Munich Ins2C95S mouse, which was first 654 
identified in 2007 as a novel non-obese diabetic mouse by the screening of N-ethyl-N- 655 
nitro-sourea (ENU) mouse mutagenesis project. This model carries a mutation at the 656 
C95S residue resulting in a disruption of the intra-chain disulphide bond of the insulin 657 
alpha-chain. This mutation causes hypoinsulinaemic hyperglycaemia by the age of one 658 
month. Similar to the Ins2Akita model these mice were shown to have a decreased 659 
number and size of insulin granules, enlarged ER and swollen mitochondria in the 660 
pancreatic islets consistent with ER stress related to the abnormally folded mutant 661 
insulin molecules 112,185,236. 662 
Besides genetic mouse models, toxin induced mouse models for T1D are widely 663 
used. These include high dose alloxan (ALX) and STZ models and multiple “Low 664 
Dose” STZ models. Alloxan and STZ are small molecules resembling glucose and 665 
binding the GLUT-2 glucose transporters in both pancreatic β-cells and the liver. Both 666 
molecules disintegrate in aqueous solution, leading to the production of free radicals. 667 
This in turn, damages β-cells, which in contrast to other epithelial cells, are known for 668 
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their low cytoplasmic concentrations of antioxidant enzymes, such as superoxide 669 
dismutase or catalase 148. However, besides the aimed effect of diabetes development, 670 
these substances bear a high risk of undesired side effects and toxin-induced mice also 671 
display a high mortality, as well as a high inter-strain variability in the level of 672 
hyperglycaemia that they develop 146. 673 
Other models for T1D include knockout and transgene, as well as viral infection 674 
models 146. 675 
A detailed literature review on reproductive dysfunction in T1D animal models 676 
is given in Table B-7. 677 
1.1.7 The Ins2Akita mouse model 678 
The Ins2Akita mouse model carries an autosomal dominant mutation at the Mody 679 
region and develops hyperglycaemia with notable pancreatic β-cell dysfunction 282. The 680 
following section will discuss the origin of this mouse model as well as its application 681 
and use for studies of T1D. The particular features regarding the research into 682 
reproductive abnormalities in this mouse model are discussed in section 1.2.6. 683 
1.1.7.1 Establishment of the Ins2Akita mouse model 684 
The monogenic diabetic model called the Ins2Akita mouse was first established in 685 
a colony of C57Bl/6N mice by Yoshioka and colleagues in 1997 in Akita, Japan 146,282. 686 
Originally this model was referred to as Mody4 due its dominant inheritance presenting 687 
with early juvenile onset of hyperglycaemia, since it also resembles the Maturity Onset 688 
of Diabetes in the Young (MODY) in humans, which is inherited in an autosomal 689 
dominant manner and characterized by a primary dysfunction of pancreatic β-cells 282. A 690 
spontaneous missense mutation in the Ins2 gene is found at the distal end of 691 
chromosome 7 and resulting in the conversion of cysteine Cys96 (TGC) into a tyrosine 692 
(TAC) codon at the seventh amino acid on the A chain of proinsulin. This leads to a 693 
conformational change of the protein due to the inability to form a disulphide bridge 694 
between the corresponding residues A7 and B7. This defect in protein folding leads via 695 
a so-called unfolded protein response to the induction of endoplasmic reticulum stress 696 
and β-cell apoptosis 282. 697 
Mice homozygous for the mutation exhibit high early mortality, which is why 698 
heterozygous mutants are commonly used for most studies. “To avoid the complications 699 
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of diabetic pregnancies wild type females are usually mated to young, heterozygous 700 
mutant males to produce litters with a 50:50 ratio of mutants and wild type controls” 146. 701 
Furthermore, recent studies have shown that the penetration of the dominant genotype 702 
can vary and is dependent on background strain and sex 125. Hence, both sexes of the 703 
Ins2Akita model develop hyperglycaemia at weaning, however, loss of β-cells and 704 
diabetes are more pronounced in heterozygous males than in females. Akita mice 705 
develop T1D by the age of approximately 4 to 5 weeks, manifesting with severe 706 
hyperglycaemia, hypoinsulinemia, polydipsia, and polyuria in male mice, while female 707 
mice show less severe symptoms with less impairment in β-cell function 199,235. 708 
As the mice age, the β-cell mass decreases, which is accompanied by a decline 709 
in plasma and pancreatic insulin levels. Nonetheless, insulin can still be detected in a 710 
small number of β-cells remaining in the residual islets by immunostaining. In those 711 
surviving β-cells, insulin molecules are made up from the two functional Ins1 alleles on 712 
chromosome 19, present in 25 % of the total insulin, and the one normal Ins2 allele on 713 
chromosome 7. This allows heterozygous chronically hyperglycaemic mice of both 714 
sexes to survive beyond six month of age, thereby distinguishing this model from other 715 
genetic T1D mouse models 146. Moreover, other than many other monogenic diabetes 716 
mouse models, the Ins2Akita mouse is lean and its pancreatic β-cell dysfunction does not 717 
result in pancreatic invasion of immune cells 282. 718 
1.1.7.2 Differences of the Ins2Akita mouse model to human type 1 diabetes 719 
The characteristics of a human T1D were discussed in 1.1.2. 720 
Although Ins2Akita mice exhibit several features of MODY in humans, which is 721 
inherited in an autosomal dominant manner and characterized by a primary dysfunction 722 
of pancreatic β-cells, the mutation in the mouse model is different from humans 185,257,282. 723 
Humans were found to have several point mutations resulting in amino acid 724 
substitutions within the proinsulin molecule. Patients exhibiting this mutation were 725 
found to be heterozygous for the defective gene and show a high incidence of glucose 726 
intolerance with usually mild and late-onset symptoms and, in some cases even normal 727 
glucose tolerance, due to the co-production of wild type insulin. Furthermore, 728 
hyperinsulinemia or hyperproinsulinemia is a common symptom in human subjects. 729 
Hyperinsulinemia results from a reduced clearance rate of mutant insulin molecules 730 
through insulin-receptor mediated uptake and degradation because of the low binding 731 
potency of the mutant insulin to the receptor. Hyperproinsulinemia on the other hand 732 
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reflects a decreased cleavage or altered subcellular sorting of mutant proinsulin. Thus, 733 
in human MODY significant amounts of both wild type and mutant (pro)insulin are 734 
being secreted from the islets 282. 735 
In contrast, Wang et al. state that Akita mice have diabetes with a severe 736 
decrease in insulin secretion (hypoinsulinemia) and a 100 % penetrative phenotype 282. 737 
However, this penetrance is in contrast to the Akita mice bred in the animal facility at 738 
Mannheim (Germany) for more than 30 generations, with a prevalence of 50 % of a 739 
severe hyperglycaemic, hypoinsulinaemic diabetic phenotype. These mice will not gain 740 
weight with age and display reduced fat and lean body mass compared to non-diabetic 741 
littermates. According to insulin blood levels, heterozygous Akita mice are comparable 742 
to T1D patients with about one-tenth residual insulin secretion capacity. Therefore, 743 
hyperglycaemic mice will survive 24 weeks and more so that long-term diabetic 744 
complications can be investigated. Littermates with near-normal glycaemia (<11.1 745 
mmol/l non-fasting blood glucose concentrations) or severe hyperglycaemia (>33.3 746 
mmol/l) can be compared. Although it remains to be elucidated, this heterogeneous 747 
phenotype of the Ins2Akita+/- mice might arise from a different mutation of the Ins2 gene. 748 
Therefore, it is possible that mice with a fasting blood glucose of <11.1 mmol/l have 749 
sufficient remaining circulating insulin to prevent the animal from developing diabetes. 750 
1.1.7.3 Applications of the Ins2Akita mouse model 751 
After its establishment the Ins2Akita mouse model has been used for the study of 752 
several diabetes-related complications, such as diabetic nephropathy, retinopathy, 753 
neuropathy, and diabetes-induced osteoporosis. Furthermore, the impact of T1D on 754 
reproduction has been studied by several groups using this mouse model, which will be 755 
discussed in greater detail in section 1.2.6. 756 
Diabetic nephropathy is a major complication in both T1D and T2D patients, 757 
being a leading cause of end-stage renal disease (ESRD) in approximately 50 % of all 758 
cases 130,154. Mice with a mutation in the Ins2 gene exhibit features of human diabetic 759 
nephropathy, such as decreased body and heart weight, as well as increased kidney to 760 
body weight and kidney weight to tibia length ratio, and increased plasma glucose, 761 
plasma triglycerides, and thiobarbituric acid reactive substances in plasma. Further, they 762 
have a significantly increased renal albumin excretion, resulting in albuminuria. These 763 
are accompanied by a drastic increase in the albumin/creatinine ratio, a decrease in 764 
nephrin expression and glomerular filtration rate 25,130,154.  765 
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Diabetic retinopathy (DR), a sight-threatening consequence of diabetes, is 766 
mainly characterised by neural retinal degeneration together with microvascular 767 
dysfunction 115. As diabetic retinal retinopathy is accompanied by a progressive loss of 768 
inner retinal neurons, including the amacrine and retinal ganglion cells, similar 769 
observations have been noted in the Ins2Akita model. Thus, Akita mice have been shown 770 
to develop very early DR-related retinal abnormalities, including increased vascular 771 
permeability, retinal ganglion cell (RGC) apoptosis, reduced retinal thickness, 772 
decreased retinal blood flow, as well as abnormal electroretinographic responses 773 
resulting in vision loss. Using a scopic electroretinogram (ERG), a diagnostic test that 774 
measures the electrical activity generated by neural and non-neuronal cells in the retina 775 
in response to a light stimulus, neuropathic abnormalities were evaluated within the 776 
Akita mouse model. Ins2Akita mice show ERG abnormalities and neuropathic lesions 777 
including degeneration of cone photoreceptors at early stages of the disease, and severe 778 
ERG defects, loss of synaptic structures in second order neurons, such as the outer 779 
plexiform layer, and decreased number of amacrine cells and RGCs at later stages. 780 
Further, these changes are accompanied by early thinning of the neurosensory retina 781 
within outer retinal layers, progressing towards the inner retina with the duration of the 782 
disease 100,115. 783 
It is well known that diabetes adversely affects the skeleton, which is why bone 784 
mineral loss is a further serious complication of T1D. Ins2Akita mice were shown to have 785 
significantly less bone mineral density compared to wild type controls 130. Furthermore, 786 
when severe hyperglycaemia has developed, these mice show diminished bone 787 
formation and suppressed periosteal bone appositions, which is mainly due to 788 
alterations in the calcium signalling of osteocytes 199. 789 
Diabetic neuropathy is the most common, but still poorly studied complication 790 
of diabetes, and is known to affect approximately 60 % of all patients. It results in 791 
cardiovascular, genitourinary, sudomotor and alimentary symptoms or subclinical 792 
disease in humans and manifests in sensory loss, electrophysiological measures of nerve 793 
impairment and anatomical evidence of nerve fibre loss 232,259. Studies of the 794 
neuropathological features in the Ins2Akita mouse model have shown controversial 795 
results. On the one hand, male Ins2Akita mice exhibit unambiguous, spontaneous, rapidly 796 
developed neuropathology similar to that found in humans. These are characterised by 797 
progressively developed markedly swollen axons and dendrites in the prevertebral 798 
superior mesenteric and celiac ganglia with an overall increase in presynaptic axon 799 
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terminal cross sectional area 232. Supporting these neuronal findings, Choeiri et al. have 800 
shown that a decrease in the sensory nerve conduction velocity occurs together with an 801 
increase in gait disturbances. These results were further shown to become more severe 802 
with age 63. Apart from these findings, Ins2Akita mice showed no defect in the procession 803 
of spatial memory 63. On the other hand, Sullivan et al. suggested that Ins2Akita mice at 804 
24 weeks show only minimal signs of diabetic neuropathy based on heat sensation and 805 
nerve conduction velocity analysis 130,259. This is supported by findings from Yaguchi et 806 
al., who undertook neuropathological examinations, which failed to show remarkable 807 
abnormalities in the brain, spinal cord or sciatic nerve of Akita mice up to 48 weeks of 808 
age 299. 809 
1.1.8 Other models of type 1 diabetes 810 
Other than the mouse models described above, various genetic rat models and 811 
toxin-induced diabetic rats are frequently used models for the study of T1D 118,306. 812 
Besides these models, the nematode Caenorhabditis elegans was shown to be a 813 
valuable model organism in the study of glucose-induced cell toxicity, and thus the 814 
study of hyperglycaemic effects of DM 71,84. This model organism was used to study 815 
glucose toxicity on reproductive function, which will be described in section 3.1. 816 
1.2 Testis biology 817 
The testis is a specialized organ and site of the production of spermatozoa and 818 
androgens. It is composed of two distinct compartments: the seminiferous epithelium, 819 
where spermatogenesis occurs nourished by the Sertoli cells, and the interstitium 122. 820 
This section will provide a short overview about the male reproductive tract, followed 821 
by a more detailed description of the Sertoli cell, including an insight into 822 
spermatogenesis and spermiogenesis. Furthermore, steroidogenesis and the reproductive 823 
complications associated with T1D will be discussed. 824 
1.2.1 Anatomy of the male reproductive tract 825 
In mammals the male reproductive tract (Fig. 1-3) is composed of testes (Fig. 826 
1-4), epididymides, ductus deferentes, accessory sex glands, and penis 239. 827 
Introduction 
 21 
 828 
Fig. 1-3. Anatomy of the human male reproductive tract. 829 
Anatomy of the male reproductive tract 108. 830 
 831 
The development of the testis from the gonads starts after migration of sexually 832 
indifferent germ cells into the bipotential genital ridge. This process takes place in the 833 
first quarter of gestation in humans and in the third quarter of gestation in mice and is 834 
triggered by the expression of the sex-determining region of the Y chromosome (SRY) 835 
by the Sertoli cells. In contrast, in females not SRY, but Wnt4 is expressed, resulting in 836 
the differentiation of female gonads into ovaries. In the initial phase of testicular 837 
development, pre-Sertoli cells migrate into the developing gonad, where they aggregate 838 
to form the sex cords between which the endothelial and interstitial cells are found. The 839 
sex cords progress to subsequently form the seminiferous tubules. 840 
The interstitial spaces between the seminiferous tubules contain blood and 841 
lymphatic vessels, macrophages, nerves, fibroblast cells, lymphocytes, as wells as 842 
Leydig cells. Leydig cells play a crucial role in male fertility since they are the sites of 843 
testosterone production both during development of the testis and later during pubertal 844 
development to adulthood. The steroidogenic function of the Leydig cells is critically 845 
dependent on the pituitary-derived luteinizing hormone (LH) 32,190,239. The seminiferous 846 
tubules are the site of sperm production (spermatogenesis) and sperm maturation 847 
(spermiogenesis) and contain various germ cells, as well as somatic Sertoli cells. The 848 
Introduction 
 22 
latter have essential nutritive and physiological functions essential for the developing 849 
germ cells. The tubules themselves are enclosed by a peritubular tissue comprising a 850 
basement membrane and myoepithelial cells or myofibroblasts, further interspersed 851 
with layers of collagen fibres and glycosaminoglycan and proteoglycan matrices. The 852 
peritubular tissue comprising of peritubular myoid cells is capable of contracting and 853 
these contractions facilitate transport of fluid, secreted by the Sertoli cells, together with 854 
the spermatozoa in the seminiferous tubules into the rete testis and further into the 855 
efferent ducts and the epididymis. The contractions are initiated in response to oxytocin, 856 
vasopressin, prostaglandin F2α, and endothelin 239. 857 
 858 
Fig. 1-4. Structure of the testis, seminiferous tubule, and Sertoli cell. 859 
Structure of the testis (A), the seminiferous tubule (B), and the Sertoli cells (C) 65 with 860 
permission. 861 
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The basic structure of the testis is reached by eight weeks post fertilization in 862 
humans and by fourteen days in mice. Enlargement of the seminiferous tubules is due to 863 
proliferation of Sertoli cells and germ cell expansion resulting in growth of testis size 864 
190. 865 
Masculinization of the embryo is triggered by the expression of anti-müllerian 866 
hormone (AMH) by Sertoli cells and androgens from Leydig cells. Furthermore, fetal 867 
testis development is mainly characterized by Sertoli cell proliferation and androgen 868 
production of the Leydig cells, which makes both cell types crucial for male fertility. 869 
Following this, the primordial germ cells which are initially centrally placed in the 870 
seminiferous cords then migrate towards the basement membrane of the seminiferous 871 
tubules and give rise gonocytes that in turn develop into the spermatogonial stem cells 872 
(SSC) from which full spermatogenesis develops during the hormonal induction of 873 
puberty. The process of spermatogenesis is described in section 1.2.4. At puberty, LH 874 
secretion by the pituitary gland stimulates Leydig cell precursors to form the adult 875 
population of Leydig cells and increase levels of testosterone. Testosterone stimulates 876 
germ cells to initiate spermatogenesis and is thus required for fertility and normal male 877 
behaviour. During the same period, Sertoli cells proliferate to increase their numbers 878 
and then cease mitosis and undergo a maturation process in which they form the blood- 879 
testis-barrier (BTB) dividing the seminiferous epithelium into a basal and an adluminal 880 
compartment 190. Both the role of Sertoli cells as well as of the BTB is extensively 881 
described in section 1.2.3. 882 
After completion of fetal testicular development, secretion of androgens by 883 
intra-testicular Leydig cells induces differentiation of the mesonephric (or wolffian) 884 
duct into the epididymis and ductus deferens as well as some of the accessory sex 885 
glands. It is also responsible for the development of the indifferent external genitalia 886 
into a penis and a scrotum 32,190,239. 887 
During fetal life, the testes migrate from their initial site close to the kidneys 888 
caudally into a scrotum, which provides the optimal lower temperature for the process 889 
of spermatogenesis and also for sperm storage. This process is referred to as testicular 890 
descent and is further divided into two stages: transabdominal migration and inguino- 891 
scrotal phase. While the transabdominal migration is completed early during fetal 892 
development, the inguino-scrotal phase occurs late in fetal life in humans, and after 893 
birth in mice. Besides the testis itself, both the cranial suspensory ligament and the 894 
gubernaculum are involved in the descent of the testis. The gubernaculum runs between 895 
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the testis and the inguinal area and will eventually lead to an outpouching of the 896 
peritoneum forming a sac, the processus vaginalis. This vaginal process is surrounded 897 
by fibres of the cremaster muscle that enables the testis to be retracted into the 898 
peritoneal cavity in rodents through the inguinal canal. The processus vaginalis remains 899 
patent in rodents throughout life but closes in humans after birth. The nephric 900 
replacement is a tightly controlled process regulated by various factors such as insulin- 901 
like growth factor 3 (Insl3), calcitonin gene-related peptide (CGRP), AMH, and 902 
androgens 239. 903 
The testes are surrounded by a tough fibrous capsule called the tunica albuginea, 904 
which consists of an outer layer of visceral peritoneum built of mesothelial cells and an 905 
inner layer consisting of fibroblasts, collagen fibres, and smooth muscle cells 239. 906 
 “Both ends of each seminiferous tubule open into the tubuli recti and then into 907 
the rete testis through short transitional zones lined by cells resembling Sertoli cells, 908 
which appear to form a valve or a plug” 239. It is known that in humans up to six 909 
seminiferous tubules can join a single tubulus rectus, whereas in mice the total number 910 
of these cords is between 12 and 18. In mice, as in most rodents, the rete testis is located 911 
on one side of the testis, whereas in humans it lies alongside one edge of the testis in a 912 
fibrous mediastinum. Therefore, in humans the rete testis can be divided into a septal, 913 
tunical, and extratesticular region. The rete testis is connected to the epididymal duct 914 
through efferent ducts that coil to form the caput epididymis. The epididymal duct 915 
arises from the mesonephric duct. It is arranged in lobules and can, according to the 916 
structure of the epithelium and the gross morphology, be divided into caput, corpus, and 917 
cauda, with the latter terminating in the vas deferens. The epididymal duct is lined by an 918 
epithelium consisting of principal, apical, narrow, light, and basal cells, as well as by 919 
intraepithelial leucocytes. Distally, the epididymis joins the vas deferens, an 920 
unconvoluted duct which distally joins the prostatic urethra 190,239. 921 
Similar to the epididymal duct, accessory sex glands arise from the mesonephric 922 
duct, but also in part from the prostatic and penile urethra. They comprise vesicular, 923 
ampullary, bulbourethral, and prostate glands. The secretion of the accessory sex glands 924 
contains various substances, such as fructose, citric acid, zinc, and acid phosphatase, 925 
which are added to the semen at ejaculation. In mice the secretion from these glands 926 
forms a large, hard, copulatory plug within the vagina, which is thought to fulfil several 927 
functions such as prevention from sperm leakage, facilitation of sperm transport, 928 
facilitation of gradual release of sperm within the female tract, and prevention of 929 
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subsequent fertilizations by other males 239. 930 
Semen is then eventually deposited in the female reproductive tract by an 931 
intromittent organ, the penis 239. 932 
1.2.2 Steroidogenesis in the adult male 933 
Since inter- and intra-cellular processes in spermatogenesis are driven by signals 934 
originating from hormones, it is important to discuss molecular mechanisms of 935 
steroidogenesis in this context. 936 
Spermatogenesis is driven by three major hormones, namely, LH and follicle- 937 
stimulating hormone (FSH), which are both derived from gonadotrophs in the anterior 938 
pituitary, and testosterone, which is mainly secreted by testicular Leydig cells. These 939 
hormones work in concert to promote the initiation of spermatogenesis, as well as germ 940 
cell proliferation, development, and differentiation. For this, FSH acts on Sertoli cells to 941 
activate gene expression and signalling pathways that support the process of sperm 942 
production, whereas LH acts on Leydig cells to promote the production of testosterone. 943 
To stimulate testosterone, LH binds to its cognate receptor, luteinizing hormone– 944 
chorionic gonadotropin receptor (LHCGR), on Leydig cells, which in turn activates the 945 
production of enzymes that is required for the biosynthesis of testosterone 250. 946 
Biosynthesis of testosterone and of all other steroids starts with the cleavage of 947 
cholesterol to pregnenolone, which is the common precursor of all other steroids (Fig. 948 
1-5). This first step, as well as all following steps, is catalysed by various steroidogenic 949 
enzymes, which can be divided into three categories. The first category contains the 950 
cytochromes P450, including mitochondrial (CYP11A1, CYP11B1, CYP11B2), 951 
microsomal (CYP17A1, CYP21A2, CYP19A1), and redox proteins (FDX1, FDXR, 952 
POR, CYB5A). Cytochromes P450 are steroid hydroxylases and their names derive 953 
from the specific enzymatic function. For instance CYP17A1 (P450c17, steroid 17- 954 
hydroxylase/17,20-lyase) is named after its role in the cleavage of cytochrome b5 955 
(CYB5A) in the 17,20-lyase reaction. The second category comprises the 956 
oxidoreductases, such as hydroxysteroid dehydrogenases (HSD) 17βHSDs, 11βHSDs, 957 
3βHSDs, and 3αHSDs, and 5α-reductases. The third category comprises conjugating 958 
enzymes (sulfotransferases, sulfatases, uridyldiphosphate, glucuronyltransferases) and 959 
steroidogenic acute regulatory protein (StAR), which mobilizes cholesterol into the 960 
steroidogenic pathways 23. 961 
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 962 
Fig. 1-5. Human steroidogenesis. 963 
Human steroidogenesis 23 with permission. 964 
 965 
Most of the steps in steroidogenesis are irreversible transformations. Thus, the 966 
cytochrome P450-catalyzed oxygenations, such as the 3βHSD/Δ5→Δ4-isomerase 967 
(3βHSD) reactions, and the 5α- and 5β-reductase reactions proceed only in one 968 
direction, whilst the 3α-, 3β-, 11β-, 17β-, and 20αHSD reactions are reversible 23. 969 
During steroidogenesis, testosterone arises from the cleavage of the side chain of 970 
cholesterol by CYP11A1, leading to the formation of pregnenolone after loss of six 971 
carbon atoms. Pregnenolone can be further converted into progesterone via 3βHSD or 972 
17OH-pregenenolone via CYP17A1. Thereafter, CYP17A1 catalyses the formation of 973 
17OH-progesterone from progesterone or of didehydroepiandrosterone (DHEA) from 974 
17OH-pregnenolone. These products will then further be converted into androstendione 975 
via 3βHSD or CYP17A1. In the final (reversible) step, androstendione is reduced by 976 
17βHSD to yield testosterone. Another pathway for the yielding of testosterone is the 977 
conversion of DHEA to Androst-5-ene-3β-17β-diol, which is then irreversibly reduced 978 
to testosterone via 3βHSD. 979 
Testosterone is secreted by Leydig cells in a pulsatile manner, which is due to 980 
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the pulsatile stimulation of the Leydig cells by episodic LH secreted by the anterior 981 
pituitary gland, since LH activates cholesterol transfer via StAR. Testosterone acts via 982 
the androgen receptor (AR) in somatic cells and is essential for maintaining 983 
spermatogenesis and has a crucial role in the process of masculinization and the 984 
maintenance of male secondary sexual characteristics. It further supports 985 
spermatogenesis by acting upon Sertoli and other testicular cells to regulate gene 986 
expression and the activation of signalling pathways 250.  987 
Moreover, testosterone is also released into the bloodstream, where it acts to 988 
regulate LH secretion by the pituitary through a negative feedback loop. Hence, 989 
increased circulating testosterone concentrations feed back at the level of the 990 
hypothalamus and pituitary to suppress LH secretion by the pituitary, which 991 
subsequently reduces LHCGR-mediated stimulation of Leydig cells and thereby 992 
reduces testosterone production. Equally, a reduction in circulating testosterone 993 
concentrations induces LH secretion by the pituitary and a concomitant increase in 994 
testosterone production by the Leydig cells 250. This communication between 995 
hypothalamus, pituitary and testicular cells is also known as hypothalamic-pituitary- 996 
gonadal (HPG) axis. 997 
1.2.3 The Sertoli cell  998 
First discovered in 1865 by the Italian physiologist and histologist Enrico 999 
Sertoli, the eponymous Sertoli cell was described as the non-spermatogenic “mother 1000 
cell” of the seminiferous tubules (Fig. 1-4). Sertoli found that these cells do not produce 1001 
spermatozoa, based on the finding that firstly spermatozoa have been observed in only a 1002 
few extensions of these cells, secondly that spermatozoa are only found in extensions, 1003 
where it would be possible for them to have entered accidentally, and lastly that the 1004 
formation of spermatozoa is not associated with neither the form of the branched cells, 1005 
nor with the constant position inside the tubule, nor their tendency to enclose the 1006 
seminiferous cells among their branches, nor their communication with one another 1007 
through the extensions 285.  1008 
 Today it is known that Sertoli cells serve two distinct functions: first the 1009 
formation of the seminiferous cords, and second the provision of nutritional and 1010 
structural support of developing germ cells during spermatogenesis (discussed in 1011 
section 1.2.4) 264. Their number increases exponentially during fetal development, 1012 
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followed by a further postnatal increase. During this time, Sertoli cells build the 1013 
foundation of normal adult testicular function. Thus, in the fetus Sertoli cells support 1014 
testis formation by coordinating the migration and differentiation of all other cell types. 1015 
This starts with the differentiation of the primordial gonad into a testicular phenotype 1016 
through the expression of the sex-determining region of the Y (SRY) chromosome 1017 
gene, followed by the regulation of the proliferation, differentiation, and function of all 1018 
other cell types, such as primordial germ cells, somatic Leydig cells, and peritubular 1019 
myoid cells 264. Moreover, during testicular development Sertoli cells induce the 1020 
regression of Müllerian ducts via secretion of AMH 264. Hence, Sertoli cells play a 1021 
central role in testicular development. At this time, Sertoli cells are undifferentiated and 1022 
responds to FSH, which promotes proliferation, and thyroxine, which inhibits the 1023 
proliferative activity of the Sertoli cells 264. Until recently, Sertoli cells were thought to 1024 
reach their final, non-proliferative, state at puberty with Sertoli cell numbers per testis 1025 
reaching about 3 x 106 in rodents and 1800 x 106 in humans 190. Hence, any damage to 1026 
the Sertoli cell environment was thought to be a cause of infertility, displayed as 1027 
spermatogonial arrest 308. However, several studies show that Sertoli cells express a 1028 
mixture of proliferation inducing and inhibiting genes in an adult stage, making them 1029 
different from other terminally differentiated quiescent cells 5,35,36,60. This in turn 1030 
suggests, that Sertoli cells rather resemble arrested proliferating than terminally 1031 
differentiated somatic cells. Moreover, observations in Sertoli cells of hamsters and 1032 
mice have now suggested that under pathological conditions, Sertoli cells might regain 1033 
their proliferative capabilities due to hormonal changes and a disruption in 1034 
spermatogenesis, further supporting that non-proliferative Sertoli cells are more likely 1035 
to display a proliferation arrest rather than a final differentiation 5,263. 1036 
At puberty, the role of Sertoli cells switches to the support of germ-cell 1037 
differentiation, meiosis, and spermatid transformation. This functional change is 1038 
initiated by alterations in protein expression and gene transcription, and the formation 1039 
of a functional BTB. The latter takes place through the formation of highly specialized 1040 
tight junctions between adjacent Sertoli cells thereby preventing inter-cellular transport 1041 
of macromolecules. Thus, the Sertoli cells control the intertubular environment as all 1042 
germ cells other than spermatogonia and preleptotene spermatocytes, are located 1043 
internal to the Sertoli cell tight junctions playing an important role for intra-testicular 1044 
immune system and intra-tubular immunity 32. The formation of the BTB is an essential 1045 
step in the development of spermatogenesis and any delay will prevent the onset of 1046 
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meiosis, whereas disruption of the BTB will lead to infertility due to an inability of the 1047 
spermatogonia to differentiate into spermatocytes 190. 1048 
In order to study Sertoli cells function in vitro, many researchers use isolated 1049 
primary Sertoli cells 290 or Sertoli cell lines, that were generated using different models 1050 
and methods 144,168,172,203,225,237,279. Within this study, primary mouse Sertoli cells and the 1051 
WL-3 Sertoli cell line were used to determine diabetes-induced changes in Sertoli cell 1052 
function with respect to activin metabolism, which will be discussed in section 1.3. 1053 
1.2.4 Spermatogenesis 1054 
Spermatogenesis is a highly conserved progression of cellular maturation steps, 1055 
which allows male germ cells to develop into mature spermatozoa (Fig. 1-6). This 1056 
process takes places within the seminiferous tubules of the adult testis, where the 1057 
spermatogonial stem cells are maintained by regular mitosis, at intervals entering the 1058 
process of meiosis to develop into spermatocytes, and lastly undergoing 1059 
spermiogenesis, where the morphological transformation of haploid round spermatids 1060 
into elongated spermatids is completed. Following this last step of spermatogenesis, 1061 
spermatozoa are released into the tubule lumen and transit towards the excurrent ducts 1062 
32. 1063 
 1064 
Fig. 1-6. Schematic presentation of spermatogenesis. 1065 
Spermatogenesis in the human (A) 245 with permission and in mice (B) 223. 1066 
 1067 
Throughout adult life, spermatogenesis is preserved by spermatogonial stem 1068 
cells (SSCs), which can be grouped into type Asingle (AS) spermatogonia in mice and type 1069 
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Apale (AP) and Adark (Ad) spermatogonia in humans. Loss of spermatogonial stem cell 1070 
receptors, such as glial-cell-derived neurotrophic factor (GDNF), Gfr1a and c-ret, as 1071 
well as gradual reduction in neurogenin 3 marks the first steps of maturation. 1072 
Differentiation is completed when the SSCs completely loose their ability to function as 1073 
stem cells and concurrently express the cell surface signalling receptor tyrosine kinase 1074 
kit. SSCs are now being referred to as A1, A2, A3, A4, In and B spermatogonia. For 1075 
further maturation spermatogonia undergo mitosis. Following mitosis, spermatogonia 1076 
enter meiosis to become primary spermatocytes, that undergo sister chromatid exchange 1077 
and a nuclear division during the first phase of meiosis to yield secondary 1078 
spermatocytes. Subsequently, the second meiotic division produces four haploid round 1079 
spermatids from each progenitor, which further undergo chromosomal remodelling to 1080 
bundle the genetic content and to initiate formation of mature sperm including 1081 
formation to the tail from a pair of centrioles through the process termed 1082 
spermiogenesis 32,69. Sertoli cells together with the contractile peritubular myoid cells 1083 
build the basement membrane of the seminiferous tubules. The contractions of the 1084 
myoid cells allow spermatozoa to transit through the seminiferous tubule lumen towards 1085 
the epididymis 32. Since each Sertoli cell supports the maturation of a definite number of 1086 
germ cells, the number and function of the Sertoli cells formed prior to puberty 1087 
determine the adult sperm output 32,69. 1088 
1.2.5 Type 1 Diabetes and reproduction 1089 
Since diabetes mellitus is a major public health problem it has been reported to 1090 
cause not only serious complications such as retinopathy, nephropathy, and neuropathy, 1091 
but also impairment in fertility in women and men. Hence, women suffering from 1092 
diabetes were shown to have a high prevalence of sexual dysfunction with a mixed 1093 
pattern of sexual symptoms, including loss of sexual interest or desire, arousal or 1094 
lubrication difficulties, painful intercourse (dyspareunia), and loss of the ability to reach 1095 
orgasm 78. Additionally, T1D in pregnant women was shown to also affect the child 1096 
during pregnancy, resulting in placental transfer of maternal excess glucose leading to 1097 
fetal hyperinsulinaemia and accelerated fetal growth 216. 1098 
However, since the prevalence of patients suffering from T1D is steadily 1099 
increasing, affecting many more men during their reproductive age, this study 1100 
concentrates on the impact of diabetes on male reproductive health. A large number of 1101 
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studies in diabetic men, as well as in animal models have indicated that diabetes 1102 
mellitus disrupts fertility at various levels including altered spermatogenesis, 1103 
degenerative and apoptotic changes in testes, altered glucose metabolism in Sertoli 1104 
cells, reduced testosterone synthesis and secretion, erectile dysfunction, ejaculatory 1105 
dysfunction, reduced libido, and impotence 12,124. When studying sperm parameters and 1106 
sperm quality markers, the literature shows some conflicting results, with evidence for 1107 
alterations in sperm morphology and motility in some studies 141,173, but not in others 1108 
2,3,162. Interestingly, in many studies that reported normal semen parameters, a higher 1109 
degree of sperm microstructure damage, such as alterations in mitochondrial DNA 1110 
(mDNA), was observed, indicating that DM is more likely to affect male fertility at a 1111 
molecular level 2,3,131,162. 1112 
The interpretation of clinical results is, however, exacerbated by inconsistent 1113 
study design with many clinical studies concentrating on T2D patients or, when both 1114 
types of diabetic patients were recruited, results not distinguishing between T1D and 1115 
T2D. Moreover, these studies seem to mainly focus on the clinical significance, rather 1116 
than the molecular mechanisms underpinning DM-induced alterations of male fertility. 1117 
Additionally, factors such as the glycaemic control, the type of treatment, as well as all 1118 
the comorbidities associated to DM can mask the outcomes of the studies that relate 1119 
with DM and male fertility. This exacerbates the interpretation of how much of the 1120 
observed disrupted fertility is due to changes in glycaemic status and which is attributed 1121 
to other factors, such as body weight/ adipose tissue and DM related comorbidities. 1122 
Hence, the use of animal models, which allow investigations under tightly controlled 1123 
conditions, are crucial for the study of DM-induced male infertility 12. 1124 
In accordance with the clinical data, many animal studies have reported a 1125 
reduced fertility, gonadal dysfunction, and alterations in sperm motility and 1126 
morphology. Moreover, these studies also reported altered sexual behaviour, reduced 1127 
testicular weight and sperm content, as well as reduced epididymal sperm content 30,106. 1128 
To date, several animal experiments have also aimed to investigate the underlying 1129 
molecular mechanisms that cause diabetes-induced infertility, but comprehensive 1130 
studies remain scarce. One proposed mechanism is the disruption of the HPG axis, since 1131 
DM is known to cause changes in the HPG axis, such as altered levels of FSH and LH, 1132 
which in turn can be related to diabetes-induced impotence 30,166,235. Also atrophic 1133 
changes within the epididymis, resulting in the loss of spermatozoa in the epididymal 1134 
lumen and oxidative stress, affecting both testis and epididymis, have been proposed to 1135 
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contribute to DM-induced disruption in male fertility 252. 1136 
A more detailed review of the literature on the impact of T1D on male 1137 
reproductive health is given in Table B-6 and Table B-7. 1138 
Nevertheless, molecular mechanisms beyond glucose deregulation remain 1139 
poorly investigated and most of the biochemical changes involved in DM-induced 1140 
infertility remain unknown. Hence, it is crucial to evaluate the molecular mechanisms of 1141 
testicular insulin and glucose regulation to determine the impact of DM on male 1142 
reproductive function. 1143 
Optimal glycaemic control in diabetic individuals is crucial to reduce and avoid 1144 
DM-related complications and comorbidities, since hypo- and hyperglycaemia lead to 1145 
molecular alterations, which in turn can also lead to detrimental effects on male 1146 
reproductive health 12,221. Moreover, it was shown that disease onset and disease 1147 
duration are important impact factors in this matter 141,186,229,248. Indeed, the actions of 1148 
insulin on the male reproductive tract has been studied since the early 1980’s, showing 1149 
that not only insulin itself, but also insulin-like growth factor-1 (IGF-1) and insulin 1150 
receptors are involved in the regulation of the energy metabolism of Sertoli cells by 1151 
regulating the uptake of nucleotides (ATP, GTP, UTP), and the secretion of transferrin, 1152 
pyruvate, and lactate. Therefore, insulin is actively involved in initiation and 1153 
maintenance of spermatogenesis 41,95,129,249. This is further supported by findings, which 1154 
show that insulin not only regulates glycine metabolism, but also lipid metabolism 1155 
within Sertoli cells by regulating the biosynthesis of arachidonic acid 195. Further studies 1156 
imply that insulin secreted from Sertoli cells acts in an autocrine-paracrine manner 94,202. 1157 
Recent studies suggest, that insulin may also be involved in male reproductive function 1158 
via regulation of the HPG-axis 235. Lastly, there is also evidence that insulin can regulate 1159 
human sperm fertilization capacity through regulation of glucose metabolic pathways 1160 
during sperm acrosome formation and capacitation 17. 1161 
Glucose is an energy substrate required to maintain spermatogenesis, a 1162 
metabolically active process, which depends upon tight cooperation among testicular 1163 
cells. In this context, Sertoli cells play a crucial role in providing pyruvate and 1164 
glycolytic converted lactate for developing germ cells 129. Thus, disturbance in glucose 1165 
metabolism, as in diabetic individuals, can lead to major disruptions in the cellular 1166 
organisation, ranging from vacuolization to a high degree of degeneration. This in turn, 1167 
has dramatic consequences for the cellular interaction during spermatogenesis 12. 1168 
These findings show that a deregulation of the insulin and glucose metabolism 1169 
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plays a significant role in DM-induced male infertility and/or subfertility. 1170 
1.2.6 Reproduction in the Ins2Akita mouse model of type 1 diabetes 1171 
Various studies have shown that male mice homozygous for the mutation within 1172 
the Ins2 gene show testicular atrophy starting by the age of 5 weeks with an observed 1173 
reduction in testis size, reduction in seminal vesicle weight, arrested spermatogenesis, 1174 
and an absence of mature spermatozoa as well as a decreased numbers of spermatocytes 1175 
and spermatids. By the age of 7-8 weeks these mice exhibit infertility 136,235,236. Data on 1176 
heterozygous Ins2Akita mice is conflicting, with one study stating that these mice become 1177 
infertile at the age of approximately 24 weeks and cease to sire pups after the age of 4 to 1178 
6 month 235 and another study showing that these mice maintain fertility 236. The latter is 1179 
also supported by findings from Fox et al., who showed that testicular morphology of 1180 
heterozygous Akita mice did not differ from wild type mice 86. 1181 
By the age of 8 to 9 weeks the seminiferous tubules of homozygous mice display 1182 
an intact BTB, show, however, a marked atrophy, characterized by a loss of germ cell 1183 
populations and an increase in the presence of large, multinucleated cells as well as 1184 
vacuolization. This is accompanied by fewer germ cells in the epididymis. Additionally, 1185 
sperm from homozygous Akita mice fertilize fewer embryos, and those embryos that 1186 
get fertilized show developmental damage at blastocyst stage, such as fragmentation 1187 
and poor embryo development. This is likely to be due to the observed increased 1188 
amount of DNA damage in germ cells within the seminiferous tubules of these mice 1189 
136,235,236. 1190 
Schoeller et al. went on to investigate molecular mechanisms behind the 1191 
observed testicular damage and showed that these mice, despite having a reduction in 1192 
testis size as well as abnormal testis and sperm morphology, do not display any increase 1193 
in ER stress in the testis. This suggests, that the observed testicular phenotype of 1194 
homozygous Akita mice is not caused by ER stress, but by diabetes itself 235. 1195 
Furthermore, both the testes and sperm of homozygous Akita mice show an increase in 1196 
apoptotic germ cells as well as a lower number in motile and progressively and rapidly 1197 
moving sperm. Investigations from Schoeller et al. on sperm morphology revealed that 1198 
sperm from homozygous mice lack acrosomes, show membrane blebbing and numerous 1199 
detached sperm heads, as well as abnormal mitochondria 235. Moreover, Schoeller et al. 1200 
observed decreased serum levels of testosterone and LH, which could be partially 1201 
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rescued by exogenous insulin. This suggests that the observed testicular phenotype 1202 
might be due to a disruption within the HPG-axis 235. The finding that homozygous 1203 
Ins2Akita mice show reduced levels of leptin further supports this view 236. Leptin has 1204 
been shown to play a role in the HPG-axis by acting upon the hypothalamus, thus 1205 
inducing the secretion of testosterone within the testis 143. 1206 
To further support the impact of diabetes on the reproductive outcome in those 1207 
mice, Kim and Moley investigated the glucose metabolism in these mice. Thus, Akita 1208 
mice exhibit a reduced expression in the glucose transporter SLC2A8 within the testes 1209 
and a loss of expression in SLC2A9b within testes and sperm. Also, expression of 1210 
SCL2A9b was found to be significantly lower within the acrosome and principal piece 1211 
of Akita sperm. All together these findings indicate that the expression of glucose 1212 
transporters may be regulated by insulin signalling and/ or hyperglycaemia and that 1213 
therefore diabetes in Akita mice has an important impact on sperm maturation and 1214 
fertilization 136. 1215 
Moreover, O’Neill et al. proposed the involvement of oxidative stress in the 1216 
diabetes-induced disruption of fertility in heterozygous Akita mice, since they showed 1217 
an increase in the advanced glycation endproduct CML within the testes, epididymides 1218 
and sperm. Moreover, the receptor for advanced glycation endproducts (RAGE) was 1219 
found to be present on the developing acrosome and epididymal sperm, with the latter 1220 
showing an increase in nDNA damage 189. 1221 
Within the present study the heterozygous Ins2Akita model was used to investigate 1222 
long-term effects of diabetes on male reproductive functions with focus on the 1223 
regulation of the activins. 1224 
1.3 Activin and the TGF-β superfamily 1225 
Many testicular functions, such as formation and programming of sexually 1226 
indifferent germ line cells for spermatogenesis, as well as spermatogenesis itself, 1227 
require progressive, interactive instructions between multiple cell types. Members of the 1228 
TGF-β superfamily play a crucial role in this system by providing a complex, 1229 
interactive system, allowing different cell types to communicate with one another 305. 1230 
The TGF-β superfamily compromises approximately 40 structurally related 1231 
proteins, including 3 TGF-β homodimeric proteins (TGF-β-1, -2 and -3), several 1232 
activins, Nodal, over 15 bone morphogenetic proteins (BMPs), AMH, growth and 1233 
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differentiation factors (e.g. GDF9, also named BMP15), and the divergent GDNF 1234 
subfamily 305. It was named after its first member TGF-β1, which was first described in 1235 
1983 21. 1236 
The following section will discuss the signalling processes of the TGF-β 1237 
superfamily, with a particular focus on activin signalling and the role of activins in male 1238 
reproduction. 1239 
1.3.1 Activin and Inhibin 1240 
Activin and inhibin are both recognized as pleiotropic growth factors, which 1241 
were first described based on their ability to regulate FSH synthesis and secretion by the 1242 
anterior pituitary 32,72. Both are highly conserved across different species, and have 1243 
conserved functions. Activins are homodimers formed by dimerization of two β 1244 
subunits, whereas inhibins are heterodimers formed by dimerization of an α-subunit 1245 
(encoded by the Inha gene) and one β-subunit. To date, four different β subunits, 1246 
including βA (Inhba), βB (Inhbb), βC (Inhbc) and βE (Inhbe) have been described in 1247 
mammals. 1248 
 1249 
Fig. 1-7. Activins, inhibins, follistatin, and TGFβ . 1250 
A schematic representation of the formation of different dimeric proteins from three 1251 
basic subunits 99. 1252 
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Originating from a precursor protein, which consists of a pro-region and a C- 1253 
terminal mature peptide, the biologically active mature protein is formed after 1254 
disulphide-bonded dimerization and cleavage of the pro-region. Each of the mature 1255 
subunits forms three intra-molecular disulphide bonds and two subunits are joined by a 1256 
further disulphide bond resulting in activin A (βA: βA homodimer), activin B (βB: βB 1257 
homodimer) or activin AB (βA: βB heterodimer) or inhibin A or B. Activins A and B are 1258 
the bioactive forms, while activins C and E are weak agonists or antagonists. For the 1259 
formation of inhibin A the α subunit binds to the βA subunit, whereas for the formation 1260 
of inhibin B it binds to the βB subunit. The inhibins are antagonists of activin A and B. 1261 
Additionally, in vitro studies of the βC subunit showed that it can either form a 1262 
homodimer or heterodimers with the βA and βB subunits resulting in a functional 1263 
inhibitory protein of activin A in vivo 32,156,305. A scheme of the structure of activins, 1264 
inhibins, and their precursor molecules is shown in Fig. 1-7. 1265 
1.3.2 TGF-β superfamily signalling – The Smad pathway 1266 
Members of the TGF-β superfamily are known to signal through the formation 1267 
of a multimeric receptor complex. This receptor complex is formed of two distinct 1268 
receptor subunit classes, which are common to nearly all TGF-β superfamily ligands. 1269 
The first subclass is termed type I receptors and contains receptors termed anaplastic 1270 
lymphoma kinase (ALK) 1 to ALK7. The second subclass is termed type II receptors, 1271 
known as TGFBR2, ActRIIA (Acvr2a), and ActRIIB (Acvr2b), with two subunits that 1272 
hold intrinsic serine/threonine kinase activity 32,156,305. 1273 
Activins signal through binding to the type II receptor subunit, either ActRIIA or 1274 
ActRIIB, which further enables the phosphorylation of the type I receptor via the 1275 
constitutively active kinase domain. Distinct receptor binding affinities, such as 1276 
TGFBR2 and ALK1 or 5 for TGF-βs and Acvr2a or 2b plus ALK2, 4 or 7 for activins, 1277 
BMPs and Nodal allow a crosstalk between the ligands at the level of receptor 1278 
utilization. Furthermore, it provides a structural basis for signalling intensity and 1279 
duration. Thus, after binding to the type II receptors activin A activates the type I 1280 
receptor ALK4, whereas activin B activates ALK4 and ALK7. Inhibins, on the other, 1281 
can recruit another receptor type, known as type III receptors (TGFβRIII, betaglycan), 1282 
which then binds to the type II receptor and prevents activin receptor type I and II 1283 
dimerization and signalling 32,156,305. 1284 
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Thereafter, the receptor kinase activity of the type I receptors leads to the 1285 
recruitment and phosphorylation of downstream signalling molecules such as regulatory 1286 
Smads (R-Smads) 2 and 3, which are typically activated by activins, Nodal and TGF-βs, 1287 
or Smads 1, 5 and 8, which are used by BMPs. Being phosphorylated these Smads are 1288 
able to bind to the common Smad4 in order to build a complex which can translocate 1289 
into the nucleus to affect gene transcription 32,156,305. 1290 
This pathway can be negatively regulated by either inhibitory Smads on an intra- 1291 
cellular level or by cell surface antagonists. The inhibitory Smads 6 and 7 can bind to 1292 
R-Smads to inhibit their signalling. Negative regulation by cell surface antagonists, 1293 
such as inhibin, Bambi, follistatin, noggin, gremlin, and chordin, was shown to be either 1294 
due to direct binding of the receptor ligands or by competitive binding to the type II 1295 
receptors 32. A scheme of the Smad signalling pathway is shown in Fig. 1-8. 1296 
 1297 
Fig. 1-8. Smad signalling pathway. 1298 
Smad signalling pathway 156 with permission. 1299 
 1300 
Bambi, also known as BMP and activin membrane-bound inhibitor, is a 1301 
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transmembrane glycoprotein related to the type I receptors. It exerts its actions as a 1302 
pseudo-receptor, lacking an intracellular serine/threonine kinase domain required for 1303 
signalling. Thus, it allows binding of the receptor ligands without processing the signal 1304 
further, since it prevents the formation of the receptor complexes 194. 1305 
Follistatin (FST) is a glycosylated monomeric protein, which antagonises 1306 
activins by binding to the β-subunits to form a stable complex that effectively prevents 1307 
the activins from interacting with the type II receptor. Through alternative splicing 1308 
multiple transcript variants that encode multiple follistatin isoforms are being built. 1309 
These include FST315 and FST288 (comprised of 315 and 288 amino acids, 1310 
respectively), which differ at their C-terminus, and have different affinities for cell 1311 
surface heparan sulphate-containing glycoproteins. Another isoform, FST303, is 1312 
thought to be produced by proteolytic cleavage of FST315. While FST315 is a freely 1313 
circulating protein, FST288 is largely tissue-bound, and FST303 appears to be gonad- 1314 
specific 258. 1315 
Noggin, gremlin, and chordin are glycosylated proteins known for their 1316 
inhibitory effects on BMP. Thus, they inhibit BMP signalling by blocking the molecular 1317 
interfaces of the binding epitopes for both type I and type II receptors by sequestering 1318 
its ligand in an inactive complex 116,205,226. 1319 
The crosstalk amongst all ligands of the TGF-β superfamily is understood to be 1320 
a tightly regulated system and will finally determine the response within the signalling 1321 
cascade 32,156,305. It is therefore important to identify which components of this signalling 1322 
cascade are present in each cell and within every physiological context to fully 1323 
understand how cell respond to its activation. 1324 
1.3.3 The role of activin in reproduction 1325 
Since male reproductive function depends on the production of hormones from 1326 
the HPG axis, it is of great importance that activin serves both paracrine and autocrine 1327 
actions in each organ of this axis. Activin is known to stimulate GnRH release from the 1328 
hypothalamus and FSH release from the pituitary. It can further increase the number of 1329 
GnRH receptors on the surface of gonadotropes and augment the GnRH-mediated 1330 
transcriptional activation of GnRH receptors in order to enhance the pituitary response 1331 
to GnRH 32. 1332 
In the testis itself, the local production of activin and the control of its signalling 1333 
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pathway are critical for germ and Sertoli cell development as well as for adult testis 1334 
function 32. However, activins were also shown to be of great importance during testis 1335 
development, since the gonad shows a sexually dimorphic response to activin and its 1336 
inhibitors 32,156,305. 1337 
1.3.4 The role of activin in diabetes 1338 
To date, several studies have proposed an important role for several members of 1339 
the TGF-β superfamily in maintaining β cell function under physiological conditions 1340 
and that they hence play a crucial role in the pathology of diabetes. Specifically, 1341 
activins A and B, as well as their binding protein follistatin, have been shown to be 1342 
involved in the regulation of glucose metabolism and inflammation 15,62,104,191,260,293. 1343 
Moreover, since gene expression of the activin βB subunit as well as that of the 1344 
canonical activin receptors ALK4, ActRIIA, and ActRIIB has been demonstrated in the 1345 
pancreatic bud in mice 73, and the activin βA subunit was localized in α, β, and δ cells 1346 
of the pancreatic islet 192,303, the involvement of activins in the development and onset of 1347 
diabetes seems likely. 1348 
Hashimoto and Funaba reported that activins A and B are regulators of the 1349 
differentiation and activation of pancreatic β-cells and that they are moreover involved 1350 
in controlling the response of insulin target cells 104. Additionally, they have been 1351 
proposed to modulate events involved in insulin sensitivity in a tissue dependent 1352 
manner and therefore regulate whole-body insulin responsiveness 104. Hence, activin A 1353 
is capable of reducing target tissue sensitivity to insulin, while activin B was shown to 1354 
enhance insulin gene transcription 104,295. This is further supported by the finding that 1355 
activin enhances glucose stimulated insulin secretion (GSIS), and augments the 1356 
expression of genes characteristic to mature β-cells, such as insulin, solute carrier 1357 
family 2 (Scl2a2 or GLUT2), and PC2, which suggests that activin is actively involved 1358 
in β-cell differentiation. 1359 
With regard to diabetes, many studies focus on the interaction of activin activity 1360 
and T2D. This is due to the fact that activin A was shown to affect inflammation in 1361 
adipose tissue by stimulating macrophage formation from a pro- into an anti- 1362 
inflammatory phenotype. This is supported by the finding that toll like receptor 4 1363 
signalling is increased in recently diagnosed T2D patients and that activin A was shown 1364 
to be activated through this mechanism 295. Additionally, activin A was shown to be 1365 
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released by murine bone marrow derived neutrophils after stimulation with tumor 1366 
necrosis factor (TNF-α), a response that was abolished after pre-treatment with insulin 1367 
293. This supports the hypothesis that activin A is directly involved in inflammation 1368 
associated with T2D and that insulin directly impacts activin A release. Furthermore, 1369 
these data suggest that a loss of insulin sensitivity could lead to an increase in activin A 1370 
levels and inflammation, and thereby exacerbating the disease. 1371 
Focussing on the role of activin in T2D, Wu et al. found that, although serum 1372 
levels of activin A or follistatin in diabetic patients did not differ from control patients 1373 
or patients with impaired glucose tolerance, activin A and/ or B measures could still be 1374 
positively correlated to parameters of insulin resistance and T2D, such as fasting 1375 
glucose, fasting insulin, and HbA1c 295. Furthermore, they found that serum levels of 1376 
activin A, but not activin B or follistatin, were positively correlated with age in control, 1377 
but not in diabetic subjects. This indicates that increasing levels of activin A with age 1378 
are necessary to maintain a healthy metabolism and that this mechanism is disrupted in 1379 
diabetic patients, despite the fact that acute changes of glucose and insulin did not alter 1380 
activin A and B levels 295. In contrast to this finding, Chen et al. did not confirm a 1381 
correlation between serum activin A levels and fasting glucose, fasting insulin, or M- 1382 
value for insulin sensitivity, while they showed a positive correlation for activin A with 1383 
age in T2D men 62. However, they were able to show an association between circulating 1384 
plasma activin A levels in T2D men without cardiovascular complications and 1385 
myocardial glucose metabolism as well as left ventricular mass/ volume (LVMV)-ratio. 1386 
This indicates that activin has a potential role in early human diabetic cardiomyopathy 1387 
62. Further support for a role of activin A in diabetic cardiomyopathy was provided by 1388 
Blumensatt et al. who showed that activin A release from epicardial adipose tissue in 1389 
T2D patients inhibits proper function of insulin by inhibiting the Akt pathway, a signal 1390 
transduction pathway that promotes survival and growth in response to extracellular 1391 
signals. Hence, insulin-stimulated glucose uptake is reduced 38. Adding to investigations 1392 
on the role of activin A in diabetic cardiomyopathy, Andersen et al. established that 1393 
activin A levels are positively correlated with abnormal glucose regulation in patients 1394 
with acute myocardial infarction (MI). This involved a correlation for blood activin A 1395 
levels with glucose levels at admission, glucose levels during and oral glucose tolerance 1396 
test (OGTT), HbA1c, as well as insulin and C-peptide. Furthermore, they showed that 1397 
glucose enhanced activin A release in endothelial cells, whereas activin A in turn 1398 
attenuated the release of the inflammatory cytokine IL-8, while concurrently enhancing 1399 
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levels of the anti-oxidative enzyme metallothionine. Thus, they proposed an anti- 1400 
inflammatory role for activin A in this context, a view further supported by findings that 1401 
activin weakened the suppressive effect of IL-8 on insulin release in islet cells 15. 1402 
Taken together, these results suggest that, even though there seems to be no 1403 
difference in circulation serum activin A levels in diabetic and non-diabetic men, 1404 
activin A does play an important role in glucose metabolism. This mainly involves the 1405 
regulation of differentiation and activation of pancreatic β -cells and controlling of the 1406 
response of insulin target cells 110. 1407 
Besides the involvement of the activins in diabetes and diabetes-induced 1408 
complications, recent studies have also focussed on the regulation of the downstream 1409 
signalling pathway of the activins. Thus, Smad 3 was shown to promote hepatic 1410 
gluconeogenesis during T2D, while inhibition of Smad 3 signalling suppressed 1411 
endogenous glucose production 297. Moreover, phosphorylation of the Smad 2/3 1412 
complex was shown to be enhanced in T2D animals, which is likely accompanied by a 1413 
diminished expression of the inhibitory Smad 7 150,301. 1414 
A detailed literature review on the role of activin in DM is given in Table B-8. 1415 
1.4 Hypothesis and aims of the study 1416 
The previous chapters demonstrate that there is evidence linking T1D and male 1417 
reproductive dysfunction, however, the underlying mechanisms are still poorly 1418 
understood. In this study, I hypothesize that hyperglycaemia will induce local low-grade 1419 
inflammation regulated by activins and their binding protein follistatin. Thus, the aim of 1420 
this study is to identify this interaction as novel underlying mechanism of diabetes- 1421 
induced male reproductive dysfunction, providing new insights into this field of 1422 
research.  1423 
To accomplish this, I used mev-1 mutant nematodes, heterozygous Ins2Akita 1424 
(Ins2Akita+/-) mice, and cultured Sertoli cells to investigate the following research 1425 
objectives: 1426 
 1427 
1) To investigate the effect of hyperglycaemia on the brood size of mev-1 1428 
mutant nematodes and to delineate the impact of high glucose treatment 1429 
on Sma/Mab pathway genes in mev-1 nematodes, which are closely 1430 
related to the TGF-β signalling pathway in mice and humans 1431 
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2) To assess the reproductive phenotype of Ins2Akita+/- mice 1432 
3) To assess the regulation of activins and their signalling pathway in 1433 
Ins2Akita+/- mice 1434 
4) To study the effects of high glucose and high activin on cultured Sertoli 1435 
cells 1436 
 1437 
Results from these investigations will give insights into the role of activins and 1438 
their signalling pathway in diabetes-induced male infertility allowing for a better 1439 
understanding of the pathogenesis of male reproductive dysfunction in diabetic males. 1440 
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2 Material and Methods 
In order to investigate the impact of T1D and high glucose levels on male 
reproduction, with focus on the activin signalling pathway, animal experiments were 
carried out using the C. elegans strain mev-1, as well as C57Bl/6J and heterozygous 
Ins2Akita (Ins2Akita+/-) mice. Further, in vitro experiments using primary Sertoli cells as 
well as a Sertoli cell line (WL-3) were conducted in order to evaluate the influence of 
altered insulin and glucose on Sertoli cell function. This section will describe the 
handling of these animals and cells as well as the methods used. Section A will give a 
detailed list of consumables, instruments, chemicals and reagents, buffers and solutions, 
and software used in these studies. 
2.1 C. elegans experiments 
Studies on the C. elegans model organism were carried out in the laboratory of 
Prof. Dr. Uwe Wenzel at the Institute for Molecular Nutritional Research of the Justus-
Liebig-University. 
Nematodes used in the present study were N2 (wild type, Caenorhabditis 
Genetics Center (CGC) University of Minnesota, Minneapolis, USA) and mev-1 
(constructed in the lab of Dr. Kai Lüersen, University of Kiel), both generously 
provided by Prof. Uwe Wenzel. 
According to the methods of Stiernagle et al., C. elegans were cultured on 
nematode growth medium (NGM) agar plates seeded with concentrated Escherichia coli 
(E. coli) OP50 (obtained from the CGC) liquid culture at 20°C 256. OP50 seeded NGM 
agar plates were kindly prepared by Eva Czynski and Alexandra Neeb. All steps for the 
production of E. coli OP50 cultures as well as their transfer onto NGM-agar-plates were 
carried out under sterile conditions using a sterile fume hood. Worms were transferred 
regularly to fresh plates before starving. 
2.1.1 Cultivating E. coli OP50 on 2xYT-agar plates 
Prior to cultivation bacterial cultures (with or without RNAi) were stored as 
glycine cultures at -20°C. In order to cultivate E. coli OP50, bacterial smears were 
plated onto 2xYT-agar-plates using a sterile inoculation loop. Further, annealing of the 
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inoculation loop allowed isolation of bacterial colonies as shown in Fig. 2-1. Plates 
were sealed with Parafilm and incubated for 12 to 16 h at 37°C. Afterwards plates were 
stored at 4°C. 
 
Fig. 2-1. Isolation of bacterial colonies. 
2.1.2 Generation of an E. coli OP50 over culture 
In order to generate an E. coli OP50 overnight culture 3 ml 2xYT-medium were 
pipetted into a tissue culture tube. Using a sterile pick a single colony of the E. coli 
culture is taken from the 2xYT-agar-plate and added into the medium. Thereafter, the 
tube was incubated overnight at 37°C, shaking at 300 rpm. To ensure oxygen supply 
within the tube, the lid was placed loosely on top. 
2.1.3 Generation of an E. coli OP50 day culture 
In order to generate an E. coli OP50 day culture 200 ml 2xYT-medium were 
inoculated with 500 µl overnight culture in an 500 ml Erlenmeyer flask. The flask was 
closed for sterility and incubated for 6 h at 37°C, shaking at 300 rpm. 
2.1.4 Concentrating an E. coli OP50 day culture on NGM-agar-plates 
For further use of the day culture, 4 x 45 ml of the day culture were transferred 
into a 50 ml centrifuge tube and centrifuged for 5 minutes at 5000 x g. The supernatant 
was discarded and the pellet resuspended in 4.5 ml 2xYT-medium. This concentrated 
suspension was stored at 4°C until use. 
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NGM-agar plates were overlaid with either 100 µl (55 mm plates) or 600 µl (100 
mm plates) OP50 day culture, swayed and air dried under sterile conditions. Thereafter, 
plates were stored at room temperature (RT). 
2.1.5 Synchronization of C. elegans using egg-prep 
For all experiments, synchronous C. elegans mev-1 populations were used. 
Age synchronous populations of L1-larval nematodes were obtained by the 
collection as described by Donkin and Williams 75. To obtain homogeneous populations 
of L4-larval nematodes worms were synchronized by bleaching. For this, 2 to 5 ml M9 
buffer were pipetted onto NGM-agar-plates that were fully grown with gravid 
nematodes. Plates were shaken gently and nematodes, that were now swimming within 
the buffer, were washed into 15 ml centrifuge tubes. If necessary, plates were rinsed 
once more with M9 buffer to collect remaining worms. In order to obtain adult worms, 
centrifuge tubes were filled to 14 ml with M9 buffer and centrifuged for 2 minutes at 
1200 rpm. When the adult worms had settled and the supernatant (13.5 ml), containing 
bacteria and larvae, was discarded. Thereafter, the worms were washed using 13.5 ml 
M9 buffer, followed by centrifugation for 2 minutes at 1200 rpm. Washing was 
repeated until the supernatant was clear (generally, 2 times). After the last washing step, 
worms were centrifuged for 2 minutes at 1200 rpm and the supernatant was discarded, 
leaving a remainder of 3.5 ml within the tube. Thereafter, worms were lysed by adding 
1.5 ml bleaching solution (0.45 N NaOH, 2 % HOCl) into the tube, followed by intense 
shaking for 5 minutes. This procedure allows the eggs to be set free. Afterwards, this 
tube was filled to 14 ml with M9 buffer, followed by centrifugation as described above. 
In order to remove the bleaching solution, the supernatant was discarded, leaving a 
remainder of 0.5 ml within the tube that was washed for 3 times as described above. 
After the last washing step 10 ml of M9 buffer and 10 µl cholesterol were added into 
the tube, which was then left for incubation in an overhead shaker overnight at 20°C. 
During this time the larvae hatched. 
On the following day, the tube was centrifuged for 2 minutes at 1200 rpm, the 
supernatant was discarded and leaving a remainder of 1 ml. This was washed as 
described above. Hereafter the larvae were raised in NGM-liquid-media under 
experimental conditions. 
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2.1.6 Raising synchronized larvae in NGM-liquid-media 
For all experiments synchronised L1 larvae were grown in liquid NGM with 
bacteria in 96 well microtitre plates. For this, 2x 150 µl of a concentrated OP50 day 
culture were pipetted into a 1.5 ml Eppendorf tube and centrifuged for 2 minutes at 
10000 rpm. The supernatant was discarded and the pellet resuspended and vortexed in 2 
ml NGM medium. Thereafter, the optical density (OD600) of the bacterial suspension 
was measured against NGM-liquid-media. The anticipated OD600 was 1.0 ± 0.1, which 
corresponds to 8 x 108 bacteria/ ml. 
In a volume of 10 μl M9 buffer about 10 larvae were transferred to each well. To 
each well 44 µl NGM-bacteria-solution were added. Outer wells were spared and filled 
with 200 µl MilliQ H2O to avoid desiccation. Thereafter, nematodes were grown for 
three days protected from evaporation within a cardboard box at 20 ° C and shaking at 
150 rpm. 
In order to investigate the role of the activin and BMP pathway in the 
reproductive outcome of C. elegans mev-1 nematodes, worms were incubated using 
zmp-2-RNAi (Source Bioscience, Cambridge, UK) for dbl-1 (BMP-5 in humans), sma-
2 (Smad-1 in humans), sma-3 (Smad-5 in humans), sma-6 (BMPRIB in humans). When 
grown in zmp-2RNAi-NGM-medium instead of OP50 medium, worms were grown for 
four days. 
2.1.7 Incubation with treatment media and assessment of brood size 
In order to assess the effect of glucose treatment on brood size in mev-1 C. 
elegans nematodes, worms were incubated with RNAi or control NGM-liquid medium 
and treated with either glucose or M9-buffer alone (control) for a period of 24 h. To 
determine a suitable glucose concentration, a pilot experiment using 10 mM or 100 mM 
was carried out. For this, 6 µl of the 100 mM glucose solution (10 mM treatment), 6 µl 
of the 1 M glucose-solution (100 mM treatment) or 6 µl M9-buffer (control) were added 
into the wells of the 96-well microtiter plate. The following day, worms of each 
treatment group were transferred into 15 ml centrifuge tubes containing 7 ml M9-
Tween20 washing buffer. Worms were allowed to settle for 10 minutes, then the 
supernatant was discarded, leaving a remainder of 1 ml. 50 µl of the worm suspension 
were pipetted onto a fresh NGM-OP50-agar plate and air dried for 30 minutes. Brood 
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size was assessed by placing treated or control nematodes in groups of 5 onto individual 
culture plates. The pilot experiment showed no effect of the treatment with 10 mM 
glucose, whereas 100 mM glucose significantly decreased brood size. Hence, 100 mM 
glucose were chosen for all further treatments and a total of 8 plates per treatment group 
were used during each experiment. The examined nematodes were transferred to a new 
well every day for a total of three days. The total number of eggs released on the plates 
was counted. At least 24 independent replicates were performed for statistical purposes. 
2.2 Mouse handling 
Ins2Akita+/- mice were obtained from the Mannheim colony (Mannheim, Germany) 
bred for more than 30 generations on a C57Bl7/6J background. Blood glucose was 
monitored consecutively over the study period. At 8 weeks of age, approximately half 
of these mice had permanent blood glucose levels greater than 14.0 mmol/l and were 
classified as having severely hyperglycaemic, insulin-dependent diabetes according to 
criteria for diabetic ketoacidosis 93. Insulin was occasionally administered 
subcutaneously to prevent critical weight loss. Non-diabetic Ins2Akita+/- mice, defined as 
having on-going blood glucose levels <14.0 mmol/l, were included in all experiments as 
phenotypic controls with an identical genetic background. Adult (12- and 24-week-old) 
male C57Bl/6J mice were obtained from Charles River Laboratories (Sulzfeld, 
Germany) as wild type controls. All animals were housed in groups of 3 to 4 animals 
(Type II macrolon cages) at a temperature of 21±1°C with a 12 h light–dark cycle. At 
the end of experimental period, animals were killed by cervical dislocation under intra-
peritoneal ketamine (75 mg/kg body weight) + xylazine (10 mg/kg body weight) 
anaesthesia. 200 – 500 µl non-fasting blood was collected from the retro-orbital venous 
plexus from all mice and HbA1c was determined as described previously 204. Serum for 
biochemical determinations was generated by whole-blood centrifugation at 1300 rpm 
for 10 minutes. Mice had free access to food and water and were obtained following 
approval from the Animal Ethics Committee, in accordance with German Animal 
Welfare Act for the care and use of laboratory animals and the rules of the regulatory 
authorities in Baden-Württemberg (Regierungspräsidium Karlsruhe, Germany). Unless 
stated otherwise, all reagents were obtained from Sigma-Aldrich Chemie GmbH 
(Seelze, Germany). 
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2.2.1 Tissue Isolation 
12- and 24-week old C57Bl/6J mice as well as 12- and 24-week diabetic and 
non-diabetic Ins2Akita+/- mice were killed by Ketamine-Xylazine euthanasia, followed by 
cervical dislocation. Thereafter, the abdomen was opened and testes and epididymides 
were excised. Generally, one organ was used for immunohistochemistry and processed 
as described in section 2.5, whereas the other organ was snap-frozen in liquid nitrogen 
for further protein or gene analysis as described in section 2.6. 
2.2.2 Sperm analysis 
In order to perform morphological sperm analysis fresh epididymides from 
C57Bl7/6J or Ins2Akita+/- mice were placed in Petri dishes containing 1 ml of high saline 
bicarbonate (HSB) buffer and milked using forceps to release stored sperm. Sperm were 
then incubated at 37°C until assessment of sperm count and sperm morphology 
according to WHO criteria 292 by Dr. Agnieszka Paradowska-Dogan and colleagues, 
which followed shortly after excision. Briefly, 10 µl of the sperm solution were streaked 
onto an objective slide and left to air-dry. Sperm were then stained with Schorr solution 
for morphological evaluation. For this, slides with sperm were incubated in 100 % 
EtOH for 10 min., 70 % EtOH for 1 min., hematoxylin for 10 min. and 30 sec., H2O for 
3 min., 70 % EtOH for 10 sec., 95 % EtOH for 10 sec., Schorr solution for 1 min., 95 % 
EtOH for 10 sec. (twice), 100 % EtOH for 1 sec (three times), and xylol for 5 min. 
(twice). After Schorr staining 100 sperm per sample were evaluated on a cell counter 
(Assistent Counter AC-15, P+W Medizintechnik, Germany). 
2.3 Cell culture 
2.3.1 Primary mouse Sertoli cells 
In order to isolate cells for the primary Sertoli cell culture at the Hudson Institute 
of Medical Research (Melbourne, Australia), C57Bl/6J (from Monash Animal Services) 
mice were killed at 21 days of age by CO2 euthanasia, followed by cervical dislocation. 
Thereafter, the abdomen was opened and testes were excised, placed into DMEM-
medium, and processed as follows. 
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Testes of 21 days old C57Bl/6J mice (n=10 animals per isolation) were 
decapsulated by tearing the tunica albuginea from the tubules using two forceps. 
Tubules were chopped finely with a scalpel blade and placed into a 50 ml centrifuge 
tube. For the first digestion step 5 ml collagenase/DNAse solution (1 mg/ ml 
collagenase) were added. Then the tube was sealed with Parafilm and the tissue was 
allowed to dissociate in a 34ºC water bath for 20 minutes, shaking at 60 cycles/ min. 
The tube was then filled to about 40 ml with Dulbecco's Modified Eagle's Medium 
(DMEM)/F12. The tubules were allowed to settle for 5 minutes and the supernatant 
(containing interstitial cells) was discarded. This washing step was repeated twice for a 
further two times. Thereafter, the tubules were resuspended in 5 ml Trypsin/DNAse 
solution. The tube was sealed with Parafilm and the tubules were allowed to dissociate 
in a 34ºC water bath for 20 minutes, shaking at 60 cycles/ min. During this step the 
tubules dissociated and the intra-tubular cells were set free. Subsequently, 5 ml 
SBTI/DNAse solution were added and the solution was incubated for 5 minutes at RT 
in order to let the cells settle down. The supernatant, containing peritubular cells, was 
collected into a 50 ml centrifuge tube. The cells were washed twice with DMEM/F12, 
every time allowing the cells to settle for 5 minutes and collecting the supernatant, 
containing peritubular cells. 
After the second washing step, the pellet, containing the tubules, was 
resuspended in 5 ml hyaluronidase/DNAse solution. The tube was sealed with Parafilm 
and the tubules were allowed to dissociate in a 34ºC water bath for 15 minutes, shaking 
at 60 cycles/ min. Thereafter, the cells were resuspended gently within this solution 
using a 5 ml pipette. About 10 ml of DMEM/F12 were added to dilute the 
hyaluronidase, followed by centrifugation as described above. The supernatant was 
discarded and the pellet was resuspended in DMEM/F12. The cell suspension was then 
filtered through a 100 µm cell strainer to remove clumps. The filtered solution was 
diluted to 20-30 ml with DMEM/F12 and centrifuged as before. Thereafter, cells were 
resuspended in 1 ml DMEM + 0.1 % BSA. Following this step, Sertoli cells were 
counted within a Neubauer counting chamber, diluted 1:2 with trypan blue. Viable cells 
were counted in 5 squares and calculated as follows: 
 
Cell count x 5 (5 squares counted in a total of 25) x 2 (dilution factor in 
trypan blue) x 104 = X cells/ ml 
 
Material and Methods 
 50 
Following counting, Sertoli cells were resuspended to a concentration of 1x106 
cells/ ml in DMEM + 0.1 % BSA. 500 µl cell suspension (0.5x106 cells) were seeded in 
a 48-well chamber slide and incubated at 37°C with 5 % CO2 for 48 h. The medium was 
aspirated and 300 µl of hypotonic Tris solution (20 mM) were added for 1.5 minutes to 
each well. This would destroy most of the germ cells, leaving mainly Sertoli cells 
within the well. The hypotonic solution was removed and the cells were washed with 
300 µl DMEM and then incubated with 500 µl DMEM + 0.1 % BSA at 37°C with 5 % 
CO2 for 24 h. Thereafter, cells were ready for experimental treatment. These studies 
were performed in accordance with the Australian National Health and Medical 
Research Council Guidelines on Ethics in Animal Experimentation and were approved 
by the Monash Medical Centre Animal Experimental Ethics Committee. 
2.3.2 WL-3 cell line 
WL-3 mouse Sertoli-cells were kindly provided by Dr. Lutz Konrad (Giessen, 
Germany) and were originally established by Mueller and Korach 172. Cells were 
cultured in DMEM-F12 (Thermo Fisher Scientific Inc., MA, USA), supplemented with 
10 % fetal bovine serum (FBS) (Thermo Fisher Scientific Inc.) and 1 % penicillin-
streptomycin (PenStrep) (Thermo Fisher Scientific Inc.). The cells were grown in the 
suspensions at a temperature of 37 °C in 5 % CO2. Before the experiments, cells were 
grown in a single tissue culture flask angled neck and vented cap. Medium was changed 
before the start of each experiment and it was not changed during the treatments. Cell 
viability was assayed with Trypan blue staining. Cell viability was always above 80 %. 
Exposure experiments were repeated in triplicates. 
2.3.3 Dose response experiments 
In order to determine suitable and effective concentrations for the individual 
treatments, dose response experiments on WL-3 and primary Sertoli cells were carried 
out in 48-well plates according to the scheme shown in (Fig. 2-2). All treatments were 
done in triplicates per experiment. Cells were seeded at a confluence of 1.5 x 105 cells/ 
ml in the culture medium and were allowed to attach overnight. For glucose and 
mannose dose responses cells were cultured in glucose free DMEM (Thermo Fisher 
Scientific Inc.) supplemented with 10 % FBS, 1 % PenStrep and 1 mM Sodium-
pyruvate. A stock of 100 mM was used for further dilutions. DMEM-F12 medium 
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served as diluent for testosterone, insulin, and hr-FSH. A stock of 1 mg/ml, 5 mg/ml, 
and 5000 mIU/ml was used for testosterone, insulin, or FSH respectively. Supernatant 
was collected at 24 and 48 h for measurement of the activin A and inhibin levels. 
 
 
Fig. 2-2. Pipette scheme for dose response treatment on Sertoli cells. 
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2.3.4 Measurement of transepithelial resistance (TER) 
For the measurement of TER WL-3 Sertoli cells were plated at 0.25x106 
cells/cm2 at 37°C in Matrigel (BD Biosciences, Bedford, MA)-coated Millicell PCF 
bicameral chambers (12-mm diameter, 0.4 µm pore size, 0.6 cm2 surface area; 
Millipore, Bedford MA) in 24-well culture plates. Culture medium was DMEM/F12, 
supplemented with 10 % FBS and 1 % PenStrep, unless otherwise indicated. WL-3 cells 
were cultured overnight before addition of treatment media. The treatment media was 
glucose free DMEM, supplemented with 10 % FBS, 1 % PenStrep and 1 mM Sodium-
pyruvate. Cells were then cultured at glucose concentrations of either 5 or 25 mM in the 
absence or presence of recombinant activin A (50 ng/ml; R&D Systems, Minneapolis 
MN). Treatments were added to both the basal and apical compartments. All treatments 
were done in triplicates per experiment. To assess inter-Sertoli cell TJ assembly, the 
TER across the Sertoli cell epithelium was quantified using a Millipore Millicell-
electrical resistance system (Merck Millipore, Germany), with measurements taken 
daily at 37°C commencing from the day of treatment (d 0). For this, the cell culture 
plate was placed on a heat pad within the cell culture hood and the cells were allowed to 
adjust for 15 minutes before the first measurement. An electrode was placed into the 
chamber wells, measuring the resistance between the basal and apical compartments. 
Each well was measured three times and the electrode was washed in ethanol, 1X PBS, 
and glucose free medium between wells. 
2.4 RT-PCR 
Reverse transcription combined with the polymerase chain reaction (RT-PCR) 
was used to quantify gene expression in tissue and cell culture samples. 
2.4.1 Principle 
The method of real time PCR was first mentioned in 1993 by Higuchi et al. 113. 
Starting from as little as one copy of a specific gene sequence, the PCR generates copies 
of a DNA template in an exponential manner. This reaction results in a quantitative 
relationship between the amount of starting target sequence and the amount of PCR 
product accumulated at any particular cycle. In order to quantify the resulting PCR 
products double-stranded (ds)DNA-intercalating agents (DNA-binding dyes) (i.e. 
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SYBR® Green 1) are used. These reagents are bound by dsDNA, which results in the 
fluorescence of the reagent. The intensity of the fluorescence signal is dependent on the 
quantity of the dsDNA in the reaction. At the end of each elongation step of each PCR 
cycle fluorescent measurements are performed to monitor the increasing amount of 
amplified DNA 19. 
2.4.2 Protocol 
RNA isolation 
In order to purify total RNA from cultured cell and tissue, samples were 
processed using the RNeasy Mini kit from Qiagen (Qiagen, Hilden, Germany) 
according to the manufacturers instructions. For this purpose, cultured cells were 
harvested and disrupted using RLT-buffer with 1 % β-Mercaptoethanol. Snap-frozen 
tissue (one testis per animal) was homogenized in 1 ml RLT-buffer. The homogeniser 
was sterilized first with RO water and then with 70 % ethanol between each step. 
Homogenised tissue was then centrifuged at 13000 rpm for 10 minutes and the 
supernatant was transferred into a new centrifuge tube. This step was repeated 
(generally three times) until the supernatant appeared clear. 350 µl of the lysate (cells or 
tissue) were then mixed with 350 µl of 70 % ethanol in a 2 ml collection tube. 700 µl of 
the lysis solution were then transferred into an RNeasy spin column and centrifuged for 
1 minute at 13000 rpm. Thereafter, the flow through was discarded and 500 µl of RW1 
buffer were added into the column, followed by centrifugation as described above. 
Following this, the flow through was discarded again and 500 µl of RPE buffer were 
added into the column, followed by centrifugation as described above. Then, the flow 
through was discarded and the sample was washed by adding 500 µl of 80 % ethanol, 
followed by centrifugation as described above. Thereafter, the spin column was placed 
into a fresh 1.5 ml collection tube, 20 µl of RNase free water were added and samples 
were centrifuged for 2 minutes at 13000 rpm. The purified RNA remained now within 
the 1.5 ml collection tube and was stored at -80°C until further processing. 
Finally, prior to translation into cDNA, the RNA yield was quantified using a 
NanoDrop spectrophotometer. Each sample was measured twice to yield a mean RNA 
amount. 
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Generation of cDNA 
In order to generate first-strand cDNA for the use in real-time quantitative RT-
PCR (qRT-PCR) 1 µg of total RNA was reversed transcribed in 20 µl reactions using 
the Superscript III VILO Kit (Invitrogen, Carlsbad, California, United States). 
From the measured RNA yield the amount of sample needed for 1 µg RNA in a 
total volume of 8 µl was calculated as follows: 
 
Amount of sample (1 µg RNA) = 1000/ mean RNA yield in ng/ µl 
Amount of RNase free water (µl) = 8 - Amount of sample (1 µg RNA) 
 
Sample and water were mixed in a 200 µl PCR reaction tube. Then 1 µl of 
DNAse I reaction buffer and 1 µl DNAse I amplification grade was added, followed by 
centrifugation for 8 seconds at 13000 rpm. The following steps were carried out on a 
VWR thermocycler. DNA digestions was carried out at 37°C for 15 minutes. Then, 1 µl 
of 25 mM EDTA was added to the sample, followed by centrifugation as described 
above. Samples were incubated for 25 minutes at 65°C. Finally, a master mix of 4 µl 5x 
First strand buffer + 2 µl 0.1 m DTT + 1 µl 10 mM dNTP mix + 1 µl 0.5 ng/ µl Oligo 
dTs + 1 µl Superscript III was added to the sample, followed by another centrifugation 
step. The reverse transcription was then carried out at 50°C for 50 minutes and 72°C for 
another 15 minutes. 
PCR products were diluted 1:20 (20 µl CDNA + 380 µl RNase free water) in a 
0.5 µl PCR reaction tube. 
 
Primer verification 
Primers were selected using Primer3 and BLAST 181, two programmes, that 
provide primers specific to the PCR template sequence, including primer pair specificity 
checking against a selected database. Desalted primers were diluted with RNase free 
H2O to 10 times of the molecular weight, vortexed, and incubated for 10 minutes. 
Thereafter, equal volumes of the forward and the reverse primer were added into a fresh 
centrifuge tube to make up a 1:1 primer set dilution. For final use, a 1:10 dilution was 
made up of 40 µl 1:1 diluted primer set and 360 µl RNase free H2O. 
Primer efficiency was tested using the slope of a standard curve generated from 
a dilution series (1:5; 1:10; 1:15; 1:20) of 1 µg RNA template concentration from a 
C57Bl/6J testis sample of a 24 week old animal. The log of each concentration (-0,70; -
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1,00; -1,18; -1,30) was then plotted against the Ct value for that concentration. From the 
resulting standard curve the slope was derived and used to calculate the primer 
efficiency37 using the following equation: 
 
Efficiency (E%) = (10(–1/slope) –1)*100 
 
The primer efficiency for each primer used in this work is shown in Table 2-1. 
Table 2-1. Primer sequences. 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) E% 
β-Actin CCTAGGCACCAGGGTGTGAT GCTCGAAGTCTAGAGCAACA 77.5 
ppiA GCAAGCATGTGGTCTTTGGG TTGATGGGTAAAATGCCCGC 64.2 
Inhba GGAGAACGGGTATGTGGAGA TGGTCCTGGTTCTGTTAGCC 84.1 
Inhbb CTGCCAGTGTTTCAGGGTATAA CCTTCACTCCACCAGTCATTT 35.9 
Inha CTCCTTTCCTGGTAGCCCAC CCAAAAACAGGGGCTGAACC 66.8 
FST (total) CCACTTGTGTGGTGGATCAG AGCTTCCTTCATGGCACACT 82.1 
FST 288 CTCTCTCTGCGATGAGCTGTGT GGCTCAGGTTTTACAGGCAGAT 72.0 
FST 315 CTCTCTCTGCGATGAGCTGTGT TCTTCCTCCTCCTCCTCTTCCT 69.1 
Acvr1b CCAACTGGTGGCAGAGTTAT CTGGGACAGAGTCTTCTTGATG 73.3 
Acvr2a GGGACGCATTTCTGAGGATA TCCTGGAGGCATCCTACTCA 75.5 
Acvr2b CGACTTTGTGGCTGTGAAGA TCGTTCCACGTGATGATGTT 47.2 
TNF-α CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC 58.9 
SOX-9 CGGAGGAAGTCGGTGAAGA GTCGGTTTTGGGAGTGGTG 87.4 
IL-1 β CAACCAACAAGTGATATTCTCCATG GATCCACACTCTCCAGCTGCA 90.7 
IL-1α TTCTGCCATTGACCATCT AATCTTCCCGTTGCTTGA 58.3 
IL-10 GCTCTTACTGACTGGCATGAG CGCAGCTCTAGGAGCATGTG 83.8 
FSH-R AAACAGGAGCAGGCTGTGAT 
 
TCTTGGTGTCGCTTGATGAG 
 
- 
Vimentin CAGCAGTATGAAAGCGTGG 
 
GGAAGAAAAGGTTGGCAGAG 
 
- 
Occludin CCAGGTGAGCACCTTGGGAT 
 
TTCAAAAGGCCTCACGGACA 
 
- 
N-cadherin GGAATCCCGCCTATGAGTGG 
 
CGTCTAGCCGTCTGATTCCC 
 
- 
Claudin-11 CTACGTGCAGGCTTGTAGAGC 
 
GGCACATACAGGAAACCAGATG 
 
- 
GATA-4 CACCCCAATCTCGATAT 
 
GCACAGGTAGTGTCCCGTC 
 
- 
ZO-1 GGAGCTACGCTTGCCACACT 
 
GGTCAATCAGGACAGAAACACAG
T 
 
- 
AMH ACCCTTCAACCAAGCAGAGA 
 
CCTCAGGCTCCAGGGACA 
 
- 
AR GCTCAAGGATGGAGGTGCAGT 
 
TAGTCTCCTGCCTCTGCTGTA 
 
- 
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qRT-PCR 
Total RNA was extracted after sampling using the RNeasy Mini Kit from 
Qiagen according to the manufacturer’s instructions. RNA yield was quantified using a 
NanoDrop spectrophotometer (NanoDrop products, DE, USA). Total RNA (1 µg) was 
reversed transcribed in 20 µl reactions using the Superscript III VILO Kit (Invitrogen). 
Real-time PCR amplifications were performed using the IQ SYBR Green Supermix 
(Bio-Rad Laboratories GmbH, Munich, Germany) on the StepOne Plus real-time 
polymerase chain reaction system (Applied Biosystems, Waltham, MA, USA). Each 
well contained 5 µl SYBR Green, 3.2 µl RNase free H2O, 0.3 µl primer (set of forward 
and reverse) and 1.5 µl cDNA template. Cycling conditions were 95 °C for 10 min 
followed by 40 cycles at 95 °C for 15 sec, 60 °C for 30 sec and 72 °C for 30 sec. After 
amplification, a melting curve analysis was performed to analyse the specificity of the 
products using the following conditions: 95 °C for 30 sec, 60 °C for 30 sec followed by 
80 cycles at 60 °C for 10 sec. The expression of each of the genes was measured in 
triplicate for each animal tissue and cell culture sample. PCR signal of the target 
transcript was normalized to the geometric mean of two reference genes. In order to find 
the most suitable reference gene for the analysis, a housekeeping gene panel (Mouse 
housekeeping gene primer set; McLab; Cat#: mHKG-120, MCLAB, USA) was run on 
the testis samples. Evaluation of the panel suggested β-Actin and peptidylprolyl 
isomerase A (ppiA) as the most suitable genes. Thus, both reference genes were used 
within the study with beta-actin giving Ct values of 20.59 ± 1.40 and ppiA giving Ct 
values of 17.56 ± 1.25. In order to reduce the standard deviation of the primers even 
further, the mean of both primers was used with a Ct of 19.02 ± 0.87. PCR signal of the 
target transcript was normalized to the geometric mean of two reference genes and 
expression levels were assessed through relative quantification using the 2-ΔΔCt method 
37. For this the gene expression data was organised in an excel file as shown in Table 
2-2. Briefly, Ct values for β-Actin and ppiA were assessed for each sample in triplicates 
and the geometric mean was calculated. Thereafter, Ct values for each target gene were 
assessed for each sample in triplicates and the mean was calculated. The ΔCt value was 
calculated by subtracting the mean Ct value of the reference genes from the mean Ct 
value of the target gene from each sample. For the wild type control samples a mean 
ΔCt value was generated for each age group to allow the assessment of the fold-change 
in gene expression relative to wild type control transcripts. The ΔΔCt for each sample 
was calculated by subtracting the mean ΔCt wild type control value from the ΔCt value 
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of that sample. The fold change in gene expression levels was then calculated as 2-ΔΔCt. 
In order to normalise the data, the mean fold change was calculated for wild type 
control samples of each age group and the fold change of each samples was then 
divided by that value. 
Table 2-2. Organisation of gene expression data in Excel for 2-ΔΔCt calculation and 
example calculation. 
Age Sample no. Mouse strain Mouse 
number 
Ct β-Actin Ct mean β-
Actin 
Ct ppiA 
12 weeks 1 C56Bl/6J 6 20.88/ 20.03/ 
21.13 
20.68 17.01/ 16.48/ 
16.86 
Ct mean 
ppiA 
pooled Ct of 
β-Actin and 
ppiA 
Ct target 
gene 
Ct mean 
target gene 
ΔCt to mean 
HKG 
mean ΔCt 
wild type 
control 
ΔΔCt 
 
16.78 18.73 32.27/ 31.55/ 
31.40 
31.74 13.01 11.82 1.19 
2-ΔΔCt (fold 
change) - 
mean HKG 
mean fold 
change 
Normalised 
fold change 
mean norma-
lised fold 
change 
SD norma-
lised fold 
change 
Grubbs G 
value 
 
1.41 6.02 0.23 1.00 1.41 0.54  
 
After assessment of the 2-ΔΔCt value, normalised data were analysed for 
normality distribution using the Shapiro-Wilk normality test (see section 2.7). When 
normal distribution was confirmed, data was corrected for outliers using the Grubb’s 
test. For this, the mean and the standard deviation (SD) of the normalised fold change 
were calculated for each group and the respective Grubb’s value was calculated with the 
following equation: 
 
Grubb’s value = (mean normalised fold change of the respective group - 
normalised fold change of the sample)/ SD of the 
normalised fold change of the respective group 
 
Outliers were then identified according to the number of animals in the 
respective group. Data are expressed as the fold-change in gene expression relative to 
wild type control transcripts. 
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2.5 Histology and Immunohistochemistry 
2.5.1 Fixation, sectioning, and staining of organs 
Whole-mouse testes were fixed in Bouin’s fluid for 8 h (C57Bl/6J wild type 
controls) or, after optimization according to Fig 11, 24 h (Ins2Akita+/-). The separated 
epididymides were fixed for 4 h in 3.7 % paraformaldehyde. Tissues were dehydrated in 
a graded series of ethanol as follows: 80 % EtOH for 30 min., 96 % EtOH for 45 min., 
99.6 % EtOH for 45 min., EBE I for 60 min., EBE II for 60 min., EBE III for 30 min., 
and EBE IV for 30 min. Thereafter tissues were kept in paraffin (46°C – 48°C) 
overnight at 50°C, followed by 2 h at 46°C the next day before they were embedded in 
paraffin. 5 μm thick sections were processed for Harris’ hematoxylin or antibody 
staining. 
Prior to antibody staining sections were de-paraffinised and rehydrated as 
follows: 5 min. Rotihistol I, 5 min. Rotihistol II, 2x3 min. 99.6 % EtOH, 2x3 min. 96 % 
EtOH, 2x3 min. 70 % EtOH, 3 min. RO water. 
Thereafter antigen retrieval was carried out using citrate buffer. Localization of 
the Sertoli cell marker protein SRY-Box-9 (SOX-9) was performed using a polyclonal 
ChIP Grade antibody (diluted 1:300, ab3697, Abcam, Cambridge, U.K.). goat-anti-
rabbit IgG was used as secondary antibody (diluted 1:500, Vector Laboratories, CA, 
USA). The sections were counterstained with Harris’ haematoxylin and mounted under 
DPX. To localize the βA-subunit of activin (mouse monoclonal antibody (E4), diluted 
1:100, supplied by Oxford Brookes University, Oxford, U.K.) 138, sections were de-
paraffinised and rehydrated as described above prior to antigen retrieval using the 
mouse-on-mouse-HRP-polymer-bundle kit according to the manufacturers instructions 
(ZYTOMED Systems GmbH, Berlin, Germany). The sections were counterstained with 
Harris’ haematoxylin and mounted under DPX (BDH Laboratory Supply, Poole, U.K.). 
Cell death was analysed using the TUNEL (TdT-mediated dUTP-biotin nick end 
labelling) assay (Millipore, Merck KGaA, Darmstadt, Germany) on paraffin-embedded 
testis sections according to the manufacturers instructions. Specific signal was 
visualized by treatment with sheep peroxidase-conjugated anti-digoxigenin antibodies 
(Vectastain® Elite ABC Kit, Vector Laboratories, CA, USA) followed by 
diaminobenzidine (DAB) development. Both the evaluation of the staining and the 
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measurement of seminiferous tubule diameter were done using ImageJ software (open 
source image processing program) 233. For the determination of the seminiferous tubule 
diameter all tubules within one testicular cross-section were selected for the analysis. 
 
Fig. 2-3. Fixation optimization for Ins2Akita+/- testis. 
 
Using hematoxylin stained testicular sections, the state of spermatogenesis in the 
seminiferous tubules was evaluated by the spermatogenesis index (SI) using the 
Johnsen’s score 127, adapted for the mouse testis 140. For this, serial light microscopic 
pictures from each testis sample were taken at a 10x magnification. Using ImageJ a 
stationary grid with 11x9 squares was applied to each picture and a fixed area of 5x5 
squares was marked in which tubules were counted (Fig. 2-4). A Score from 1 to 10 was 
given to each tubule cross-section according to the cell types present. Score 1: No cells 
present in tubule cross-section; Score 2: Sertoli cells only; Score 3: Sertoli cells and 
spermatogonia only; Score 4: Sertoli cells, spermatogonia, few spermatocytes and no 
spermatozoa or spermatids; Score 5: Only spermatids and spermatozoa absent; Score 6: 
Only spermatozoa absent, but few spermatids; Score 7: Only spermatozoa absent, with 
numerous spermatids; Score 8: Reduced spermatozoa only; Score 9: Numerous 
spermatozoa present in lumen, but seminiferous epithelium disorganized; Score 10: 
Complete spermatogenesis with numerous spermatozoa. 
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Fig. 2-4. Assessment of the Johnsen score in mouse testicular tissue sections using 
ImageJ. 
Example picture for the assessment of the Johnsen score in mouse testicular tissue 
sections. An area of 5x5 squares was evaluated per picture. Scale = 100 µm. 
2.6 Protein methods 
2.6.1 Lysis of tissue and cells and protein concentration determination 
Tissues (testes or epididymis) were excised and kept at 4°C (if homogenized 
immediately) or frozen in liquid nitrogen and stored at -80°C until needed. All steps of 
the tissue lysis were conducted on ice. For this purpose an Eppendorf tube was weighed 
and zeroed. Then the tissue was added into the Eppendorf tube and weighed and tissue 
weight was recorded. Thereafter a Protease Inhibitor Cocktail (Sigma, P8340) was 
mixed with cold PBS (0.01 M, pH 7.4) at a dilution of 1:200 and was then added at a 
volume 10 times the wet weight of the tissue onto the tissue contained in an Eppendorf 
tube. The tissue was then homogenized at low speed for about 20 seconds (B. Braun 
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Potter S, Sartorius, Germany). After each sample the probe was washed with 70 % 
EtOH and then PBS. The homogenised tissue was then centrifuged at 13000 rpm at 4°C 
for 10 minutes and the supernatant was frozen at -20°C until measurement. 
From the cell culture samples, the treatment medium was collected into 1.5 ml 
Eppendorf tubes and kept frozen at -20°C until measurement. Adherent cells were 
washed with PBS and then lysed using RIPA buffer + Protease/Phosphatase Inhibitor 
(dilution 50:1) (Cat# 539134, Calbiochem, Merck, Germany) per well for 5 minutes. 
The lysate was then transferred into a 1.5 ml Eppendorf tube and centrifuged at 13000 
rpm for 30 min at 4°C. The remaining supernatant was collected into a fresh 1.5 ml Epi 
and stored at -80°C until analysis. 
 
The PierceTM BCA protein assay kit (#23225, Pierce Biotechnology, IL, USA) 
was used to measure total protein concentrations according to the manufacturer’s 
instructions for the microplate procedure. Briefly, diluted bovine serum albumin (BSA) 
standards were prepared according to the scheme shown in Table 2-3. The working 
reagent (WR) was prepared by mixing 50 parts of BCA Reagent A with 1 part of BCA 
Reagent B (50:1, Reagent A:B). Thereafter 25 µl of each standard or unknown sample 
were pipetted in duplicate into a well of a 96-Well plate (Thermo Fisher Scientific Inc.). 
200 µl of the WR were added to each well and the plate was mixed thoroughly on a 
plate shaker (Ratek Instruments, Australia) for 30 seconds. Thereafter, the plate was 
covered and incubated at 37°C for 30 minutes. Finally, the plate was allowed to cool to 
RT prior to measurement of the absorbance at or near 562 nm on a plate reader 
(Benchmark microplate reader, Bio-Rad Laboratories). 
Table 2-3. Preparation of diluted albumin (BSA) standards. 
Vial Volume of diluent 
(MilliQ) (µl) 
Volume and Source of 
BSA (µl) 
Final BSA 
Concentration 
(µg/mL) 
A 0 300 of stock 2000 
B 125 375 of stock 1500 
C 325 325 of stock 1000 
D 175 175 of vial B dilution 750 
E 325 325 of vial C dilution 500 
F 325 325 of vial E dilution 250 
G 325 325 of vial F dilution 125 
H 400 100 of vial G dilution 25 
I 400 0 0 = Blank 
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2.6.2 Milliplex MAP Kit assay 
The MILLIPLEX MAP Human TGFβ Signaling Magnetic Bead Panel 6-plex 
(Cat# 48-614MAG, Merck Millipore), was used in order to detect changes in 
phosphorylated Smad2 (Ser465/Ser467), phosphorylated Smad3 (Ser423/Ser425), ERK 
(Thr185/Tyr187), and Akt (Ser473), as well as total protein levels of TGFbRII and 
Smad4 in tissue lysates using the Luminex® system (Luminex Corporation, TX, USA). 
 
Principle 
The MILLIPLEX MAP method is based on the Luminex® xMAP® technology, 
which uses colour coded magnetic beads that are coated with specific detection 
antibodies. Hence, analytes within test samples are captured by the bead. Thereafter, a 
biotinylated detection antibody is introduced and incubated with a Streptavidin-PE 
conjugate, in order to complete the reaction on the surface of each microsphere. When 
the microspheres are illuminated, the internal dyes fluoresce. A second illumination 
source then excites the Streptavidin-PE conjugate. Finally, high-speed digital-signal 
processors identify each individual microsphere and quantify the result of the bioassay 
based on fluorescent reporter signals. 
 
Protocol 
In order to start the Milliplex procedure, the reagents for the immunoassay were 
prepared. Firstly, the TGFβ Signaling magnetic beads (20X) stock solution was 
sonicated for 15 seconds and vortexed for 30 seconds. Beads were diluted to 1X by 
combining 0.150 mL beads with 2.85 mL of MILLIPLEX MAP Assay Buffer 2 using 
one of the Mixing Bottles provided. The captured 1X beads were vortexed for 15 
seconds. 
Secondly, the Biotin-Labelled Detection Antibody and Streptavidin-PE were 
prepared. For this, the 20X Detection Antibody stock was vortexed for 10 seconds, and 
briefly centrifuged thereafter. The Detection Antibody was then diluted to 1X by 
combining 0.150 mL of Detection Antibody with 2.85 mL of MILLIPLEX MAP Assay 
Buffer 2 using one of the Mixing Bottles provided. The MILLIPLEX MAP 
Streptavidin-Phycoerythrin (SAPE) 1:25 was vortexed for 10 seconds, before diluting it 
by combining 0.120 mL of Streptavidin-Phycoerythrin with 2.88 mL of MILLIPLEX 
MAP Cell Signaling Assay Buffer 2 using one of the Mixing Bottles provided. 
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Lastly the lyophilized MILLIPLEX MAP Cell Lysates (Catalogue # 47-229, 47-
235, 47-216) were prepared, by reconstituting each of the lyophilized cell lysates in 100 
μl of ultrapure water. This yielded 100 μl of lysate at a total protein concentration of 2 
mg/mL for each vial. Then the lysates were vortexed and incubated for 5 min at RT 
(stored on ice). Thereafter, 150 μl of MILLIPLEX MAP Assay Buffer 2 were pipetted 
to each cell lysate vial and vortexed again. 
 
After the preparation of the reagents for the immunoassay, the assay was started 
following the manufacturers instructions for the 96-well Plate and Hand-held Magnetic 
Separation Block. Hence, 10 µg of Protein from each sample were diluted in 
MILLIPLEX MAP Assay Buffer to make up a total volume of 25 µl. Then, 50 μl of 
Assay Buffer were added into each well of the plate. The plate was covered and mixed 
on a plate shaker for 10 minutes at RT (20-25°C). The Assay buffer was decanted and 
residual liquid was removed by inverting the plate and tapping it smartly onto absorbent 
towels several times. Then the 1X bead suspension was vortexed for 10 seconds before 
25 µl were added to each well. Then 25 μl of Assay Buffer, reconstituted control cell 
lysates, and sample lysates were added to appropriate wells and incubate overnight at 2-
8°C on a plate shaker (600-800 rpm) protected from light. On the following day the 
plate was shaken for 10 min (RT) (20-25°C) before it was attached to the handheld 
magnetic separation block to plate, allowing 60 seconds for beads to settle, and the 
samples and controls were then decanted. Thereafter, the plate was removed from the 
magnetic separation block and washed with 100 μl Assay Buffer per well. The washing 
buffer was decanted as described above. This was repeated for a total of two washes. 
Then, 25 μl/well of 1X MILLIPLEX MAP Detection Antibody were added, the plate 
was sealed, covered with the lid and incubated with agitation on a plate shaker for 1 
hour at RT. Thereafter, the Detection Antibody was decanted as described above. For 
the detection 25 μl of 1X MILLIPLEX MAP SAPE were added to each well, the plate 
was sealed, covered with the lid and incubated with agitation on a plate shaker for 15 
minutes at RT. Then 25 μl of MILLIPLEX MAP Amplification Buffer were added to 
each well and incubated for another 15 minutes as described before. Lastly, SAPE 
/Amplification buffer was decanted as described before and the beads were suspended 
in 150 μl of MILLIPLEX MAP Assay Buffer, and mixed on plate shaker for 5 minutes 
before analysis using the Luminex® system. 
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2.6.3 Radioimmunoassay (RIA) 
Method background 
Solomon Berson and Rosalyn Yalow from the Veterans Administration Hospital 
in New York first described RIA, or Radioimmunoassay, in 1960 for the measurement 
of endogenous plasma insulin. This method is a very sensitive technique, which uses 
radioactive labelled proteins and specific antibodies in order to detect antigens 47,149. 
 
Test principle 
In order to detect proteins by RIA either a competitive or a solid phase RIA can 
be used. Within the competitive RIA (i.e. FST, LH, FSH or Inhibin) a constant 
concentration of 125I-Antigen (highly purified Inhibin, FST, LH, or FSH) and varying 
concentrations of unlabelled standard antigen or sample antigen compete for binding 
specifically to the antiserum. Here, immunocomplexes are precipitated after adding a 
secondary polyclonal antiserum followed by centrifugation. Unbound reagents are 
removed and the pellet is counted in a gamma counter. Within the solid phase RIA (i.e. 
testosterone), the specific antibody is adherent to the wall of the tube in which the assay 
is performed. The labelled tracer and the unlabelled antigen are added and compete for 
specific binding to the antiserum. The unbound fraction is pipetted off and the tubes are 
counted in the gamma counter. For both methods the standard curves are S-shaped 
(B/Bo plot) and are mathematically linearized by using a Log-Logit transformation, 
with LOGIT=Log(% Bound) / 100 - % Bound 47. 
 
Protocol 
To measure the concentrations of testosterone all samples were assayed in 
duplicates within a single assay using a direct testosterone RIA kit, following the 
manufacturer’s instructions (RIA testosterone direct, Ref#IM1119, Beckman-Coulter, 
Inc., CA, USA). The lower limit of detection was 0.05 ng⁄ mL and the intra-assay 
variation was 8.5 %. 
LH in serum was determined by a double-antibody radioimmunoassay using 
rLH-I-8 (AFP- 12066B) labelled with 125I using the IODOGEN method for iodination. 
The hormone concentration was calculated using the mouse LH reference preparation 
(AFP-5306A) as the standard. Briefly, standards were prepared from mouse LH (AFP-
5306A) (0.20 – 12.5 ng/ml) by preparing serial dilutions from a 25 ng/ ml stock 
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solution. Quality controls were rat LH RP-2 (QC1; dilutions 1:10, 1:20, 1:40, 1:80 
prepared from a 30 ng/ ml stock solution), Hypox (QC2), mouse (QC3), female rat 
(QC4), rat 2015 (QC5), Wistar rat (QC6), Wistar rat + spike (QC7). 40 µl of standards, 
quality controls, and samples were added into tubes respective tubes in duplicates, 
followed by the addition of 40 µl assay buffer (0.01 M PBS (pH 7.4) + 0.5 % BSA) to 
all tubes (except total counts). Then, 40 µl of normal rabbit sera (Cat# 16120099, 
Thermo Fisher Scientific) were added to non-specific binding samples and blanks, 
while antisera (AFP-240580; 1:187.500 in 1:800 normal rabbit sera) was added to all 
remaining samples (except for total counts). The assay was incubated overnight at RT. 
The following day, 40 µl of tracer (9000 cpm/ 40µl) was added to all tubes and 
incubated overnight at RT. The next day, 40 µl of secondary antibody (goat anti rabbit 
IgG (GAR), GAR#12, MIMR, Monash University, diluted 1:40) were added to all 
samples (except for total counts). Then, 40 µl of serum from an hypophysectomised 
sheep (serum ovine hypox sera, Monash University, Australia) were added to standards 
and blanks, while 40 µl of assay buffer were added to neat samples. The assay was 
incubated overnight at 4°C. Lastly, 1.5 ml of saline were added to all tubes (except for 
total counts) before centrifugation at 2500 rpm for 30 minutes at 4°C. Before counting 
on a gamma counter (GENESYS LTI, Laboratory Technologies, USA) tubes were 
tipped and drained for approximately 5 minutes. The lower limit of detection was 0.092 
ng⁄ mL and the intra-assay variation was 7.6 %. 
FST concentrations in mouse tissue homogenates were measured using a 
discontinuous RIA, as described previously 188, which detects “total” follistatin using a 
dissociating reagent that dissociates the activin–follistatin complex. The reagent has a 
working concentration of 20 % Tween-20 (Sigma), 10 % sodium deoxycholate (Pierce, 
Rockford, IL, USA), 0.4 % Sodium Dodecyl Sulphate (SDS Ultrapure Applichem), and 
0.1 % sodium azide (BDH, Poole, Dorset, UK) prepared in Milli-Q water (TDS 
reagent). The antiserum (#204) was raised in rabbits against purified 35 kDa bovine 
follistatin. Human recombinant (hr) FS288 (AF Parlow NHPP Torrance, CA, USA) was 
used as Standard and Tracer, iodinated using Iodogen reagent (Pierce, Rockford, IL, 
USA). Immune complex precipitation was achieved using GAR. 
The assay buffer was 0.01 M PBS containing 0.5 % BSA (Sigma A7906) and 
the samples were diluted appropriately in this buffer. Standard, Quality Controls and 
Samples were incubated with TDS reagent and the Antiserum (#204 1:8000 diluted in 
assay buffer with 1:1000 normal rabbit serum (NRS) (GIBCO) overnight at RT. Sample 
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and Buffer Blanks had no antisera added - only 1/1000 NRS. On day 2, the tracer was 
added at 10 000 cpm/50 µl in assay buffer and the assay incubated again overnight at 
RT. On day 3, 50 µl of second antibody GAR in assay buffer containing 0.05 M EDTA 
(BDH) was added. The assay was incubated for 3 hours at RT then 1.5 ml cold 0.9 % 
saline was added and the tubes were centrifuged in a Beckman Coulter JM19 at 2500 
rpm for 35 minutes at 4ºC. The supernatant was decanted and the pellets counted on a 
Cobra 5005 gamma counter (Packard Instrument Co., Meriden, CT). A pool of mouse 
testis homogenate diluted in a dose-dependent manner was run parallel to the standard 
curve (data not shown). The Intra-assay %CV was 9.5 % and the Inter Assay CV% was 
9.2 % (n=2) and the range of detection was <1.40 ng/ml (Effective dose (ED) 90) and 
>76 ng/ml (ED10). 
Inhibin α-subunit-containing proteins were measured using a heterologous 
equilibrium RIA, as described previously 218, using a hr-inhibin standard and iodinated 
hr-inhibin as the tracer. The antiserum was raised in rabbits against bovine 31-kDa 
inhibin (#1989) directed to the inhibin alpha subunit and detects both dimeric inhibin A 
and inhibin B as well as free inhibin alpha subunit. GAR was used as second antibody. 
Gelding Sera was added back to the assay after the 2nd antibody. Samples and standards 
and QC’s were diluted with assay buffer (0.5 % BSA-PBS). Male and Female Mouse 
Sera and various tissue homogenates have shown parallelism in this assay – assessed by 
comparison of slope values, and the recovery of spiked mouse samples was acceptable. 
Testicular Extracts and sera from inhibin knockout mice were measured and found to 
have no inhibin present using this assay. 
Briefly, standards were prepared from human inhibin standard (0.3125 – 10 
ng/ml) by preparing serial dilutions from a 10 ng/ ml stock solution. Quality controls 
were bovine follicular fluid (450IC), rat ovarian extract, RP – human male sera (low 
inhibin), mouse sera (medium – high inhibin), mouse testis homogenate pool. 
Samples were assayed in 50 µl duplicates at a 1:2 dilution plus 50 µl antibody 
and processed by adding all solutions, except the 2nd Antibody, to the tube, followed by 
an overnight incubation. Then 2nd Ab/sera and 6 % PEG (polyethylene glycol) were 
added and left for a couple of hours, before centrifugation and counting. The average 
Intra Assay CV was 6 % (n=1). The lowest limit of detection was 0.25 ng/ml (ED90) 
and the limit of reading 20.61 ng/ml  (ED10) read against a Human Inhibin Standard. 
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The RIA dose-response curves were linearized by logit log-dose transformation 
and analysed by parallel line statistics 50. The sensitivity of the RIA's was based on the 
mean ED10 value of the standard curve. 
2.6.4 Enzyme-linked immunoabsorbent assay (ELISA) 
Method background 
Based on the RIA method Peter Perlman and Eva Engvall conceptualized the 
ELISA, or Enzyme-linked immunoabsorbent assay, at Stockholm University in Sweden. 
This method differs from RIA by using enzyme rather than radioactive reporter labels 
and was first published in 1971, demonstrating a quantitative measurement of IgG in 
rabbit serum with alkaline phosphatase as reporter label 149. 
 
Test principle 
The ELISA method uses the quantitative sandwich-immunoassay technique. 
Therefore, a 96-well plate is coated with an immobilised, monoclonal antibody against 
the desired protein. A respective protein standard as well as the samples are pipetted in 
duplicates onto the plate. Hence, the protein contained in the standard or sample will 
bind to the immobilised, monoclonal antibody. Remaining unbound components are 
being removed by repeated washing steps. Within the next step, a substrate labelled 
detection antibody against the desired protein is pipetted into each well. After further 
washing to remove unbound antibody reagents the substrate is added and colour 
develops according to the protein content in the standard or sample. Finally, the colour 
development will be stopped and the optical density is measured using a photometric 
ELISA reader. The standard curve allows calculating the concentration of the samples 
assayed. Evaluation and calculation of the protein concentration from the ELISAs was 
done using the Genesis software (GENESYS LTI Laboratory Technologies). 
 
Protocol 
Activin A was measured using a specific ELISA 138 according to the 
manufacturer’s instructions (Oxford Bio-Innovations, Oxfordshire, U.K.) with some 
modifications as described previously 188. This assay measures total activin A. The 
coating antibody E4 (1.3 mg/ ml) was diluted in carbonate buffer (pH 9.6) for a total 
concentration of 650 ng/ 100 µl. A volume of 100 µl was added onto a 96-well plate 
Material and Methods 
 68 
and incubated overnight at RT in a humidified box. The following day, the plate was 
washed with PBS and 0.05 % Tween 20 (Sigma-Aldrich) using an automated plate 
washer (Wellwash 4 Mk 2, Thermo Electron Corporation, Finland) and 300 µl blocking 
buffer (1 % BSA-Tris HCl) were added to each well and incubated for 1 hour. The 
recombinant activin A standard (1 ng/ 25 µl) 217 was diluted in 5 % BSA-PBS for tissue 
samples or in media blank for cell culture samples according to the scheme shown in 
Table 2-4. 
Table 2-4. Preparation of recombinant activin A standards. 
Vial Volume of diluent (µl) Volume and Source of 
activin A (µl) 
Final activin A 
Concentration 
(pg/mL) 
A 475 25 stock (1 ng) 2000 
B 200 100 of vial A 666,67 
C 200 100 of vial B 222,2 
D 200 100 of vial C 74,074 
E 200 100 of vial D 24,691 
F 200 100 of vial E 8,230 
G 300 0 0 = Blank 
 
Tissue samples were diluted in 5 % BSA-PBS and media samples were assayed 
neat. 125 µl sample or tissue were pipetted into a glass tube and a 6 % SDS solution in 
0.05 M PBS was added (3 % final concentration) followed by boiling for 3 minutes. 
The samples were allowed to cool before the addition of 20 µl 30 % H2O2 (2 % final 
concentration, Emsure Iso Hydrogen Peroxidase 30%, Merck KGaA, Germany) and 
subsequent 30 min incubation. The E4 (anti-βA-subunit) monoclonal antibody-coated 
plate was washed and plated with 25 µl of 20 % BSA-Tris Triton buffer prior to the 
addition of 100 µl standard or sample in duplicates. Thereafter, the plate was incubated 
with shaking (Ratek Instruments, Australia) for 1 hour at RT, before the addition of 25 
µl detection antibody (E4-Biotin B in 5 % BSA-Tris Triton, 1:600) and incubation 
overnight at RT in a humid box. The next day, the plates were washed and 100 µl of 
poly HRP Streptavidin conjugated to Poly-Horseradish Peroxidase (HRP) 
(#M2051, Sanquin, Netherlands) was added to the wells and incubated at RT for 1 h. 
The poly HRP is made up in a 1 % Casein Colloid Buffer solution (#M2052, Sanquin) 
supplied with a 5 % solution (diluted 1/5 with PBS). After further washes, 100 µl of 
tetramethylbenzidine (TMB, Thermo Fisher Scientific Inc.) peroxidase substrate 
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solution (Invitrogen) was added to all wells and incubated shaking for 15–25 min at RT. 
Finally, 50 µl of 0.3 M HCL was added to stop the colour development and the 
absorbance values of each well were measured using an automated microplate reader 
(Benchmark microplate reader, Bio-Rad Laboratories, Hercules, CA, USA) with 
compatible software (Microplate Manager 5.2, Bio-Rad Laboratories), using a 
measurement wavelength of 450 nm and a reference wavelength of 620 nm. The limit 
of detection was 14.1 pg/mL and the average intra-assay CV was 4.0 %. 
Activin B was measured using a specific ELISA 157 according to the 
manufacturer’s instructions (Oxford Bio-Innovations) with some modifications and 
used a human recombinant Activin B standard. The coating antibody 46A/F (3.9 mg/ ml 
in PCS + azide) was diluted in carbonate buffer (pH 9.6) for a total concentration of 25 
µg/ 10 ml. A volume of 100 µl was added onto a 96-well plate and incubated overnight 
at RT in a humid box. The following day, the plate was washed using an automated 
plate washer (Wellwash 4 Mk 2, Thermo Electron Corporation, Finland) and 300 µl 
blocking buffer (1 % BSA-PBS + 6 % sucrose) were added to each well and incubated 
for 1 hour. The recombinant human activin B standard (1.25 ng/ 25 µl) 157 was diluted in 
5 % BSA-PBS for tissue samples or in media blank for cell culture samples according 
to the scheme shown in Table 2-5. 
Table 2-5. Preparation of recombinant activin B standards. 
Vial Volume of diluent (µl) Volume and Source of 
activin B (µl) 
Final activin B 
Concentration 
(pg/mL) 
A 475 25 stock (1,25 ng) 2500 
B 200 100 of vial A 833,3 
C 200 100 of vial B 277,8 
D 200 100 of vial C 92,59 
E 200 100 of vial D 30,86 
F 200 100 of vial E 10,288 
G 300 0 0 = Blank 
 
For optimal recovery, tissue and media samples were diluted in PBS containing 
5 % BSA at a dilution of 1 in 2. All diluted fluids and standards (150 µl) were mixed 
1:1 with 150 µl 6 % SDS in water. Samples and standards were boiled for 3 min, and 
cooled for 10 min before 50 µl Triton assay diluent (TAD, Pierce, Rockford, IL, USA) 
made up in 500 ml 25 mm Tris, 0.15 m NaCl, pH 7.2, including 10 % BSA, 5 % Triton 
X-100 and 0.1 % sodium azide was added to samples and standard tubes. 50 µl of 
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freshly diluted biotinylated detection antibody 46A/F in TAD (1:800 to a final 
concentration of 0.5 µg/ml) was added to each well. Thereafter, 100 µl sample or 
standard was added to each well in duplicate, and the plate was incubated at RT for 1.5 
h. The wells were washed with PBS and 0,05% Tween 20. Then 100 µl/well of freshly 
diluted streptavidin poly horseradish peroxidase (HRP, Mast Group Ltd, Bootle, 
Merseyside, UK) at 0.25 µg/ml in 1 % casein (1:4000) (Mast Group Ltd) was added for 
1 h at RT. Wells were then washed with PBS and 0.05 % Tween 20. 100 µl of 
tetramethylbenzidine (TMB, Thermo Fisher Scientific Inc.) peroxidase substrate 
solution (Invitrogen) was added for 15–25 min at RT. The reaction was stopped by 
adding 100 µl/well of 0.3 M phosphoric acid. The absorbance values of each well were 
measured using an automated microplate reader (Benchmark microplate reader, Bio-
Rad Laboratories) with compatible software (Microplate Manager 5.2, Bio-Rad 
Laboratories), using a measurement wavelength of 450 nm and a reference wavelength 
of 620 nm. The limit of detection was 23.0 pg/mL and the average intra-assay CV was 
4.1 %. 
IL-6 concentration in whole testis and epididymis was determined according to 
the manufacturers instructions using the BD OptEIATM ELISA assay (555240, BD 
Biosciences Pharmingen, USA). 
2.6.5 Western Blot 
Method background 
The Western blot or protein immunoblot was originally introduced in 1979 by 
Tobwin et al. and is an analytical technique used to identify specific proteins in tissue 
homogenates or extracts. Since then, Western blotting has become a common technique 
used in research laboratories worldwide for the immunodetection and quantitation of 
specific proteins in complex cell homogenates 269. 
Test principle 
In order to identify specific proteins the Western Blot method uses gel 
electrophoresis to separate proteins based on size. Thereafter, the gel is placed onto a 
membrane made of nitrocellulose or PVDF (polyvinylidene fluoride) onto which the 
proteins are transferred through an electrical current. In the final step, the membrane can 
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be further processed with specific antibodies to identify the target of interest, which is 
then visualized using secondary antibodies and detection reagents 59,269. 
Protocol 
The SDS–PAGE (SDS-polyacrylamide gel electrophoresis) was performed 
according to Laemmli (1970). The gel was made of 8 % SDS stacking gel and 10 % 
SDS separating gel as described below (Table 2-6). In order to enable access of the 
antibodies to all parts of the protein it is necessary to unfold it. Therefore, the samples 
were dissolved in 4x Laemmli buffer and RO H2O and boiled for 5 min at 95°C to 
generate reduced, denatured proteins. Thereafter, the samples were centrifuged briefly 
before loading onto the gel. Per sample 30 µg of protein were loaded into each well. 
The electrophoresis was performed in 1x running buffer at 35 mA for about 80 minutes. 
When the dye molecule (“migration front”) reached the bottom of the gel, the power 
was turned off. Thereafter, the gel was immediately preceded for transfer. Prior to wet 
transfer, PVDF membranes were soaked in methanol for 10 minutes, rinsed with RO 
H2O and then soaked in 1x transfer buffer for 10 minutes. Concurrently, sponges and 
Whatman papers were soaked in 1x transfer buffer. Subsequently, samples were 
electrophoretically transferred from the gel onto a PVDF membrane. For this, the gels 
were first equilibrated in transfer buffer for 5 minutes and then placed in a sandwich 
cassette built up of the following: sponge, four layers of blotting paper, protein gel, 
PVDF membrane, three layers of blotting paper, sponge. The sandwich cassette was 
placed into a blotting chamber and submerged with ice-cold 1x SDS-free transfer 
buffer. The wet transfer was performed at 95 V for 80 minutes at 4°C. 
In order to confirm the transfer of the proteins onto the membrane, it was stained 
for 10 min with Ponceau S stain. To visualize the proteins, the membrane was briefly 
washed with RO H2O and to remove the dye the membrane was incubated in PBS-T. 
Following this, the membranes were placed into a 120 ml container (Sarstedt, 
SA, Australia) and rinsed with 1x PBS. To prevent non-specific background binding of 
the primary and/or secondary antibodies the membrane was blocked for 1 hour at RT in 
Odyssey® blocking buffer. Subsequently, the primary antibody was incubated for 1 
hour at RT, followed by rinsing in 1x PBS and washing with PBS-T three times for 5 
minutes to remove residual primary antibody. Thereafter, the secondary antibody was 
incubated for 1 hour at RT followed by washing as described above to remove residual 
secondary antibody. 
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All antibodies were diluted in Odyssey® blocking buffer + 0.1 % Tween 20 at 
the dilutions given in Table 2-7. 
Finally, the proteins were detected using the Odyssey® imaging system (LI-
COR®). For quantification, the intensities of the total protein were normalised to β-
tubulin. 
Table 2-6. Preparation of SDS-PAGE gels. 
Stock solution  8 % stacking gel (ml) 10 % separating gel (ml) 
30 % (w/v) acrylamide 0.83 5 
1.5 M Tris-HCl pH 8.8 - 3.75 
1 M Tris-HCl pH 6.8 0.63 - 
10 % SDS 0.05 0.15 
10 % APS 0.05 0.15 
TEMED 0.005 0.015 
RO H2O 3.4 5.93 
Table 2-7. List of Western blot antibodies. 
Antibody Product number Company Dilution 
Beta-tubulin ab21057 Abcam, MA, USA WB: 1:3000 
Smad4 ab137861 Abcam, MA, USA WB: 1:300 
IRDye800CW 
(donkey anti goat IgG) 
925-32214 LI-COR, NE, 
USA 
WB: 1:15000 
IRDye680RD (goat 
anti rabbit IgG) 
925-68071 LI-COR, NE, 
USA 
WB: 1:15000 
2.7 Statistical analysis 
Raw data from the project was entered using MS Excel® for Mac and the thesis 
manuscript was generated using MS Word® for Mac (Microsoft Office for Mac, 
version 2011, Microsoft Corporation, WA, USA). 
 
Statistical analysis was performed using Graph Pad Prism 6 (GraphPad Software Inc., 
CA, USA). Values in tables and graphs are expressed as mean ± SEM (unless otherwise 
specified). Data were checked for normality of distribution using the Shapiro-Wilk 
normality test. Where data showed normal distribution unpaired t-test was performed 
for comparison between two groups and two-way ANOVA was used to test the effect of 
diabetes between several groups when multiple time-points were considered. Where the 
overall ANOVA showed significant differences among means, Tukey’s post-hoc 
comparisons between treatments were performed. When one or more groups failed the 
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normality test, samples were analysed using the Kruskal-Wallis test. Where the 
Kruskal-Wallis test showed significance, Dunn's post-hoc comparisons between 
treatment and controls were performed. To test the correlation between two parameters 
Pearson correlation analysis was performed for normally distributed data. P value <0.05 
was considered significant. Accordingly, significance was marked as * = P<0.05; ** = 
P<0.01; *** = P<0.001; **** = P<0.0001. 
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3 Results 
In order to determine the impact of T1D on male reproductive function, 
experiments using the model organism C. elegans, the Ins2Akita+/- mouse model and in 
vitro studies on Sertoli cells were conducted. The results from these investigations are 
presented below. 
3.1 Studies on C. elegans 
3.1.1 High glucose affects brood size in mev-1 strain C. elegans 
The model organism C. elegans mutant in the mev-1 gene was used in order to 
assess the general impact of high glucose on reproductive outcome. mev-1 encodes the 
C. elegans ortholog of the succinate dehydrogenase cytochrome b560 subunit, an 
integral membrane protein that is a subunit of mitochondrial respiratory chain complex 
II (ubiquinol-cytochrome c reductase). Since this protein is required for oxidative 
phosphorylation, nematodes mutant for mev-1 show an abnormal energy metabolism, 
increased sensitivity to oxidative stress and pathogen infections, as well as a shortened 
lifespan. Thus, mev-1 mutant C. elegans nematodes are used as a model system to 
study the molecular mechanisms underlying diabetic hyperglycaemia-induced 
reduction in life-span. Since they were shown to exhibit analogies to the situation 
observed in T1D, they were used in this study to assess the effects of glucose on 
reproduction 84. 
Pilot experiments were conducted to evaluate a suitable glucose concentration. 
For this, nematodes were grown in liquid NGM culture medium containing 0, 10 or 
100 mM glucose and offspring were counted over a three-day period. A first 
assessment led to the conclusion, that a concentration of 100 mM glucose may induce 
significant glucose related effects on brood size (**p=0.0061) (Fig. 3-1). Hence, a 
concentration of 100 mM glucose was used for all further experiments. In these, 
treatment of mev-1 strain C. elegans with 100 mM glucose resulted in a significant 
reduction in number of offspring per nematode compared to control (*p=0.0183, mean 
± SD 124.2 ± 20.17 vs. 108.4 ± 20.21). In order to evaluate the impact of high glucose 
treatment on Sma/Mab pathway genes, which are closely related to the TGF-β 
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signalling pathway in mice and humans, nematodes were treated with siRNA before 
glucose incubation. Genes encoding Smad-1 (Sma-2), Smad-5 (Sma-3), BMPRRIB 
(Sma-6), and BMP-5 (dbl-1) were targeted, but showed no significant effects on brood 
size (Fig. 3-2). 
 
Fig. 3-1. Pilot experiment to determine the optimal glucose concentration for the 
treatment of mev-1 nematodes. 
mev-1 strain nematodes were grown in liquid NGM culture medium containing 0, 10 
or 100 mM glucose and offspring were counted over a three-day period. (A) Arrows 
indicate mev-1 eggs as counted for the analysis. (B) Number of offspring per nematode 
is significantly decreased after treatment with 100 mM glucose. Numbers in bars 
indicate numbers of experiments, n=2 experiments, **p=0.0061, unpaired t-test. 
 
Fig. 3-2. Effect of high glucose on reproductive outcome in mev-1 strain C. elegans. 
(A) mev-1 strain C. elegans were grown in liquid NGM culture medium in the 
presence or absence of 100 mM glucose. High glucose treatment significantly reduces 
brood size in mev-1 strain C. elegans. *p=0.0183, unpaired t-test, n=3 experiments. 
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(B) mev-1 strain C. elegans were grown in liquid NGM culture medium containing 
100 mM glucose after treatment with siRNA targeting genes encoding Smad-1 (Sma-
2), Smad-5 (Sma-3), BMPRRIB (Sma-6), and BMP-5 (dbl-1). n=3 experiments. 
3.2 Ins2Akita+/- mouse model 
As described in section 1.1.8, Ins2Akita mice develop T1D due to the 
accumulation of misfolded insulin within pancreatic β-cells. Recent studies have 
already shown that T1D is associated with testicular failure in young homozygous 
Ins2Akita mice, with mice showing a reduction in testis size, reduction in seminal 
vesicle weight, arrested spermatogenesis, and an absence of mature spermatozoa as 
well as a decreased numbers of spermatocytes and spermatids starting by the age of 5 
weeks. By the age of 7-8 weeks these mice exhibit infertility 235. The long-term effects 
of T1D on male reproductive function in heterozygous Ins2Akita have not been well-
characterised, and were subjected to detailed investigation. 
3.2.1 Assessment of general parameters in the Ins2Akita+/- mouse model 
In order to characterise the heterozygous Ins2Akita mouse model used in the 
present study, body weight (BW) and blood glucose (BG) were measured at 12 weeks 
and 24 weeks of age in a total of 34 non-diabetic mice and 45 diabetic mice, using 
genotype-matched wild type mice for comparison (Fig. 3-3). Testes and serum 
samples were available from 7-14 Ins2Akita+/- animals per group for detailed 
investigation of testicular function. Testis weight (TW) and HbA1c were assessed 
(Fig. 3-4). In general, non-diabetic Ins2Akita+/- mice (blood glucose <14.0 mmol/l) 
displayed higher body and testis weights compared to wild type. Non-diabetic 
Ins2Akita+/- mice exhibited significantly elevated blood glucose levels compared to wild 
type controls indicating a mildly diabetic phenotype. 
Mean body weights of the diabetic mice were significantly decreased 
compared to non-diabetic Ins2Akita+/- mice at 12 weeks and to both non-diabetic control 
groups at 24 weeks of age. Mean blood glucose levels of diabetic mice were 
significantly elevated compared to both controls.  
There was no difference in the mean testis weights of the mice at 12 weeks, 
but by 24 weeks, the non-diabetic mice showed larger testis weights than wild type 
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controls, while the diabetic mice displayed a 20 % reduction compared to wild type, 
and a 30 % reduction compared to non-diabetic mice (Fig. 3-4A). Testis weights in the 
Ins2Akita+/- mice showed a significant negative correlation with blood glucose (Pearson 
correlation coefficient of r2=-0.2125, p = 0.0021) (not shown) and HbA1c levels (r2=-
0.4193, p=0.0002) (Fig. 3-4B), indicating that the severity and duration of 
hyperglycaemia was associated with reduced testis weight. 
 
Fig. 3-3.  Assessment of body weight (A) and blood glucose (B) in Ins2Akita+/- mice 
compared to wild type control. 
Two-way ANOVA. Numbers in bars indicate numbers of animals per group. Dotted 
line indicates level of diabetes cut-off at 14.0 mmol/l. 
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Fig. 3-4. Assessment of testis weight, HbA1c to testis weight correlation, 
testosterone, and LH in Ins2Akita+/- mice. 
(A) Assessment of testis weight in Ins2Akita+/- mice compared to wild type control. 
Two-way ANOVA. Numbers in bars indicate numbers of animals per group. (B) 
Correlation of HbA1c to testis weight within Ins2Akita+/- mice (all mice from both age 
groups combined). (C & D) Testosterone and LH levels in mouse plasma as 
determined by RIA. Two-way ANOVA. Numbers in bars indicate numbers of animals 
per group. 
3.2.2 Testicular atrophy of insulin-deficient Ins2Akita+/- mice 
The observation that long-term diabetes reduced testis weight in diabetic 
Ins2Akita+/- mice indicated that testicular function was reduced. Histological examination 
of the testes showed features consistent with moderate spermatogenic disruption in 
these mice (Fig. 3-5A-F). On average, the seminiferous tubules of the diabetic 
Ins2Akita+/- mice (205.3 ± 20.26 µm) were 10 % smaller in diameter compared to non-
diabetic (227.3 ± 9.29 µm) and 15 % compared to wild type controls (241.5 ± 14.43 
µm) (p=0.0009, n = 6 mice/ group). Assessment of spermatogenesis using the Johnsen 
score revealed that the testes of 24 week old diabetic mice showed significantly less 
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normal tubules (score 10) as opposed to wild type (76.23 ± 3.95 vs. 66.86 ± 5.37 %, 
p=0.0006) and non-diabetic Akita mice (81.73 ± 1.70 vs. 66.86 ± 5.37 % , p<0.0001). 
Diabetic mice tended to show failure in spermatogenesis reaching scores below 5 more 
frequently, when compared to wild type or non-diabetic Ins2Akita+/- controls (Table 3-1). 
Pathological changes, such as vacuolisation, spermatogenic disruption, degenerating 
cells, and Sertoli-cell only pattern in some tubules were observed (Fig. 3-5C-F). 
However, diabetic Ins2Akita+/- germ cells were not more frequently in a state of 
late apoptosis as revealed by TUNEL staining compared to controls (Fig. 3-6). In 
order to further distinguish the cause of the reduction in testis weight, testicular 
sections were stained for the Sertoli cell marker SOX-9 (Fig. 3-7A-F). All groups 
showed similar numbers of Sertoli cells within the seminiferous tubules at all ages 
analysed (Fig. 3-7G) (number of SOX-9 positive cells per tubule cross-section at 24 
weeks of age: C57Bl/6J 15.25 ± 0.75; non-diabetic Ins2Akita+/- 14.95 ± 1.51; diabetic 
Ins2Akita+/- 15.29 ± 0.45). This is also resembled in SOX-9 mRNA expression levels 
(Fig. 3-7H). 
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Fig. 3-5. Testicular morphology in Ins2Akita+/- mice compared to wild type control at 
24 weeks of age. 
Testicular sections from diabetic Ins2Akita+/- mice and controls at 24 weeks of age were 
processed for hematoxylin staining. (A) C57Bl/6J, (B) non-diabetic Ins2Akita+/- mice, 
(C-F) Pathological changes (asterixes) in diabetic Ins2Akita+/- mice: (C) vacuolisation 
(resembles Johnsen score 8); (D) spermatogenic disruption (resembles Johnsen score 
3); (E) increased number of degenerating cells (resembles Johnsen score 9); (F) 
Sertoli-cell only tubules (resembles Johnsen score 2). (A & B) Scale bar = 100 µm. 
(C-F) Scale bar = 50 µm.  
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Table 3-1. Johnsen score count in testicular sections. 
 12 weeks 24 weeks 
 C57Bl/6J non-diabetic 
Ins2Akita+/- 
diabetic 
Ins2Akita+/- 
C57Bl/6J non-diabetic 
Ins2Akita+/- 
diabetic 
Ins2Akita+/- 
 n= 3 n= 3 n= 5 n= 6 n= 3 n= 6 
10 324 328 509 698 416 624 
9 17 73 73 96 53 126 
8 5 31 26 46 27 89 
7 46 33 64 58 9 46 
6 5 3 5 3 1 3 
5 0 2 9 0 0 8 
4 0 2 6 0 1 2 
3 0 4 4 5 0 10 
2 0 1 14 8 1 27 
1 0 0 1 0 0 0 
Mean 
Score 
9.5 9.4 9.2 9.5 9.7 9.2 
n = number of animals per group 
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Fig. 3-6. TUNEL staining on testicular sections of Ins2Akita+/- mice compared to wild 
type control. 
Testicular sections from diabetic Ins2Akita+/- mice and controls at 24 weeks of age were 
processed for TUNEL staining. Inserted picture in Fig. 3-6A indicates negative control 
sample. Arrows indicate TUNEL positive cells. Scale bar = 100 µm.  
Results 
 83 
 
Fig. 3-7. Testicular SOX-9 in Ins2Akita+/- mice compared to wild type control. 
(A-F) SOX-9 staining on testicular sections of Ins2Akita+/- mice compared to wild type 
control. Inserted picture in Fig. 3-7A indicates negative control sample. Scale bar = 
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100 µm. (G) Number of SOX-9 positive cells per tubule. Two-way ANOVA. Numbers 
in bars indicate numbers of animals per group. (H) qRT-PCR assessment of SOX-9 
mRNA levels in mouse testis. Kruskal-Wallis test. Numbers in bars indicate numbers 
of animals per group. 
3.2.3 Fertility in Ins2Akita+/- mice 
To further evaluate the reproductive capacity of male Ins2Akita+/- mice sperm 
function from these mice was analysed in detail at 24 weeks of age. 
Evaluation of the sperm morphology indicated that the overall sperm density 
was significantly lower in both non-diabetic and diabetic Ins2Akita+/- mice compared to 
wild type controls. Non-diabetic Ins2Akita+/- mice further show a significantly reduced 
number of normal sperm. Most interestingly, diabetic Ins2Akita+/- mice displayed a 
significantly increased number of sperm with head failure compared to both wild type 
and non-diabetic control (Fig. 3-8).  
 
 
Fig. 3-8. Diabetic Ins2Akita+/- mice show decreased sperm density and increased 
sperm head failure at 24 weeks of age. 
Sperm morphology parameters of epididymal sperm from 24 week old Ins2Akita+/- mice 
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compared to controls. n=4-5, one-way ANOVA. 
3.2.4 The hypothalamic-pituitary-gonadal axis in Ins2Akita+/- mice 
Measurement of testosterone in serum samples revealed a number of very high 
levels in the wild type mouse group, but similar levels of testosterone in non-diabetic 
and diabetic Ins2Akita+/- mice at 12 weeks of age and amongst all groups at 24 weeks of 
age (Fig. 3-4C). Measurement of LH in serum samples showed no difference between 
groups at any time (Fig. 3-4D). 
3.2.5 Assessment of testicular inflammation in the Ins2Akita+/- mice. 
Since activins mediate inflammatory responses within the testis 111,128,134, 
expression of several key inflammatory markers was examined (Fig. 3-9). 
mRNA expression levels of IL-1α, IL-1β and TNF-α showed no changes in 
Ins2Akita+/- mice at any age. Moreover, the mRNA expression of the anti-inflammatory 
cytokine IL-10 was not altered in the testis of diabetic Ins2Akita+/- mice. This indicates 
that there was no induction of inflammatory processes within the testes of the 
Ins2Akita+/- mice. In contrast, testicular IL-6 protein production appeared to be increased 
at 12 weeks and 24 weeks in all Ins2Akita+/- mice (Fig 22 C). In contrast to IL-6 levels 
within the testis, epididymal IL-6 levels were not affected in neither non-diabetic nor 
diabetic Ins2Akita+/- mice at 12 weeks of age, but are significantly upregulated in diabetic 
Ins2Akita+/- mice at 24 weeks of age compared to non-diabetic Ins2Akita+/- and wild type 
control mice.  
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Fig. 3-9. Inflammatory markers in Ins2Akita+/- mice compared to controls. 
(A-D) qRT-PCR assessment of IL-1α, IL-1β, TNF-α, and IL-10 mRNA levels in 
mouse testis. Numbers in bars indicate numbers of animals per group. Kruskal-Wallis 
test. (E & F) IL-6 levels in mouse testis (E) and epididymis (F) as determined by 
ELISA. Numbers in bars indicate numbers of animals per group. Two-way ANOVA. 
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3.2.6 Regulation of activins and their signalling pathway in the Ins2Akita+/- mice 
Since activins and their antagonist play a major role in in the control of 
testicular function, protein and gene levels for activin A, activin B, inhibin, and 
follistatin were assessed. 
Testicular levels of Inhba mRNA, encoding the βA subunit of activin A, were 
unchanged in the Ins2Akita+/- mice at all ages (Fig. 3-10C). However, at 12 weeks of age 
there was a very high variability in mRNA expression, suggesting that some animals 
did have elevated expression. In all three groups, staining for activin A protein on 
testis sections revealed a typical pattern of strong positive staining in Sertoli cells of 
the seminiferous tubules, as well as macrophages in the interstitium (Fig. 3-11). 
 
Fig. 3-10. Activins A and B in Ins2Akita+/- mice compared to controls. 
(A &B) Assessment of activin A and activin B protein levels in mouse testis. Numbers 
in bars indicate numbers of animals per group. Two-way ANOVA. (C & D) qRT-PCR 
assessment of Inhba and Inhbb mRNA levels in mouse testis. Numbers in bars indicate 
numbers of animals per group. Kruskal-Wallis test. 
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Fig. 3-11. Immunohistological staining for the activin βA subunit. 
Testicular sections from diabetic Ins2Akita+/- mice and controls at 24 weeks of age were 
processed for activin βA subunit staining. Wild type (A), non-diabetic Ins2Akita+/- mice 
(B), and diabetic Ins2Akita+/- mice (C) at 24 weeks of age. Inserted picture in Fig. 3-11 A 
indicates negative control sample. Scale bar = 25 µm. 
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ELISA analysis was conducted in order to quantify activin A levels in 
testicular samples (Fig. 3-10A). These data showed that activin A protein was 
increased in both non-diabetic and diabetic Ins2Akita+/- mice at 12 and in diabetic mice at 
24 weeks of age, when compared to wild type control. This suggests that within the 
testis of Ins2Akita+/- mice there is upregulation of activin A.  
In order to further assess the role of activins within Ins2Akita+/- mice mRNA 
expression levels of Inhbb, encoding the inhibin βB subunit, were analysed. qRT-PCR 
results showed no changes in Inhbb mRNA levels at 12 weeks of age, but a trend 
towards a reduction in Inhbb expression in some Akita mice, when compared to wild 
type control (Fig. 3-10D). In contrast to these findings, activin B protein levels showed 
a significant downregulation at 12 weeks of age in both non-diabetic and diabetic 
Ins2Akita+/- mice, which seemed to recover at 24 weeks of age (Fig. 3-10B). This 
suggested that a higher proportion of the inhibin βB produced may have been diverted 
to the production of inhibin B within the Ins2Akita+/- testis. However, while there was an 
increase in Inha in some animals of the diabetic Ins2Akita+/- group at 12 weeks of age, 
overall qRT-PCR results for Inha, encoding the inhibin α subunit, showed no changes 
in mRNA expression in Ins2Akita+/- mice at any age (Fig. 3-12C). This finding was 
supported by the data of the measurements of total inhibin α-subunit containing 
proteins by RIA (Fig. 3-12A). 
Evaluation of gene expression levels of the activin affinity binding protein, 
follistatin, revealed increased total follistatin (FST (total)) levels in some diabetic 
Ins2Akita+/- mice at 24 weeks of age, but no significant change in the overall expression 
level (Fig. 3-12D). This was also reflected in follistatin protein production measured 
by RIA (Fig. 3-12B). 
To further assess the involvement of the TGF-β pathway signalling in T1D 
induced activin regulation, the expression of the relevant signalling receptors (Fig. 
3-13A-C) was analysed. Gene expression in diabetic Ins2Akita+/- mice showed an 
upregulation of the type 1 activin receptor 1B (Acvr1b) at 12 weeks of age, which 
returns to baseline levels at 24 weeks of age. In contrast, in diabetic Ins2Akita+/- mice the 
type 2 activin receptor Acvr2a showed a marked downregulation at 24 weeks of age, 
while the type 2 activin receptor Acvr2b was markedly decreases at both 12 and 24 
weeks of age. 
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Fig. 3-12. Activin antagonists in Ins2Akita+/- mice compared to controls. 
(A &B) Assessment of inhibin and follistatin protein levels in mouse testis. Numbers 
in bars indicate numbers of animals per group. Two-way ANOVA. (C & D) qRT-PCR 
assessment of Inha and FST mRNA levels in mouse testis. Numbers in bars indicate 
numbers of animals per group. Kruskal-Wallis test. 
 
In order to determine if the Smad pathway was activated by changes in ligand 
expression in the testis, a multiplex analysis for phosphorylated Smad2 and 3, and 
Smad4 (Fig. 3-13D-E), as well as Western Blot analysis for Smad4 (Fig. 3-14) were 
undertaken. While pSmad2 appeared not to be regulated in Ins2Akita+/- mice, pSmad3 
was significantly upregulated in diabetic Ins2Akita+/- mice at 24 weeks of age. Most 
interestingly, this upregulation occurred in parallel with an increase in Smad4 in 
diabetic Ins2Akita+/- mice at 24 weeks of age, when compared to non-diabetic Ins2Akita+/- 
mice and wild type control. This was also confirmed by Western Blot analysis (Fig. 
3-14). 
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Fig. 3-13. Activin signalling in Ins2Akita+/- mice compared to controls. 
(A-C) qRT-PCR assessment of Acvr1b, Acvr2a, and Acvr2b mRNA levels in mouse 
testis. Numbers in bars indicate numbers of animals per group. Kruskal-Wallis test. (D 
& E) Multiplex analysis of pSmad3 and Smad4 in mouse testis. Data expressed as 
median fluorescence intensity (MFI) ± SEM, numbers in bars indicate numbers of 
animals per group. Two-way ANOVA. 
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Fig. 3-14. Smad4 is elevated in the testis of diabetic Ins2Akita+/- mice. 
Western Blot for Smad4 in 24 week old animals (A) and quantitative Smad4 protein 
analysis from Western Blot analysis (B) (n=6). 
 
In order to determine if the effects of T1D on the production activin A, activin 
B, inhibin, and follistatin are also seen in the rest of the male reproductive tract, 
ELISA and RIA analysis was also conducted on epididymal samples from the three 
different groups of mice (Fig. 3-15). These data revealed that, in contrast to activin A 
production within the testis, epididymal samples showed a significant upregulation of 
activin A in diabetic Ins2Akita+/- mice compared to non-diabetic and wild type controls 
at 12 weeks of age and a significant upregulation compared to non-diabetic controls at 
24 weeks of age. 
Protein levels of activin B within the epididymis show a similar pattern to that 
seen within the testis, with a significant downregulation at 12 weeks of age in both 
non-diabetic and diabetic Ins2Akita+/- mice. This downregulation seems to recover at 24 
weeks of age in non-diabetic Ins2Akita+/- mice only. 
Similarly to the protein levels within the testis, epididymal levels of 
inhibin and follistatin were not affected by the diabetic conditions. 
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Fig. 3-15. Assessment of activin A, activin B, inhibin, and follistatin protein levels in 
mouse epididymis. 
Numbers in bars indicate numbers of animals per group. Two-way ANOVA. (A & B) 
Activin A and B levels in mouse testis as determined by ELISA. (C & D) Inhibin and 
follistatin levels in mouse testis as determined by RIA. 
3.3 Cell culture studies 
Sertoli cells are the major sites for activin and inhibin production within the 
testis. In order to determine the direct impact of diabetic conditions, such as 
hyperglycaemia and hypoinsulinemia, on these cells and how these conditions regulate 
activin and inhibin signalling, in vitro experiments were carried out using primary 
mouse Sertoli cells generated from C57Bl/6J mice as well as an immortalized mouse 
Sertoli cell line (WL-3). 
3.3.1 Confirmation of the Sertoli cell character in WL-3 mouse Sertoli cells 
The WL-3 cell line was first established in 2001 by Mueller and Korach 172. In 
order to confirm the Sertoli cell character that was described in the original 
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publication, qRT-PCR analyses for various Sertoli cell specific genes was carried out 
(Table 9). These experiments confirmed the expression for Inha, Inhbb, vimentin, 
SOX-9, β-Actin, and the androgen receptor (AR). Further, they confirmed the presence 
of Inhba, N-Cadherin, Claudin-11, GATA-4, ZO-1, and AMH. As already shown by 
Mueller and Korach these cells do not express the FSH receptor. Therefore, this gene 
analysis confirmed the Sertoli cell like character of this cell line, allowing further 
experiments within this study. 
Table 3-2. Sertoli cell gene markers in WL-3 cells. 
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3.3.2 Establishment of treatment conditions using dose responses 
In order to determine suitable treatment conditions for the diabetes experiments 
on Sertoli cells, dose response treatments for the single substances were carried out on 
primary mouse Sertoli cells (Fig. 3-16) and WL-3 cells (Fig. 3-17and Fig. 3-18). 
Single treatments with glucose, mannose (as an isoosmotic control for glucose), 
insulin, FSH, or testosterone were conducted over a period of 24 and 48 h and the 
protein levels of activin A were measured in order to determine Sertoli cell response. 
Although Mueller and Korach as well as qRT-PCR data from the present study 
did not confirm the expression of the FSH receptor within the WL-3 cell line, dose 
response experiments were conducted in these cells. This was done in order to provide 
a comparable approach in both study systems as well as to provide evidence for the 
fact that, additionally to the qRT-PCR data, WL-3 cells are unresponsive to FSH. This 
is particularly necessary since recent data suggests that FSH also acts in a steroid-
independent manner via Tgf-β, Hedgehog, Wnt and Notch signalling pathways 66. In 
order to distinguish the impact of hyperglycaemia in Sertoli cells, WL-3 cells were 
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also analysed for inhibin production after glucose and mannose dose response 
treatment (Fig. 3-18). 
 
Dose response treatments revealed that primary Sertoli cells and WL-3 cells 
reacted similarly to most of the various substances. In WL-3 cells there was a 
pronounced increase of activin A release at 48 h incubation with glucose or mannose 
as compared to glucose free medium (Fig. 3-17A). Interestingly, the plateau of activin 
A release was attained at physiologic glucose levels (5.5 mM) and did not further 
increase with hyperglycaemic glucose levels. In primary SC’s this effect was not 
observed (Fig. 3-16). 
 
Fig. 3-16. Activin A production after dose response treatment in primary mouse 
Sertoli cells. 
Activin A production in primary mouse Sertoli cells was measured via ELISA after 
treatment with (A) glucose or mannose, (B) insulin, (C) FSH, or (D) testosterone. (A-
C) n=3 experiments, (D) n=1 experiment. 
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Fig. 3-17. Activin A production after dose response treatment in the WL-3 mouse 
Sertoli cell line. 
Activin A production in the WL-3 mouse Sertoli cell line was measured via ELISA 
after treatment with (A) glucose or mannose, (B) insulin, (C) FSH, or (D) testosterone. 
n=3 experiments. 
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Fig. 3-18. Inhibin production after dose response treatment in the WL-3 mouse 
Sertoli cell line. 
Inhibin production in the WL-3 mouse Sertoli cell line was measured via RIA after 
treatment with glucose or mannose for 24 or 48 h. n=1-2 experiments. 
3.3.3 Evaluation of the effect of diabetic conditions on mouse Sertoli cells 
Based on the evaluation of the dose response treatments (section 3.3.2) and 
review of the literature 55,68,79,126, combined treatments of glucose, insulin, and 
testosterone for both primary and WL-3 Sertoli cells were chosen as shown in Table 
3-3. 
Table 3-3. Treatment conditions for combined treatment on mouse Sertoli cells. 
Treatment 1 
(cntr) 
2 3 4 5 6 7 8 
(diab) 
Glucose (mM) 5,5 25 5,5 25 5,5 25 5,5 25 
Insulin 
(ng/ml) 
5000 5000 2,44 2,44 5000 5000 2,44 2,44 
Testosterone 
(ng/ml) 
500 500 500 500 12,5 12,5 12,5 12,5 
 
Additional concentrations of FSH were considered, but after review of the dose 
response treatments, which showed no effect, and review of the literature, which 
shows that under diabetic conditions FSH levels are not subject to change, no further 
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studies were performed on this topic. Hence, eight different treatment conditions were 
established, ranging from treatment 1 as physiological control treatment (cntr), over 
changing concentrations of glucose, insulin and testosterone to treatment 8, which can 
be considered as diabetic condition (diab). Cells were then treated over a period of 24 
or 48 h and the culture medium analysed for production of activin A and inhibin (Fig. 
3-19). 
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Fig. 3-19. Activin A and inhibin production after combined treatment on WL-3 
cells. 
Activin A and Inhibin production in the WL-3 mouse Sertoli cell line were measured 
via ELISA or RIA, respectively, after treatment with varying concentrations of 
glucose, insulin, and testosterone for (A) 24 h or (B) 48 h. n=3 experiments. Two-way 
ANOVA.  
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These results suggest that after 24 h of treatment there is only little effect with 
regard to activin A and inhibin, however after 48 h low concentrations of testosterone 
seem to induce a stronger activin A, but not inhibin response. This seems to be 
unaffected by changing conditions of glucose and insulin. 
3.3.4 Evaluation of the effect of hyperglycaemia and increased activin A levels 
on mouse Sertoli cells 
Since the combined treatment did not show a distinct effect of neither high 
glucose nor the diabetic condition on Sertoli cell function, further treatment options 
were considered. Results from the insulin-deficient Ins2Akita+/- mice had shown that 
activin A is upregulated in both non-diabetic and diabetic mice (Fig. 3-10), but only 
the mice that developed diabetes displayed testicular atrophy (Fig. 3-4). Hence, it was 
hypothesised that increased systemic activin A levels make Sertoli cells prone to 
glucose induced damage, and cells were treated with varying concentrations of glucose 
and a single dose of activin A for 24 and 48 h. The culture medium was then analysed 
for the production of activin A and inhibin (Fig. 3-20). While, after 48 h of treatment, 
activin A production showed an additive effect compared to 24 h treatment, there was 
no increase in production due to activin A treatment at any time point. Moreover, 
increasing glucose concentrations had no effect on activin A production at any time 
point. Other than activin A, inhibin levels remained constant over the time of 
treatment. Interestingly, after 48 h inhibin production was significantly downregulated 
by high glucose concentrations and this response was even more pronounced in the 
presence of activin A. 
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Fig. 3-20. Activin A and inhibin production after treatment with varying 
concentrations of glucose in the presence or absence of activin A on WL-3 
cells. 
 Activin A and Inhibin production in the WL-3 mouse Sertoli cell line were measured 
via ELISA or RIA, respectively, after treatment with varying concentrations of 
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glucose in the presence or absence of activin A (50 ng/ml) for (A) 24 h or (B) 48 h. 
n=3 experiments. Two-way ANOVA. 
 
To further investigate the impact of glucose and activin treatment on Sertoli 
cell function, the influence of this treatment combination on the formation of inter-
Sertoli cell tight junctions was investigated by measurement of transepithelial 
resistance (TER). In order to determine optimal culture conditions for the 
measurement of TER pilot experiments were conducted using varying cell densities 
(0.25 and 0.5x106 cells per PCF insert) plated on PCF inserts with and without 
matrigel. Moreover, cells were monitored at different time points (-1, 0, 1, 2, 3 days) 
(Fig. 3-21). 
 
Fig. 3-21. Tight junction integrity in WL-3 cells after treatment with varying 
concentrations of glucose in the presence or absence of activin A.  
 (A and B) Tight junction integrity as determined by measuring transepithelial 
electrical resistance (TER) across a monolayer of WL-3 cells. WL-3 cells were seeded 
at 0.25x106 cells/well (A) or 0.25x106 cells/well (B). Following the formation of stable 
TJs for 24 h under control (medium alone) conditions WL-3 cell monolayers, cells 
were treated varying concentrations of glucose in the presence or absence of activin A 
(50 ng/ml). n=3 experiments. 
 
A first assessment led to the conclusion, that cells grow better when the inserts 
are coated with matrigel. Further, a density of 0.25x106 cells allowed for a longer 
culture period. After monitoring the cells for up to 3 days after treatment, neither 
glucose nor activin treatment showed any difference with respect to TER. After 
treatment day 2, TER decreased, which was mainly due to apoptosis induced by 
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overgrowth. Therefore, the time points 2 and 3 days were neglected for further 
experiments. 
To further optimize the treatment with activin A, two different treatment 
options were tested. In the first, activin A was added to the culture medium from the 
commencement of the treatment, in the second activin A was added at day 1. 
Moreover, cells were seeded in glucose free medium prior to the treatment 
(starvation). Results from this pilot run show a constant decrease in TER after 
treatment, regardless of the presence of activin A. Microscopic observation showed 
that cells were confluent at treatment day 2, however TER measurement suggests that 
there was no formation of tight junctions (Fig. 3-22). 
 
Fig. 3-22. Optimization of activin A treatment on W-3 Sertoli cells for the 
measurement of TER. 
(A and B) Tight junction integrity as determined by measuring transepithelial 
electrical resistance (TER) across a monolayer of WL-3 cells. Following the formation 
of stable TJs for 24 h under control (medium alone) conditions WL-3 cell monolayers, 
cells were treated with 5.5 mM (A) or 25 mM (B) glucose in the presence or absence 
of activin A added at different time points. n=3 experiments. 
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4 Discussion 
Type 1 diabetes is one of the most prominent public health threats in modern 
societies with rapidly rising prevalence. This is accompanied by a rise in the number of 
childhood and adolescent males with T1D affecting an increasing number of men in 
their reproductive age 246. 
Up to the present time, a large number of studies have described a negative 
impact of T1D on male reproductive function leading to degenerative changes within 
the testis and epididymis, erectile dysfunction, ejaculatory dysfunction, as well as a 
reduction in semen volume, sperm counts, sperm motility, and altered sperm 
morphology 12,124. However, the mechanisms responsible for T1D induced changes in 
male fertility remain to be elucidated. 
Many studies in diabetic men, as well as in animal models, have indicated that 
T1D disrupts fertility at various levels including degenerative and apoptotic changes in 
spermatogenesis, altered glucose metabolism in Sertoli cells 11,136,209, reduced 
testosterone synthesis and secretion, erectile dysfunction, ejaculatory dysfunction, 
reduced libido, and impotence 12,124,136. To date, several clinical studies as well as animal 
experiments have aimed to address the underlying molecular mechanisms responsible 
for diabetes-induced male infertility, but conclusive studies remain scarce. Suggested 
mechanisms include sperm DNA and mitochondrial damage 2,3, oxidative stress 164,166, 
atrophic changes within the epididymis 141, and a disruption of the hypothalamic-
pituitary-gonadal axis 30,236. 
Moreover, the unique characteristics of glucose metabolism within testicular 
cells make them prone to alterations under diabetic conditions. It is likely that the 
glucose sensing machinery as well as the hormonal control within these cells to 
counteract hyper- und hypoglycaemia play a crucial role in the subfertility and/or 
infertility associated to DM 12. 
Besides its association with male reproductive function, T1D has recently been 
shown to have features of an inflammatory disease with levels of inflammatory markers 
correlating with the glycaemic status in T1D patients 111,134. Moreover, the immune 
imbalance in autoimmune diseases such as T1D is known to cause inflammatory 
processes 20. 
Along with their role in testicular physiology, activins are also known as growth 
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factors and cytokines that regulate inflammation and immunological mechanisms 
109,111,128,134. However, little is known about the role of the activins in diabetes mellitus. 
To this point, serum activin A levels were reported to positively correlate with blood 
glucose levels in diabetic patients and patients with myocardial infarction. Further, 
activins A and B, as well as their binding protein follistatin have been shown to be 
involved in the regulation of glucose metabolism by promoting the differentiation of 
insulin-producing and insulin-responsive cells, and regulating the function of the 
differentiated cells 15,62,104,191,260,293. Hence, the activins could provide an important link 
between T1D and male infertility. 
In the course of this work, the hypothesis that hyperglycaemia may affect 
testicular function by destabilizing the testicular equilibrium of the activin family of 
proteins and, thus, induces intratesticular inflammation was examined. To address this 
aim, hyperglycaemia induced changes within three different models were investigated: 
the model organism C. elegans, male heterozygous Ins2Akita+/- mice, and cultured Sertoli 
cells. 
4.1 High glucose effects reproductive outcome in C. elegans 
nematodes 
In the present work, the C. elegans mutant strain mev-1 (methyl viologen 
sensitive) was used as model organism to study hyperglycaemia-induced infertility. 
These mutant nematodes carry a mutation within the cytochrome b subunit of succinate 
dehydrogenase resulting in excessive mitochondrial superoxide production and 
premature death 121. This in turn closely resembles the metabolic situation of diabetic 
patients who exhibit a deficiency in the signalling of reactive oxygen species (ROS) 
leading to the initiation of autoimmune diabetes as well as diabetes induced 
morphological changes in mitochondria, which are closely linked to the presence of 
superoxide anion 159,266. C. elegans exists as self-fertilizing hermaphrodite and as male, 
allowing easy generation and maintenance of homozygous populations with a large 
number of progeny, which made it a suitable model for the purpose of this study 9. 
In order to simulate severe hyperglycaemia, which occurs as a consequence of β-
cell destruction in T1D patients, nematodes were incubated in liquid NGM containing 
E. coli as food source as well as 100 mM glucose. The use of a liquid culture medium 
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ensured the adequate uptake of glucose through a continuous delivery to the intestinal 
tract by the pumping activity in the worm pharynx 103. 
Most interestingly, glucose treatment resulted in a significant decrease in brood 
size, suggesting a functional role of glucose within the reproductive cycle of C. elegans 
nematodes. This effect, however, did not correlate with changes in Sma/Mab pathway 
signalling. This pathway is known to be involved in the regulation of body size, 
reproductive aging, the development of male-specific sensory rays as well as copulatory 
spicules, and is closely related to BMP subfamily ligands and signal transducers as they 
are found in mice and humans 98. 
However, it is well known that between TGF-β secreting and receiving cells, the 
ligands do not simply diffuse to their receptors on the receiving cell, but are tightly 
regulated 98. Hence, even though hyperglycaemia had no effect on the ligands and signal 
transducers themselves, it is possible that they interact via the extracellular regulation of 
ligand activity. 
Besides the Sma/Mab pathway, the DAF-7 pathway is known as a further TGF-β 
signalling pathway in C. elegans nematodes. Still, although components of this pathway 
have common sequence features with the TGF-β/Activin/Nodal/GDF pathway 
components, it is mainly known for its regulatory role within the dauer/continuous 
development switch 98. Only few studies have reported a role within the negative 
regulation of the proliferative pool of germ cells, involving an unknown downstream 
signalling pathway 98,200. Hence, the DAF-7 pathway seems to play a minor role in the 
reproduction of C. elegans nematodes, leaving the Sma/Mab pathway as a more suitable 
target for investigation in the context of hyperglycaemia induced infertility. 
Previous studies have shown, that hyperglycaemia induces a reduction in brood 
size in C. elegans nematodes 224,265, with recent work from Teshiba et al. suggesting, that 
this effect is dependent on serotonergic signalling 265. 
Taken together these findings show that hyperglycaemia has a negative effect on 
the reproductive outcome in C. elegans, however, evidence that this is linked to 
disruptions within the TGF-β signalling pathway was not found. Therefore, a higher 
organism was used to investigate this interaction in more detail. 
4.2 Reproductive changes in male Ins2Akita+/- mice 
The Akita mouse is a model of T1D that results from a mutation in the Ins2 
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gene. This mutation leads to a misfolded protein product, which accumulates in the 
endoplasmic reticulum (ER), causing ER stress and, ultimately, death of the insulin 
producing β-cells of the pancreas 282. The diabetic Akita mouse is thus similar to 
humans with T1D, which is caused by an autoimmune destruction of the β-cells of the 
pancreas 1. The Akita model also displays a severe onset of diabetes, similar to 
untreated diabetes in human adults, and does not have the drug induced toxicity of a 
toxin-induced model, which makes the Akita mouse model a unique model to study 
diabetes induced male infertility.  
In this study, the heterozygous Ins2Akita mice, bred in a colony in Mannheim 
(Germany), were used to investigate long-term effects of insulin deficiency and 
hyperglycaemia on the function of the activins within the reproductive tract. These mice 
have a phenotype penetrance of 50 %, which makes this model unique as it allows to 
study the effects of long-term hyperglycaemia by comparison of mice from an identical 
litter with near-normal glycaemia (<14.0 mmol/l non-fasting blood glucose 
concentrations) or severe hyperglycaemia (>33.3 mmol/l). 
In order to investigate the working hypothesis, C57Bl/6J wild type mice, as well 
as non-diabetic, and diabetic Ins2Akita+/- mice were analysed for general parameters, such 
as body weight, blood glucose levels, and HbA1c value. Moreover, reproductive 
parameters like testis weight, testicular morphology, and sperm morphology were 
assessed. To study the regulation of the activins, mRNA and protein content of targets 
of the activin family was investigated in testis and epididymis samples. Lastly, the 
involvement of inflammation and the HPG-axis was assessed by analysis of 
inflammatory cytokines in testis samples and hormones in serum. 
The major finding of these studies was that prolonged exposure to elevated 
blood glucose was associated with progressive testicular disruption in Ins2Akita+/- mice, 
based on the observation that only the Ins2Akita+/- mice that developed diabetes exerted 
progressive decrease in testis weight and increased evidence of spermatogenic 
disruption with age. Immunohistochemical determination of the number of Sertoli cells 
present within the testis revealed that the testis phenotype is not due to differences in 
this parameter. However, it is possible that the density of Sertoli cells is unaffected, but 
the length of seminiferous tubules and, therefore, total Sertoli cell number is reduced. 
This, in turn, would influence testicular weight as well as sperm output. This hypothesis 
is further supported by sperm analysis data, revealing that the Ins2Akita+/- mice show a 
significantly lower number of sperm compared to wild type controls and that diabetic 
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Ins2Akita+/- mice have a higher percentage of misshaped sperm heads compared to both 
controls. However, in light of the testicular morphology, which appeared to be grossly 
normal, the drastic reduction in sperm number and the increase in sperm head failure 
seems surprising and suggests that further disruption takes place in distal parts of the 
reproductive tract. Since activin A protein was solely upregulated in the epididymides 
of diabetic Ins2Akita+/- mice, it could be that activin signalling is also dysregulated within 
the epididymis, further influencing sperm maturation, and, ultimately, sperm 
morphology and concentration. To examine this further, it would be of interest to 
investigate activin signalling within the epididymides of Ins2Akita+/- mice as well as 
changes in sperm themselves, such as DNA fragmentation or acrosome formation. 
Further, data from the Johnsen score count demonstrates that diabetic Ins2Akita+/- 
mice exhibit an increase in lower score counts. These changes might be due to acute or 
chronic adverse effects of severe hyperglycaemia. However, even though there appear 
to be substantial changes in testicular function within the heterozygous Ins2Akita mouse 
model, these changes seem not to result in complete infertility in these mice. This 
finding is in contrast to the studies of Schoeller et al. who reported infertility in 
heterozygous Ins2Akita mice at the age of 24 weeks 235. One explanation for these 
conflicting results might be the different genetic background, since mice on an FVB 
background were used previously, whereas mice on a C57Bl/6J background were used 
in the present study. Mouse strain differences have been implicated in the susceptibility 
of various factors 151,278. Besides the involvement of moderate elevations of blood 
glucose concentrations, the reduction of effective circulating insulin levels could be 
another explanation for the observed effect within the testis. This is supported by recent 
findings that show that the diabetic genotype determines the balance of T-cell 
inflammatory vs. regulatory responses to insulin in peripheral blood of diabetic patients 
177. Hence, one could presume that insufficient insulin levels trigger inflammatory 
responses within the testis of Ins2Akita+/- mice. Moreover, it is known that the regulation 
of insulin levels directly impacts on the expression of the insulin receptor (InsR), as 
well as the receptor for insulin like growth factor 1 (Igfl1r), leading to the activation of 
downstream signalling pathways involved in proliferation, differentiation, metabolism, 
and cell survival 24,262. Thus, upregulation of insulin results in the downregulation of 
InsR and Igfl1r, whereas downregulation of insulin might results in the upregulation of 
both receptors 88,89,275. Recent studies suggest that this specifically affects Sertoli cell 
function. Thus, a downregulation of the insulin receptors results in a 75 % reduction in 
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testis size and daily sperm production in adult testes 206. 
However, testicular disruption was only observed in mice with an extreme 
elevation of glucose (>14 mmol/l), while induction of inflammatory cytokines, as 
determined by Il-1α, IL-1β, TNF-α and IL-10 levels, was not found. This in turn 
suggests that the testicular damage is more likely to be related to the increased glucose 
rather than inflammation related to the insufficient insulin levels. 
 
Activins have recently been reported to play an important role in glucose 
metabolism by regulating the differentiation and activity of the insulin-producing 
pancreatic β-cells, as well as the response of insulin target cells 15,48,49. Additionally, they 
have been proposed to modulate events involved in insulin sensitivity in a tissue 
dependent manner and therefore regulate whole-body insulin responsiveness 38,293,294,296. 
Moreover, our group has recently shown that activin A levels in the blood of patients 
with T2D show a positive correlation with increasing severity of the disease 293. 
Therefore, the involvement of activins in the development and onset of diabetes related 
male subfertility and/or infertility seems likely. Here it was shown that with blood 
glucose concentrations rising 2.9-fold from 76 ± 3 to 223 ± 8 mg/dl (4.2 ± 0.2 to 12.4 ± 
0.4 mmol/l) testicular activin A levels are significantly upregulated in Ins2Akita+/- mice, 
but did not rise further with the higher magnitude of hyperglycaemia. It seems that the 
severely diabetic phenotype is not associated with a further increase as compared to 
mild diabetes indicating that testicular activin A levels may be linked more closely to 
moderate elevations of blood glucose concentrations and/or the genetic background of 
the Ins2Akita+/- mouse model. 
In contrast to activin A levels, activin B production was significantly down 
regulated within Ins2Akita+/- mice at 12 weeks of age. While the role of activin B in the 
regulation of inflammation, as well as in testis function, is completely unknown, it was 
previously shown that levels of activin B within the testis of wild type mice appear to be 
about 10-fold higher than those of activin A. However, activin B is about 10-fold less 
potent than activin A in several of its effects, and activin B is suggested to act as a weak 
agonist of activin A 291. Hence, the inverse regulation of activin A and activin B found 
in this study might suggest that each compensates for the effect of the other. This is 
further supported by the fact that neither of the main regulators of activin activity 
(inhibin and follistatin) was substantially affected by the diabetic conditions or elevated 
activin A levels. Most interestingly, only in diabetic Ins2Akita+/- mice were mRNA levels 
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of the activin receptor subunit Acvr1b significantly upregulated at 12 weeks of age, 
whereas the receptor subunits Acvr2a and Acvr2b were significantly downregulated at 
24 or at both 12 and 24 weeks of age, respectively. This suggests that, even though the 
protein levels of activin A were equally increased in both Ins2Akita+/- genotypes, only 
within the diabetic mice was transmission of the activin signal disrupted. This is further 
supported by the finding that Smad4 was significantly upregulated in diabetic Ins2Akita+/- 
mice, likely due to an increased phosphorylation of Smad3 in this group. A selective use 
of Smad second messengers by activins has recently been proposed in insulin secretion 
studies 16,294. However, these studies suggested that activin A favours Smad2, which is 
in contrast to our findings 16,294. Nonetheless, overexpression of Smad3, as it was found 
in the present study, but not Smad2, was associated with a decrease in glucose 
stimulated insulin secretion in pancreatic islets 16,294. This might suggest that the increase 
in pSmad3 further exacerbates the detrimental effects of hyperglycaemia within the 
Ins2Akita+/- mouse model. To strengthen this finding, future studies would benefit from 
interventions within the Ins2Akita+/- mice using follistatin treatment to revoke the 
dysregulation of the activins. If this approach would result in a normalized activin 
receptor expression as well as Smad phosphorylation, the activins could be considered 
major regulators of diabetes-induced male reproductive dysfunction. Another approach 
to explore this proposal would be a conditional activin knockout in T1D mice, to study 
the local molecular dysregulation of the activin signalling. 
A scheme of the proposed mechanisms of activin action in different stages of 
hyperglycaemia is shown in Fig. 4-1. 
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Fig. 4-1. Proposed actions of activin in the testis in different grades of 
hyperglycemia. 
Mild hyperglycaemia (left panel), as investigated in non-diabetic Ins2Akita+/- mice, leads 
to an upregulation of activin A and a downregulation of activin B without further effect 
on the Smad signalling pathway. Severe hyperglycaemia (right panel), as investigated in 
diabetic Ins2Akita+/- mice, leads to an upregulation of activin A and a downregulation of 
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activin B, affecting activin receptor types II and I and promoting Smad signalling via an 
increase in phosphorylated of Smad3 and Smad4. 
 
In spite of the increase in testicular activin A levels and the upregulation in 
Smad4, protein expression of the pro-inflammatory cytokine IL-6 and mRNA 
expression of the pro-inflammatory cytokines IL-1β and TNF-α remained unchanged in 
Ins2Akita+/- mice, suggesting no further inflammatory response to activin action. 
Previous studies on T1D mice, including the Ins2Akita+/- mouse model, have 
suggested that the observed testicular damage results from impairment in production of 
FSH and LH by the pituitary, the latter being consistent with a loss of androgen support 
for spermatogenesis 30,166,235,236. In contrast to these earlier findings, the present study 
shows that testicular damage in the heterozygous Ins2Akita mouse model does not 
correlate with changes in the HPG axis as shown by protein levels for testosterone and 
LH. 
Besides investigations on the testis, the activins were also examined in tissue 
homogenates of epididymides in order to investigate their actions along the reproductive 
tract. These data revealed that, in contrast to activin A production within the testis, its 
concentrations in epididymal samples show a significant upregulation in diabetic 
Ins2Akita+/- mice compared to controls, suggesting that, even though there seems to be no 
effect of diabetes on activin A production within the testis, there is a strong effect of 
diabetes within the epididymis of Ins2Akita+/- mice. In contrast to activin A production, 
neither activin B, nor inhibin, nor follistatin exhibited significantly different levels 
compared to the testis. It is further noteworthy, that the levels, for both activin A and 
activin B, are about 5 fold higher in the epididymis compared to the testis, which makes 
it likely that the actions of the activins within the epididymis are more pronounced, 
especially in terms of inflammation. 
Taken together, these data show that in mice that are heterozygous for the 
Ins2Akita gene, hyperglycaemia leads to an upregulation of activin A levels and a 
downregulation of activin B levels, while the levels of the antagonists FST and inhibin 
remain unchanged. These effects were already observed at moderate elevations of blood 
glucose concentrations. Of interest however was that activin downstream signalling, 
with regard to activin receptor expression and Smad signalling, was only affected in 
mice with extreme elevation of glucose (>14 mmol/l). These mice also exhibited 
progressive testicular disruption. 
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Moreover, the observed effects were not linked to a disruption in pituitary LH 
support or reduced testosterone production. The testicular damage may have been 
exacerbated by an upregulation of IL-6 and activin A, or dysregulation of activin 
signalling, as IL-6 and activin are involved in the fine control of Sertoli cell function 
during spermatogenesis 109. 
Further, it is likely that the detrimental effects of activin become more 
pronounced in the distal parts of the reproductive tract, as diabetic Ins2Akita+/- mice 
showed an upregulation of activin A within the epididymis. 
This is the first study to demonstrate that chronic elevation of glucose during 
diabetes may have a direct inhibitory effect on spermatogenesis. The activins are likely 
to be involved in diabetes-induced male infertility, but the mechanisms by which this 
occurs requires further investigation. 
4.3 Impact of hyperglycaemia on Sertoli cell function 
Changes in glucose metabolism as well as insulin signalling are known to 
disturb male reproduction by affecting the regulation of the energy metabolism of 
Sertoli cells by regulating the uptake of nucleotides (ATP, GTP, UTP), and the 
secretion of transferrin and lactate. Hence, both spermatogenesis and the blood testis 
barrier can be disturbed by these conditions 12,41,95,123,249. 
Furthermore, glucose is a crucial energy substrate in order to maintain 
spermatogenesis, a metabolically active process, which requires tight cooperation 
among testicular cells 11. In this context, the Sertoli cells play a crucial role in providing 
pyruvate and glycolytic converted lactate for developing germ cells 11,12. Thus, 
disturbance in glucose metabolism, as in diabetic individuals, can lead to major 
disruptions in the cellular organisation, ranging from vacuolization to a high degree of 
degeneration. This in turn, has dramatic consequences for the cellular interaction during 
spermatogenesis 12. 
Activins are known to be involved in the fine control of Sertoli cell function 
during spermatogenesis and were previously identified as a factor capable of 
reprogramming Sertoli cells to an immature, dedifferentiated phenotype 109,184. With 
regard to diabetes, activins A and B, as well as their binding protein follistatin have 
been shown to be involved in the regulation of glucose metabolism and inflammation 
15,62,104,191,260,293. 
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Therefore, the impact of hyperglycaemia on Sertoli cell function was 
investigated using in vitro approaches using primary mouse Sertoli cells as well as an 
immortalized mouse Sertoli cell line (WL-3). This allowed the compensation of 
disadvantages that are associated with the use of a single model, since primary mouse 
Sertoli cells can only be isolated from immature, juvenile mice and, thus, might lack the 
properties of adult Sertoli cells, whereas immortalised Sertoli cells show proliferation, 
which is not seen under physiological conditions in adult mice 264. 
In order to examine the impact of hyperglycaemia cells were first treated with 
varying doses of glucose, insulin, testosterone, or FSH to determine optimal culture 
conditions. Thereafter, a treatment combination of glucose, insulin, and testosterone 
was chosen to mimic different stages of diabetes ranging from physiological to diabetic. 
Of interest, none of the single treatments resulted in changes in activin A 
production. This observation was made in both primary and immortalised cells. Hence, 
further experiments were only conducted with the use of the cell line. With the 
combined treatment, however, WL-3 cells reacted with an increase in activin A 
production when low concentrations of testosterone were present. This was not 
accompanied by changes in protein levels of the activin antagonist inhibin. Furthermore, 
changing concentrations of glucose and insulin had no effect on either of the proteins. 
This suggests that within Sertoli cells, activin A is regulated by changing 
concentrations of testosterone, but not glucose or insulin. This is in accordance with 
recent studies that show that the metabolic cooperation of testicular cells is tightly 
controlled by hormones, such as testosterone 13,90,209. Therefore, any disruption in 
hormonal control of Sertoli cells can lead to changes in spermatogenesis 13. 
Furthermore, the formation of tight junctions under diabetic conditions was 
investigated. Preliminary experiments showed that neither varying concentrations of 
glucose, nor the addition of activin A had an effect on tight junction formation in Sertoli 
cells. However, the majority of publications on this method uses primary cells to 
investigate tight junction formation, whereas here, immortalized WL-3 Sertoli cells 
were used. Thus, it is likely, that the experimental conditions need further optimization 
before the results can be evaluated. 
Glucose is a crucial metabolite for the maintenance of spermatogenesis and 
blood-to-germ cells transport of glucose and other metabolic intermediates is highly 
controlled. This is mainly due to the presence of the blood–testis barrier 219, across 
which glucose transporters (GLUTs) ensure the passive transport of glucose. To date, 
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GLUT1, GLUT3 and GLUT8 isoforms have been identified and were shown to regulate 
glucose uptake by Sertoli cells 54,90. In line with this, previous studies have demonstrated 
that disruptions in glucose or insulin metabolism lead to an adaptation within glucose 
transport machinery in order to ensure the appropriate lactate production 193,215. Thus, it 
is likely that whilst changing concentrations of glucose and insulin had no effect on 
activin and inhibin production, Sertoli cell function is disrupted at the level of the 
glucose transport machinery. 
A limitation of the use of an in vitro culture system is that, in vivo, Sertoli cells 
are highly sensitive to their environment and are surrounded by numerous germ cells at 
different stages of spermatogenesis. Further, they are under the influence of Leydig and 
peritubular myoid cells as well as the presence of local and endocrine factors. Thus, 
results derived from in vitro studies using Sertoli cell lines or primary Sertoli cells 
should be taken with caution since they may not necessarily reflect the in vivo situation. 
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5 Summary 
Type 1 diabetes mellitus is a chronic, lifelong condition with worldwide 
increasing incidence. Furthermore, it affects a growing number of men of reproductive 
age since 90 % of these patients are diagnosed before the age of 30. Numerous studies 
have indicated that diabetes mellitus disrupts fertility at various levels including altered 
spermatogenesis, degenerative and apoptotic changes in testes, and altered glucose 
metabolism in Sertoli cells, but little is known about the underlying mechanisms. 
In the present work, the mev-1 mutant of the nematode Caenorhabditis elegans, 
the Ins2Akita+/- mouse model, as well as cultured Sertoli cells were used to investigate 
whether hyperglycaemia alters the secretory patterns and actions of the activin family of 
proteins. 
It was found that glucose at a concentration of 100 mM significantly reduced 
brood size in mev-1 nematodes. Most interestingly, diabetic Ins2Akita+/- mice showed 
progressive testicular disturbance, with a 30 % reduction in testis weight at 24 weeks of 
age, which correlated with blood glucose and HbA1c values. Diabetic mice showed 
significantly reduced seminiferous tubule diameters and increased spermatogenic 
disruption, although testes morphology appeared grossly normal. Serum LH and 
testosterone were similar in all groups. All Ins2Akita+/- mice showed elevation of the 
testicular inflammatory cytokines activin A and IL-6 at 12 and 24 weeks of age, while 
other key inflammatory cytokines were unaffected. Conversely, intratesticular activin B 
was downregulated at both time-points, while the activin regulatory proteins, follistatin 
and inhibin, were unchanged. At 24 weeks, activin type 2 receptor subunit expression 
was reduced in the diabetic mice, but Smad signalling was enhanced. Finally, 
investigations on in vitro cultured Sertoli cells did not show an effect of hyperglycaemia 
on activin A regulation or the formation of tight junctions. 
In conclusion the present work demonstrates that hyperglycaemia disrupts 
fertility in both mev-1 nematodes and the Ins2Akita+/- mouse model. Moreover, it was 
shown that prolonged exposure to elevated blood glucose in the Ins2Akita+/- mice leads to 
progressive testicular disruption, which may be exacerbated by dysregulation of 
testicular activin activity rather than by dysregulation of the hypogonadal pituitary 
gonadal-axis. 
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6 Zusammenfassung 
Typ 1 Diabetes mellitus ist eine chronische, lebenslange Erkrankung mit 
weltweit steigender Inzidenz. Ferner ist eine steigende Zahl an Männern im 
reproduktiven Alter betroffen. Zahlreiche Studien weisen darauf hin, dass T1D die 
männliche Fertilität auf verschiedenen Ebenen, darunter Veränderungen in der 
Spermatogenese und ein veränderter Glucose Stoffwechsel in Sertoli Zellen, beeinflusst. 
Jedoch ist wenig über die zugrundeliegenden Mechanismen bekannt. 
Im Rahmen dieser Arbeit wurden die mev-1 Mutante der Nematode 
Caenorhabditis elegans, das Ins2Akita+/- Mausmodel sowie kultivierte Sertoli Zellen 
verwendet, um zu untersuchen, ob Hyperglykämie die Sekretionsmuster und Funktionen 
der Activin Proteinfamilie verändert. 
Es konnte gezeigt werden, dass eine Glucosekonzentration von 100 mM die 
Wurfgröße in mev-1 Nematoden erheblich vermindert. Darüber hinaus wiesen 
diabetische Ins2Akita+/- Mäuse eine progressive testikuläre Störung mit einer 30 %igen 
Reduktion des Hodengewichts im Alter von 24 Wochen auf. Diese korrelierte mit den 
Blutglucose und HbA1c Werten. Diabetische Mäuse zeigten signifikant reduzierte 
Tubulidurchmesser sowie vermehrte Störungen in der Spermatogenese. Serumwerte für 
LH und Testosteron waren in allen Gruppen ähnlich. Alle Ins2Akita+/- Mäuse hatten 
erhöhte Werte für die inflammatorischen Zytokine Activin A und IL-6, während andere 
Zytokine unbeeinträchtigt blieben. Im Gegensatz dazu war intratestikuläres Activin B 
herunterreguliert, während die regulatorischen Proteine Follistatin und Inhibin 
unverändert blieben. Im Alter von 24 Wochen wiesen diabetische Mäuse eine 
Reduktion des Activin Typ 2 Rezeptors auf, während der Smad Signalweg verstärkt 
war. Letztlich konnten die Untersuchungen an in vitro kultivierten Sertoli Zellen keine 
Wirkung von Hyperglykämie auf die Regulation von activin A oder die Formation von 
tight junctions nachweisen. 
Zusammenfassend wurde in der vorliegenden Arbeit gezeigt, dass 
Hyperglykämie die Fertilität sowohl in mev-1 Nematoden als auch in Ins2Akita+/- Mäusen 
beeinträchtigt. Ferner wurde nachgewiesen, dass, im Ins2Akita+/- Model, andauernde 
Einwirkung von erhöhtem Blutzucker zu progressiven Störungen im Hoden führt, 
welche möglicherweise durch eine Dysregulation der testikulären Activin Aktivität 
verstärkt wird.  
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List of abbreviations 
ActRIIA Activin receptor 2 A 
ActRIIB Activin receptor 2 B 
A.D.  Anno Domini 
AGE  Advanced glycation endproduct 
ALX  Alloxan 
ALK  Anaplastic lymphoma kinase 
AMH  Anti-müllerian hormone 
AR  Androgen receptor 
APC  Antigen presenting cells 
ATP  Adenosine-tri-phosphate 
BG  Blood glucose 
BMI  Body mass index 
BMP  Bone morphogenetic protein 
BSA  Bovine serum albumin 
BTB  Blood-testis-barrier 
BW  Body weight 
C. elegans Caenorhabditis elegans 
CGC  Caenorhabditis Genetics Center 
CGRP  Calcitonin gene-related peptide 
CML  Carboxymethyl-lysine 
C-peptide Connecting peptide 
CTS  Cataract-prone subline 
CYB5A Cytochrome b5A 
CYP  Cytochromes P450 
DAB  Diaminobenzidine 
dbl-1 Drosophila decapentaplegic (Dpp) and bone morphogenetic 
protein (BMP)-like-1 gene, homologous to Smad-1 in humans 
DHEA  Didehydroepiandrosterone 
DM  Diabetes mellitus 
DMEM Dulbecco's Modified Eagle's Medium 
DNA  Deoxyribonucleic acid 
DR  Diabetic retinopathy 
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dsDNA Double stranded deoxyribonucleic acid 
E. coli  Escherichia coli 
ED  Effective dose 
ELISA  Enzyme-linked immunosorbent assay 
ENU  N-ethyl-N-nitro-sourea mouse mutagenesis project 
ER  Endoplasmic reticulum 
ERG  Electroretinogram 
ESRD  End-stage renal disease 
FST  Follistatin 
FDX1  Ferredoxin 1 
FDXR  Ferredoxin Reductase 
FSH  Follicle-stimulating hormone 
GAD65 Glutamic acid decarboxylase 65 
GAR  Goat anti-rabbit IgG 
GnH  Gonadotropin 
GnRH  Gonadotropin releasing hormone 
GDF  Growth and differentiation factor 
GDNF  Glial-cell-derived neurotrophic factor 
GSIS  Glucose stimulated insulin secretion 
GTP  Guanosine-tri-phosphate 
HbA1c Glycated hemoglobin, hemoglobin A1c 
HLA  Human leukocyte antigen 
HPG-axis Hypothalamic-pituitary-gonadal axis 
hr  Human recombinant 
HRP  Horse reddish peroxidase 
HSB  High saline bicarbonate buffer 
HSD  Hydroxysteroid dehydrogenases 
IA  Insulin antibodies 
IA-2  Insulinoma antigen-2 
ICSI  Intracytoplasmic sperm injection 
IGF-1  Insulin-like growth factor-1 
IgG  Immunoglobulin G 
IFIH1  Interferon-induced with helicase C domain 1 
IFNγ  Interferon γ 
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IL  Interleukin 
IL2RA  Interleukin-2 receptor-α 
Ins  Insulin gene 
Ins1  Preproinsulin 1 
Ins2  Preproinsulin 2 
Insl3  Insulin-like growth factor 3 
IT  Insulin therapy 
IVF  In vitro fertilization 
LH  Luteinizing hormone 
LHCGR Luteinizing hormone–chorionic gonadotropin receptor 
LVMV Left ventricular mass/ volume 
MDA5  Melanoma differentiation-associated protein 5 
Mev-1  Methyl viologen sensitive-1 
MHC  Major histocompatibility complex 
MI  Myocardial infarction 
MODY Maturity onset diabetes of the young 
mtDNA Mitochondrial deoxyribonucleic acid 
nDNA  Nuclear deoxyribonucleic acid 
NGM  Nematode growth medium 
NOD  Non-obese diabetic mouse 
NK-cells Natural killer cells 
OAD  Oral anti-diabetica 
OD  Optical density 
OGTT  Oral glucose tolerance test 
OHdG  Hydroxydeoxyguanosine 
PBS  Phosphate buffered saline 
PEG  Polyethylene glycol 
PenStrep Penicillin-streptomycin 
PC  Prohormone convertase 
PCR  Polymerase chain reaction 
POR  P450 Oxidoreductase 
ppiA  Peptidylpropyl isomerase A 
PTPN22 Protein tyrosine phosphatase, non-receptor type 22 
PVDF  Polyvinylidene fluoride 
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qRT-PCR Quantitative reverse transcriptase polymerase chain reaction 
RAGE  Receptor for advanced glycation endproducts 
RGC  Retinal ganglion cell 
RIA  Radioimmunoassay 
RNA  Ribonucleic acid 
RNAi  Ribonucleic acid interference 
ROS  Reactive oxygen species 
RT  Room temperature 
RT-PCR Reverse transcriptase polymerase chain reaction 
SAPE  Streptavidin-Phycoerythrin 
SBTI  Soybean trypsin inhibitor 
SDS  Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate poly acrylamide gel electrophoresis 
SI  Spermatogenesis index 
SLC  Solute carrier family 
Sma  small body size gene 
Smad Contraction of Sma (small body size) and Mad (Mothers against 
decapentaplegic) 
SNP  Single-nucleotide polymorphisms 
SOX-9  SRY-Box-9 
SRP  Signal-recognition particle 
SRY  Sex determining region of the Y chromosome 
SSC  Spermatogonial stem cells 
StAR  Steroidogenic acute regulatory protein 
STZ  Streptozocin 
TAC  Total antioxidant capacity 
TAD  Triton assay diluent 
TCR  T-cell receptor 
TER  Transepithelial resistance 
TGF-β  Transforming growth factor-β 
Th1  Type 1 helper cells 
Th2  Type 2 helper cells 
TLR  Toll-like receptors 
TMB  Tetramethylbenzidine 
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TNF-α  Tumor necrosis factor-α 
T-reg  Regulatory T-cells 
TUNEL TdT-mediated dUTP-biotin nick end labelling 
TW  Testis weight 
T1D  Type 1 diabetes 
T2D  Type 2 diabetes 
UTP  Uridine-tri-phosphate 
WHO  World Health Organization 
WR  Working reagent 
ZnT8  Zinc transporter 8 
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A Appendix: Materials 
A.1 Consumables 
Consumable material was purchased from Brand GmbH (Wertheim, Germany), 
Carl Roth GmbH & Co. KG (Karlsruhe, Germany), Duran Group GmbH 
(Wertheim/Main, Germany), Greiner Bio-One GmbH (Frickenhausen, Germany), 
ThermoScientific (MA, USA), Pechiney (Chicago, USA), Sarstedt AG & Co. 
(Nürnbrecht, Germany), Schleicher & Schuell (Dassel, Germany), and EMD Millipore 
(MS, USA). 
Table A-1. List of consumables with order number and manufacturer 
Consumables Manufacturer 
Beakers  Duran  
Cell culture microplates 96 well  Greiner Bio-One  
Cell culture tubes  Greiner Bio-One  
Erlenmeyer flasks  Duran  
Laboratory glass bottles  Duran  
Measuring cylinders Brand 
Micro tubes (1.5 ml, 2 ml)  Sarstedt  
Parafilm® M Pechiney Plastic Packaging  
Pasteur pipettes (150 mm)  Carl Roth  
Petri dishes  Carl Roth  
Pipette tips (10 µl, 200 µl, 1000 µl) Sarstedt 
Reagent and centrifuge tube (15 ml, 50 ml)  Sarstedt 
Rotilabo ®-cryo boxes  Carl Roth  
Rotilabo ®-disposable cuvettes semi-micro  Carl Roth  
Rotilabo ®-inoculating loops  Carl Roth  
Scalpel  Carl Roth  
Serological pipette (2, 5, 10, 25 ml)  Sarstedt 
Steristoppers ® Carl Roth  
Toothpicks  Carl Roth  
Reaction tube (1.5 ml, 2 ml)  Sarstedt 
Glass tubes ThermoScientific  
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PVDF membrane Immobilon-P EMD 
GB002 gel-blotting-paper Schleicher & Schuell 
120 ml container Sarstedt 
Magpix Performance Verification Kit EMD 
Magpix Performance Calibration Kit EMD 
A.2 Instruments 
Instruments that were used in the present work are listed in Table A-2. Instrument 
manufacturers were Carl Zeiss GmbH (Jena, Germany), Hettich (Tuttlingen, Germany), 
Eppendorf (Hamburg, Germany), Schott AG (Mainz, Germany), Gilson (Bad Camberg, 
Germany), Heraeus (Hanau, Germany), Lovibond (Dortmund, Germany), Binder 
(Tuttlingen, Germany), Hirschmann (Eberstadt, Germany), Kern & Sohn (Bailingen, 
Germany), neoLab (Heidelberg, Germany), Bandelin electronic (Berlin, Germany), 
Heidolph Instruments (Schwabach, Germany), Bosch (Gerlingen, Germany), 
Köttermann GmbH & Co KG (Uetze, Germany), Fried Electric (Haifa, Israel), IKA®-
Werke GmbH & CO. KG (Staufen, Germany), Satorius (Göttingen, Germany), Leica 
Microsystems GmbH (Wetzlar, Germany), Apple Inc. (CA, USA), Brother Industries 
Ltd. (Nagoya, Japan), NanoDrop (DE, USA), Vilbert Lourmat (Eberhardzell, 
Germany), Von Keutz (Reiskirchen, Germany), Peqlab Biotechnologie GmbH 
(Erlangen, Germany), VWR International (Leuven, Netherlands), Lewis plastics PTY. 
LTD. (VIC, Australia), Applied Biosystems (CA, USA), John Lewis (Sheffield, UK), 
Hoefer scientific instruments (San Francisco, USA), Dell (TX, USA), ThermoScientific 
(MA, USA), MS major science (CA, USA), Ratek Instruments (Boronia, Australia), 
EMD Millipore (MS, USA), Labsystems (Vantaa, Finnland), Sigma Laborzentrifugen 
(Osterode am Harz, Germany), Industrial equipment & control PTY. LTD (VIC, 
Australia), Ohaus (Nänikon, Switzerland), Pharmacia (Uppsala, Sweden), and Stuart 
Scientific (Staffordshire, UK). 
Table A-2. List of instruments with model description and manufacturers. 
Instrument Manufacturer 
Axioskop 2 MOT microscope  Carl Zeiss  
Benchtop centrifuge universal 320R  Hettich 
Biophotometer Plus  Eppendorf 
Appendix A: Material 
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Cold light source KL200  Schott 
Distriman® Gilson 
HERAsafe® KS safety cabinet  Heraeus 
Incubator  Lovibond 
Incubator  Binder 
Pipetman® P Gilson 
Pipetus®   Hirschmann  
Precision balance  Kern 
Rotating shaker  neoLab 
Ultrasonic bath  Bandelin 
Vacuum pump  neoLab 
Vortex mixer REAX control  Heidolph  
Water bath  Bandelin 
Hera Safe KS 12laminar flow cabinet Heraeus 
CO2 incubator Heraeus 
fridge-freezer Bosch 
Universal 32R cooling table centrifuge Hettich 
Biofuge fresco  Heraeus 
Biofuge 13  Heraeus 
fume cupboard Köttermann 
WBS-8 water quench Fried Electric 
Type REAX 1R vortex mixer Heidolph 
RCH magnetic mixer IKA 
Typ L610D scale (d = 0,01 g) Satorius 
Labovert FS microscope (inverse) Leica 
freezer Bosch 
iMac Apple 
MFC-7820N printer brother 
ND-1000 Spectrophotometer NanoDrop 
Darkroom-CN-3000 Vilbert Lourmat 
rocking shaker Von Keutz 
Power supply Von Keutz 
PCR Gel chambers Consort  E844 Von Keutz 
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Double gel system PerfectBlue Twin S peqLab 
PCR Thermocycler 173L VWR 
StepOnePlus Real-time PCR System Applied Biosystems 
Smoothflow fume hood SF 2000 FK 1200 Lewis 
Dual gel caster Mighty smallTM SE245 Hoefer 
Eppendorf Pipette 20 µl Eppendorf 
Eppendorf Pipette 200 µl Eppendorf 
1000 µl pipette ThermoScientific 
Dry Bath incubator MD-01N-220 MS 
Plate shaker MPS1 Ratek 
ELISA plate reader, Labsystem Multiscan RC Type: 351 Labsystems 
Dimension 1100 (Computer attached to ELISA scanner) Dell 
Magnetic stirrer N1471 Industrial equipment 
Scales ARB120 Ohaus 
Automated plate washer Wellwash 4 MK 2 ThermoScientific 
Vortex mixer VM1 Ratek 
Multipipette® Plus Eppendorf 
Multiple pipette (8-channel) Labsystems 
Centrifuge Model 1-15 
 
Sigma 
Laborzentrifugen 
Electrophoresis Power Supply EPS 500/400 Pharmacia 
Roller SRT-1  Stuart Scientific 
SE250 Western Blot electrophoresis chamber Hoefer 
L2CRD Western Blot Transfer Chamber Plaztek Scientific 
Western Blot Transfer Power Supply Bio-Rad 
Roller Mixer BTR10-12V Ratek 
Odyssey® Scanner LI-COR 
Hand held magnetic separation block for 96-well plate EMD 
Magpix (Milliplex Map Multiplex Assays) EMD 
A.3 Chemicals and reagents 
Chemicals and reagents (Table A-3) were purchased from Bio-Rad Laboratories 
GmbH (München, Germany), Carl Roth GmbH & Co. KG (Karlsruhe, Germany), Life 
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Technologies GmbH (Darmstadt, Germany), Merck KGaA (Darmstadt, D), Sigma-Aldrich 
Chemie GmbH (Munich, Germany), Serva Electrophoresis GmbH (Heidelberg, Germany), 
VWR International (Leuven, Netherlands), Chem-Supply Pty. Ltd. (SA, Australia), 
AnalaR® (VIC, Australia), BD Biosciences (CA, USA), LI-COR (NE, USA), 
AppliChem GmbH (Darmstadt, Germany), Peqlab Biotechnologie GmbH (Erlangen, 
Germany), Calbiochem (CA, USA), Otto Fischar GmbH & Co. KG (Merchweiler, 
Germany), Amresko LLC (OH, USA), ThermoScientific (MA, USA), and Sanquin 
(Amsterdam, Netherlands). 
Table A-3. List of chemicals with order number and manufacturer 
Chemical Order number Manufacturer 
2-Propanol 67-63-0 Roth 
2-β-Mercaptoethanol (min. 98 %) M3148 Sigma 
30 % Acrylamide/ Bis solution, 37.5:1 (2.6 % C) 161-0158 Bio-Rad  
Acetic acid 100% 64-19-7 Merck 
Acetic acid-n-butylester (EBE) 123-86-4 Roth 
Acetone 67-64-1 Roth 
Agar Agar SERVA Kobe I  11392  Serva 
Agarose 35-3020 peqlab 
Ammoniumpersulfate (APS) 161-0700 Bio-Rad  
Ammoniumpersulfate APS A3678 Sigma 
Ampicillin sodium salt  K029.1  Roth 
Bovine serum albumin (BSA) 9048-46-8 Sigma 
Bovine serum albumin (BSA) A3294 Sigma 
Bromphenolblue 8122 Merck 
Calcium chloride dihydrat (CaCl2 · 2 H2O)  5239.2  Roth 
Calciumchlorid-Dihydrate 10035-04-8 Roth 
Calciumchloridedihydrate 10035-04-8 AppliChem 
Carbenicillin disodium salt  C1389  Sigma  
Cholesterol C8667  Sigma  
Citric acid monohydrate 5949-29-1 Roth 
D(+) Mannose M6020 Sigma 
D(+)-Glucose monohydrate 6780.1  Roth 
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D(+)-Saccharose 57-50-1 Roth 
Deoxycholic acid D2510 Sigma 
Di-Sodium hydrogen phosphate (Na2HPO4)  P030.1  Roth 
Di-Sodiumhydrogenphosphate 7558-79-4 Roth 
Dimethylsulfoxide (DMSO) 67-68-5 Roth 
Dimethylsulfoxide (DMSO) 20385 Serva 
Diphenylthiocarbazone 60-10-6 Sigma 
Dithizone   Sigma 
DPX mountant for microscopy 360294H VWR 
EDTA 11278.01 Serva 
Ethanol (> 99.5 %)  5054.3  Roth 
Ethanol 100 % undenaturated EL043-20L-P Chem-Supply 
Ethanol 100% 64-17-5   
Formaldehyde 3.5-3.7% 50-00-0 Fischar 
Fuchsin 21916 Serva 
Glycin 0167 Amresco 
Harris Hematoxylin HHS16 Sigma 
HCl (37 %, fuming) K35557371 603 Merck 
Hematoxyline  1051750500 Merck 
Hepes 7365-45-9 Roth 
Hepes buffer pH 7.5 A6916 AppliChem 
Hydrochloric acid 1mol/L 110165 Merck 
Hydrochloric acid 25 % 7647-01-0 Roth 
Hydrochloric acid 37 % fuming 100317 Merck 
Hydrochloric acid 6mol/L 0281.1 Roth 
Hydrogen peroxide (30 %) K44176709 304 Merck 
Hypdrogenperoxide 30% 7722-84-1 Merck 
Igepal CA-630 I3021 Sigma 
Isopropanol (2-Propanol) K43192934 232 Merck 
Isopropyl-β-D-thiogalactopyranoside (IPTG)  59740  Sigma 
KCl PA054 Chem-Supply 
KH2PO4 10203.4B AnalaR® 
L-Lactic acid-sodium-salt  Serva 
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Levamisol hydrochloride  46944  Sigma  
Magnesium sulphate heptahydrate (MgSO4 · 7 
H2O)  
P027.2  Roth 
Magnesiumsulfateheptahydrate 10034-99-8 AppliChem 
MassRuler DNA Ladder Mix #SM0403 Thermo 
Scientific 
MassRuler Low Range DNA Ladder #SM0383 Thermo 
Scientific 
Methanol MA004-20L-P Chem-Supply 
Mouse IL-6 ELISA Set 555240 BD 
Na2CO3 A0313192 211 Merck 
Na2HPO4 F1786486 321 Merck  
NaCl SA046 Chem-Supply 
NaHCO3 K45372729 428 Merck 
NaN3   
NewBlotTM PVDF Stripping Buffer 928-40032 LI-COR 
Nicotinamide 98-92-0 Sigma 
Nystatin Suspension  N1683  Sigma 
Odyssey® Blocking buffer 927-40000 LI-COR 
Odyssey® protein molecular weight marker 928-40000 LI-COR 
Omnipur Tris-HCl 1185-53-1 Calbiochem 
Peptone ex soya  2365.1  Roth 
Pikrinsäure 1.2% 88-89-1 AppliChem 
Ponceau S Solution (0.2 %) 33427 Serva 
potassium chloride 7447-40-7 AppliChem 
Potassium dihydrogen phosphate (KH2PO4)  3904.1  Roth  
Potassium hexacyanoferrate ( II) 3- hydrate 14459-95-1 AppliChem 
Pyruvic Acid 113-24-6 Sigma 
Roti®-Histokitt 6638 Roth 
Roti®-Histol 6640 Roth 
Sodium chloride (NaCl)  3957.1  Roth  
Sodium hydroxide (NaOH)  677.1  Roth 
Sodium hydroxide 10% 1310-73-2 Roth 
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Sodium hydroxide 1mol/L 137031 Merck 
Sodium hypochlorite solution (NaClO in H2O, 
12 % Cl)  
9062.3  Roth 
Sodium pyruvate 113-24-6 Sigma 
Sodium-dodecyl-sulfate (SDS) 161-0301 Bio-Rad 
Sodium-dodecyl-sulfate SDS 151-21-3 AppliChem 
Sodiumchlorid 7647-14-5 AppliChem 
sodiumhydrogencarbonate 144-55-8 Roth 
Strepavidin Poly-HRP M2051 Sanquin 
SYTOX ® Green nucleic acid stain  S7020  Life 
Technologies  
TEMED 161-0801 Bio-Rad 
Tetracycline hydrochloride  T7660  Sigma 
Tetramethylbenzidin (TMB) 002023 Life 
Technologies 
Tris Buffer grade 77-86-1 AppliChem 
Tris-base 648310 Calbiochem 
Tris-hydrochloride 1185-53-1 Roth 
Triton X-100 T-9284 Sigma 
Trypanblue T8154 Sigma 
Tween®-20 P1379 Sigma 
A.4 Buffers and solutions 
Table A-4. List of buffers and solutions 
Buffer Ingredients 
10x PBS stock solution (pH 7.5) 28.8 g Na2HPO4 + 4.8 g KH2PO4 + 160 g NaCl 
+ 4 g KCl + 1.8 L MilliQ H2O, pH to 7.5 then 
make up to 2 L with MilliQ H2O 
1x PBS 100 ml 10x PBS stock solution (pH 7.5) + 900 
ml RO H2O 
2x YT-agar 2x YT-medium + 15 g agar, solution was 
autoclaved for 1 h at 121 °C, cooled for 1 h in a 
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55°C water bath, + Ampicillin (final 
concentration 100 µg/ ml) 
2x YT-medium 16 g Bacto-pepton + 10 g Bacto-Yeast-Extract 
+ 5 g NaCl + 1 L MilliQ H2O, adjust pH to 7.0, 
solution was autoclaved for 1 h at 121 °C and 
stored at RT afterwards 
6 % SDS in 0.05 M PBS water for 
ELISA media samples 
30 g SDS + 500ml 0.05 M PBS 
6 % SDS in MilliQ water for ELISA 
sera samples 
30 g SDS + 500ml MilliQ H2O 
Activin A ELISA Blocking buffer 
(50 mM Tris-HCl, pH 7.4) 
7.88 g Tris-HCl (Omnipure) + 950 ml MilliQ 
Water, pH to 7.4 then make up to 1 L with 
MilliQ H2O 
add 1 % BSA prior to use 
Activin B ELISA Blocking buffer (1 
% BSA-PBS-6 % Sucrose) 
3 ml 10x PBS (pH 7.5) + 27 ml MilliQ H2O + 
1.8 g Sucrose, mix until sucrose is dissolved, 
0.3 g BSA 
Ammoniumpersulfate (10%) 250 mg Ammoniumpersulfate + 2500 µl RO 
H2O 
Ampicillin 100 mg dissolved in 1 ml of 50 % EtOH 
Bicarbonate buffer 50 ml HS buffer + 0.063 g NaHCO3 
Bleaching-solution 0.5 ml NaClO (12 % Cl) + 0.5 ml NaOH (5 N) 
+ 0.5 ml MilliQ H2O 
Bromphenolblue (0,5%) 0.05 g Bromphenolblue + 10 ml RO H2O, filter 
solution 
CaCl2 0.1 M 
Carbenicillin 25 mg dissolved in 1 ml 50 % EtOH 
Carbonate buffer (pH 9.6) for 
ELISA 
6.1.1.1.1.1.1 0.8 g Na2CO3 (acid) + 1.5 g 
NaHCO3 (alk) + 500 ml MilliQ H2O 
Casein colloid buffer 2 ml 5 % Casein + 8 ml 1x PBS + 2.5 µl Strept-
poly-HRP 
Cholesterin 5 mg dissolved in 1 ml 100 % EtOH 
EBE solution I EBE (1 part) + 99 % Ethanol (2 parts) 
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EBE solution II EBE (2 parts) + 99 % Ethanol (1 part) 
EBE solution III & IV EBE (pure) 
ELISA assay buffer 1 ml 10x PBS (pH 7.5) + 9 ml MilliQ water + 
0.5 g BSA 
ELISA stop solution – 0.3 M HCl 1 ml concentrated HCl + 59 ml MilliQ H2O 
ELISA Wash buffer 100ml 10x PBS (pH 7.5) + 900 ml MilliQ + 0.5 
ml Tween-20 
HS buffer 100 ml HS buffer stock solution + 0.3 g 
glucose + 4 ml HEPES (1 M, pH 7.4) + 0.5 ml 
lactate + 0.022 g pyruvate à fill up to 200 ml 
and adjust pH to 7.4 
HS buffer stock solution 270 mM NaCl (15.77 g) + 10 mM KCl (0.745 
g) + 2 mM MgSO4 + 4 mM CaCl2 
HSB-buffer (pH 7.2) 5 ml bicarbonate buffer + 0.025 g BSA 
IPTG 1 M 
KH2PO4 (pH 6,0) 1 M 
Levamisol (2 mM) 120.38 mg Levamisol-Hydrochlorid + 250 ml 
MilliQ H2O; solution was stored at 4°C 
M9-buffer 3 g KH2PO4 + 6 g Na2HPO4 + 5 g NaCl + 1 L 
MilliQ H2O, solution was autoclaved for 1 h at 
121 °C, cooled for 1 h in a 55°C water bath, + 
1 ml MgSO4 solution (1 M), pH was adjusted 
to 7.0, solution was stored at RT 
M9-buffer/Tween®20 50 ml M9-buffer + 500 µl Tween®20 
MgSO4 0.1 M 
NaCl-Pepton-solution (autoclaved 
for 15 minutes at 121.9°C) 
3 g NaCl + 2.5 g Bacto-Pepton + 1 L MilliQ 
H2O 
NGM-Agar  3 g NaCl + 2.5 g Bacto-Pepton + 17 g Agar + 
947 ml MilliQ H2O, autoclaved for 15 minutes 
at 121.9°C, cooled for 1 h in a 55°C water bath, 
+ 25 ml KH2PO4 (1 M) + 1 ml MgSO4 (0.1 M) 
+ 1 ml CaCl2 (0.1 M) + 1 ml Cholesterol (5 mg/ 
100 ml) + 10 ml Nyastatin (10000 U/ml) 
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ca. 9 ml of the 55°C NGM-Agar were casted 
into 92 mm Petri dishes; dishes were left to 
solidify for 1 h under sterile conditions 
(slightly covered); afterwards plates were 
stored at RT 
NGM-liquid-media (prepared freshly 
for every trail) 
9.72 ml NaCl-Pepton-solution + 10 µl 
Cholesterol (5 mg/ 100 ml) + 10 µl CaCl2 (0.1 
M) + 10 µl MgSO4 (1 M) + 250 µl KH2PO4 (1 
M) + 10 µl Carbenicillin 
Nystatin (10000 U/ml) 2.14 mg/ ml 
Reagent Diluent (10 % BSA in TAD 
(Triton Assay Diluent) (Tris-
buffered Saline, 25 mM Tris, 0.15 M 
NaCl, 5 % Triton X-100, 0,.1 % 
NaN3 and 10 % BSA) 
1.51 g Tris + 4.39 g NaCl + 25 ml Triton X-
100 + 0.5 g NaN3 + 475 ml MilliQ H2O 
Adjust pH to 7.2 
For use in assay add 10 % BSA prior to use (15 
ml TAD + 1.5 g BSA) 
RIPA-Buffer 0.438 g NaCl + 0.25 g Sodiumdeoxycholate + 
0.05 g SDS + 0.5 ml Igepal CA 630 + 50 mL 
Tris buffer (50 mM, pH 8.0) 
Running buffer (1x) 200 ml Running Buffer stock solution (5x) + 
800 ml RO H2O 
Running Buffer Stocksolution (5x) 15 g Tris-base + 72 g Glycin + 800 ml RO 
H2O, adjust to pH 8.3, fill up to 1000 ml with 
RO H2O 
Sample buffer (4x Laemmli) 2.4 ml 1 M Tris (pH 6.8) + 0.8 g SDS + 4 ml 
Glycerol (100 %) + 0.2 ml Bromphenolblue 
(0.5 %) + 1.9 ml ß-Mercaptoethanol + 2.8 ml 
RO H2O, 500 µl aliquots stored at -20°C 
SDS (10%) 50 mg SDS + 10 ml RO H2O 
SYTOX Green 5 mM 
TAE (50-fold, 250 ml) 60.5 g TRIS base, 14.28 ml acetic acid (1 M), 
4.65 g Tidiplex, Aqua dest. 
Tetracyclin  25 mg dissolved in 1 ml 50 % EtOH 
Transfer buffer (1x) 800 ml RO H2O + 100 ml Transfer buffer stock 
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solution (10x) + 100 ml Methanol 
Transfer buffer Stocksolution (10x) 29 g Glycin + 58 g Tris-base + 3.7 g SDS + 
1000 ml RO H2O 
TRIS 1 M 7.88 g TRIS-HCl + 40 ml RO H2O, adjust to 
pH 6.8, fill up to 50 ml with RO H2O 
TRIS 1.5 M 18.18 g TRIS-base + 70 ml RO H2O, adjust to 
pH 8.8, fill up to 100 ml with RO H2O 
Tris buffer (50 mM, pH 8.0) 0.606 g Tris base + 100 ml RO H2O 
TRIS stock solution (10-fold) 60.5 g TRIS base, 700 ml A. dest, adjust to pH 
7.6 using 25 % HCl, fill up to 1 L using A. 
dest, add 90 g NaCl 
TRIS-HCl (pH 8.2) 1.576 g TRIS-HCl dissolved in 100 ml 
Triton assay buffer 
(0,1 M Tris – 5 % Triton X-100 – 0.9 
% NaCl) 
6.06 g Tris-base + 4.5 g NaCl + 25 ml Triton 
X-100 + 450 ml MilliQ H2O, pH to 7.5 then 
make up to 500 ml with MilliQ H2O 
Plate buffer: add 20 % BSA prior to use 
Antibody diluent: add 5 % BSA prior to use 
A.5 Software 
Table A-5. Software 
Software Company 
ChemDraw Professional 15.0 PerkinElmer Inc., MA, USA 
Genesis Novell, UT, USA 
ImageJ Open source 
Luminex Software XPonent42 EMD Millipore, MS, USA 
Milliplex Analyst Software EMD Millipore, MS, USA 
Odyssey LI-COR, NE, USA 
OS X El Capitan Version 10.11.5 Apple Inc., CA, USA 
Windows XP home edition on ELISA computer Microsoft Corporation, WA, USA 
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B Appendix: Supplementary tables 
Table B-6. Clinical studies on the effect of T1D on male reproductive function 
Subjects Mean Age Reproductive Effects References 
27 patients 
with T1D 
34 ± 2 • significant reduction in Semen volume in 
diabetic men 
• no differences in sperm concentration, 
total sperm output, percentage motility or 
percentage normal morphology 
• significantly higher levels of fragmented 
sperm nDNA and mtDNA sperm 
deletions in diabetic patients 
• authors conclude that the “significant 
differences lie at a ‘molecular’ and not at 
‘cellular’ level” 
3 
11 male 
T1D 
patients 
32.0 ± 1.6 • no changes with regard to semen volume, 
sperm concentration, motility, and 
morphology 
• significantly higher levels of sperm 
nDNA fragmentation 
• significant increase in 7.8-dihydro-8-oxo-
2-deoxyguanosine (8-OHdG 10-5dG) in 
sperm form T1D patients 
• 8-OHdG 10-5dG was significantly 
associated with nDNA fragmentation 
• T1D is related to increased oxidative 
stress and nDNA damage in sperm 
2 
100 T1D 
patients 
15-80 
years of 
age 
• significant increase in prolactin, FSH, 
and LH levels 
• significant decrease in testosterone levels 
• testicular dysfunction with intertubular 
fibrosis or tubular sclerosis, organic 
8 
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vascular disease (i.e. hypogonadotropic 
hypogonadism), and alteration in Leydig 
cell morphometry 
22 diabetic 
patients 
38 ± 6 • no differences in basal hormonal levels 
(LH, FSH, testosterone), but reduced 
response to GnRH 
• no differences in seminal fluid volume, 
sperm, concentration or total sperm 
number 
• significantly lower sperm motility  
• abnormal acrosome shape in 78 % 
• reduced acrosome dimension in 57 % 
• abnormal nuclear shape in 74 % 
• incorrectly assembled mitochondria in 45 
%  
• broken plasma membrane in 32 % of 
germinal cells 
28 
15 T1D 
patients 
18.5 years • lower sperm values in T1D group  
• significant changes in sperm motility and 
morphology 
33 
1 T1D 
patient 
33 years 
of age • retrograde ejaculation 
• poor sperm motility and density 
• acidic ejaculate 
• sperm motility and density were 
recovered by alkalinisation of the patient 
45 
10 diabetic 
patients 
45.6 ± 4.1 
• impotence, nocturnal tumescence 
• testicular sections show minimal to 
moderate pathology 
• germ cell depletion 
• maloriented spermatids 
• thickened seminiferous tubule walls 
53 
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• some tubules devoid of germ cells 
• altered apical Sertoli cell cytoplasm with 
vacuolization, discontinuity of cell 
membranes, mitochondrial lysis 
• cellular debris 
• abnormal or absent Sertoli cell junction 
specification 
• banded collagen in interstitial area 
38 male 
patients 
with T1D 
26.45 ± 
0.89 
• mean total testosterone concentration 
(22.89 ± 1.23 nmol/l) mean free 
testosterone concentration (0.489 ± 
0.030) in T1D patients was comparable to 
normal subjects 
• any observed hypogonadotrophic 
hypogonadism was related to BMI, but 
not to T1D 
57 
27 diabetic 
patients 
26 – 74 
years of 
age 
• no changes in serum testosterone levels 
• 34.6 % of patients had retrograde 
ejaculation 
• no correlation of RE with HbA1c or 
testosterone levels 
82 
7 T1D 
patients 
< 40 years 
of age 
• significant decrease in seminal volume,  
sperm density, percentage of sperm with 
progressive forward movement, and 
viable sperm or sperm with normal 
morphology 
• incomplete arrest of sperm maturation  
• hypospermatogenesis 
• no difference in serum concentrations of 
FSH and LH 
• rise in plasma prolactin levels 
• decrease in plasma testosterone levels 
91 
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643 
diabetic 
patients (69 
T1D, 574 
T2D) 
- • 7 % of men with T1D had low total 
testosterone 
• 20.3 % of men with T1D had low 
calculated free testosterone 
• low testosterone levels were 
independently associated with insulin 
resistance 
96 
28 T1D 
patients 
< 50 years 
of age 
• reduction in testicular volume, semen 
volume, total and total motile sperm 
output  
• elevated plasma LH and FSH levels 
• no direct correlation of glycemic control 
and spermatogenesis 
101 
333 male 
patients 
with T1D 
45.9 ± 
16.4 
• significantly fewer children in T1D 
individuals 
• no significant difference in sex ratio 
114 
32 male 
T1D 
patients 
35.84 ± 
8.89 
• no significant differences in sperm 
concentration, morphology and motility 
between 
• no difference in lipid profiles 
• significantly elevated AGEs levels in the 
seminal plasma of diabetic men 
• no difference in CML levels 
• significant increase in lipid peroxidation 
in spermatozoa and seminal plasma 
• lower total antioxidant capacity (TAC) in 
seminal plasma 
• lipid peroxidation directly correlated with 
AGEs 
• inverse correlation between AGEs and 
TAC 
131 
32 diabetic 35.84 ± • no significant differences in volume of 132 
Appendix B: Supplementary tables 
 168 
patients (17 
T1D, 15 
T2D) 
8.89 semen, sperm concentration, morphology 
and motility of sperms 
• significantly higher levels of RAGE 
protein  
• significantly higher DNA fragmentation 
in spermatozoa 
• sperm RAGE was directly correlated to 
sperm DNA fragmentation in diabetic 
men 
32 patients 
with T1D 
27 • diabetic patients had lower percentage of 
spermatozoa with progressive motility 
and a higher percentage of spermatozoa 
with abnormal mitochondrial function 
• greater post-ejaculatory diameters of 
caput and cauda epididymis 
• higher percentage of spermatozoa with 
low mitochondrial membrane potential 
• these changes correlated with fasting 
glycemia and disease duration 
• no changes in sperm volume or 
concentration 
• no changes in hormone levels of FSH, 
LH, testosterone 
• no correlation between HbA1c and 
conventional or biofunctional 
spermatozoa parameters and serum 
hormone concentrations 
141 
20 T1D 
patients 
 • serum LH levels were significantly 
decreased 
• observed pathologies correlated with the 
control of the diabetic status 
• no difference in serum testosterone levels 
155 
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• function of the HPG-axis is compromised 
in young men with poorly controlled T1D 
21 diabetic 
patients (14 
T1D, 7 
T2D) 
37.6 ± 9.5 • no difference in sperm concentration, 
number, motility, or morphology 
• the receptor for advanced glycation 
endproducts (RAGE) was found 
throughout the testis, caput epididymis, 
particularly the apical region of principle 
cells, and on sperm acrosomes 
• significantly higher number of sperm 
displaying RAGE and overall protein 
amount in sperm and seminal plasma  
163 
13 T1D 
patients 
33.0 ± 3.8 • no changes in sperm concentration, 
motility, and morphology 
• significant increase in total sperm count 
in diabetics 
• carboxymethyl-lysine (CML) was found 
throughout the seminiferous epithelium, 
the nuclei of spermatogonia and 
spermatocytes, in the basal and principle 
cell cytoplasm and nuclei of the caput 
epididymis and on most sperm tails, mid 
pieces and all cytoplasmic droplets 
• acrosomal cap, especially the equatorial 
band, was prominently stained for CML 
in diabetic samples  
• CML was significantly higher in sperm 
from non-diabetic men 
164 
12 patients 
with T1D 
- 
• no significant differences using routine 
light microscopy 
• all semen parameters above WHO 
reference values 
162 
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• perturbations in the expression of 285 
genes involved in stress response, DNA 
metabolism, replication/ repair 
• 21 genes were related to oxidative stress, 
glycation, and AGE/RAGE metabolism 
35 patients 
with T1D 
30.6 ± 4.7 • significantly low serum testosterone, 
accompanied by low LH, low FSH 
• diabetic patients also displayed 
hypercholesterolemia, hypertriglycerid-
emia, and hypoalbuminemia 
• increased oxidative stress 
166 
80 couples 
with a 
diabetic 
male of 
which 18 
underwent 
assisted 
reproductio
n treatment, 
3 patients 
were 
reported to 
be T1D 
36.1 ± 6.8; 
median 
diabetes 
duration 
17.1 years 
• fertilization rates of diabetic patients 
(IVF 68 %, ICSI 62 %) similar to non-
diabetic patients (IVF 70 %, ICSI 71 %) 
• no difference in embryo quality 
• some patients showed retrograde 
ejaculation, azoospermia, and reduced 
sperm motility 
• lower embryo transfers rate (5 % 
combined IVF/ICSI pregnancy rate/cycle 
to 28.8 %) 
• more couples with diabetic men sought 
fertility treatment 
• pregnancy rates were lower in couples 
with a diabetic male 
173 
17 T1D 
patients 
36 years • no correlations found between sperm 
motility and age, age of onset of diabetes, 
duration of diabetes or glycated 
haemoglobin 
• track speed, path velocity, progressive 
velocity, and lateral head displacement of 
sperm were not significantly different 
186 
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274 
diabetic 
patients 
59.9 ± 
11.3 
• 69.3 % had sexual disorder related to 
infrequency (79.2 %), non-sensuality 
(74.5 %), dissatisfaction with sexual acts 
(71.9 %), non-communication (70.8 %), 
impotence (67.9 %), premature 
ejaculation (56.6 %), and avoidance (42.7 
%) 
• Testosterone correlated negatively with 
HBA1c 
197 
32 T1D 
patients 
18.6 years • significantly smaller semen volume, 
lower motility, and lower normal 
morphology  
• lower sperm count  
• no alterations in testosterone levels 
• semen parameters correlated further with 
diabetic neuropathy 
198 
27 diabetic 
patients (13 
T1D, 14 
T2D) 
- • ejaculates of diabetic men contain 
significantly higher concentrations of 
spermatozoa with disrupted 
transmembrane mitochondrial potential, 
activated caspase 3, reactive oxygen 
species and fragmented DNA 
• more pronounced in men with T2D 
• all parameters were inversely correlated 
with the sperm fertilizing potential 
220 
9 T1D 
patients, 27 
T2D 
patients 
52.6 ± 7.2 • significant decrease in sexual desire, 
subjective arousal, erectile capacity, 
coital frequency and sexual satisfaction in 
diabetic patients 
• degree of nocturnal penile tumescent 
episodes 
• no differences between types of diabetes 
229 
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• significant correlation between lack of 
metabolic control, diabetic complications 
and impaired nocturnal tumescence 
• sexually non-functional diabetic men had 
significant nocturnal penile tumescence 
abnormalities 
9 T1D 
patients, 27 
T2D 
patients 
52.6 ± 7.2 • no significant difference between diabetic 
types 
• clinical penile tumescence in diabetic 
patients 
• 77,5 % showed erectile dysfunction 
• respiratory abnormalities during sleep are 
associated with erectile difficulties in 
diabetic men 
230 
37 diabetic 
patients (7 
T1D, 22 
T2D) 
- • significant negative correlation between 
age and the penile blood pressure as 
determined by penile-brachial-index 
(PBI) 
• PBI correlated with impotence in diabetic 
group 
• diabetic type, complications, and 
adequacy of metabolic control were not 
related to PBI 
228 
40 diabetic 
patients 
(type of 
diabetes not 
distinguishe
d) 
52.6 ± 7.2 • significantly lower levels of erotic drive, 
sexual arousal, enjoyment and 
satisfaction 
• no evidence that psychological distress or 
psychiatric disorders are associated with 
diabetes or its effects on sexual function 
231 
314 T1D 
patients 
- • 51 % observed sexual disturbance in 
terms of libido, potency, and fertility 
234 
18 T1D 20 – 40 • normal semen volume, sperm count, and 244 
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patients years of 
age 
spermatozoal motility 
• significantly greater numbers of 
abnormal spermatozoa  
• elevated concentrations of prostaglandins 
(E2, F2αa, and I2 and thromboxane A2 ) 
in seminal plasma 
2819 male 
patients 
with T1D 
T1D 
diagnosed 
before the 
age of 17 
• diabetic men had a smaller number of 
live births  
• hazard ratio of having a first child was 
0.77 (95 %CI 0.72, 0.83) 
• later age at onset of diabetes was 
associated with a higher rate of having a 
first child among men (p=0.04) 
248 
18 diabetic 
patients (15 
T1D, 3 
T2D)  
34 ± 5.3 • diabetics show higher sperm and round 
cell concentrations/ml as well as a higher 
total spermatozoa count 
• higher percentage of abnormal sperm 
• diabetes was not a cause of subfertility 
276 
99 T1D 
patients 
65.1 years • a total of 4.94 % show erectile 
dysfunction 
280 
761 T1D 
patients 
48.0 ± 5.9 • risk of erectile dysfunction was directly 
associated with mean HbA1c 
• intensive glycemic therapy reduced the 
risk of erectile dysfunction 
286 
3010 T1D 
affected 
and 801 
unaffected 
adult 
siblings 
(49.7 % 
men) 
T1D 
patients 
aged ≥ 18 
(31.6 ± 
11.3) 
• mean number of offspring was higher in 
unaffected than in affected siblings 
• birth cohort and time of onset had a 
significant effect on the number of 
offspring (p=0.001) 
• no significant effect of disease duration 
288 
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Table B-7. Animal studies on the effect of T1D on male reproductive function 
Model Reproductive Effects References 
STZ 
injected 
male 
Wistar 
rats 
• seminiferous tubule diameter and Johnsen score values 
were significantly decreased  
• significant reduction in the expression of proliferating 
cell nuclear antigen 
• enhancement in the number of TUNEL positive cells in 
testis tissues 
7 
STZ 
injected 
Wistar rat 
• alterations in spermatogenesis in both the testis and 
epididymis 
• overall results in mitochondrial parameters failed to 
reveal severe testicular mitochondrial dysfunction in 
diabetic animals 
• decrease in calcium load 
14 
STZ 
induced 
male 
Sprague-
Dawley 
rats 
• reduced tubular and testicular diameter 
• reduced proliferating cell nuclear antigen index 
18 
STZ 
injected 
Wistar rat 
• elevated malondialdehyde 
• reduced superoxide dismutase, glutathione, and serum 
testosterone levels 
• no histopathologic changes in the testis tissue 
• pathologies were reversed by vitamin E treatment 
26 
STZ 
injected 
Wistar rat 
• mean number of offspring was higher in unaffected than 
in affected siblings 
• decreased levels of serum insulin, testosterone, FSH, 
and LH 
• negative correlation between glucose and insulin and 
between glucose and testosterone 
• positive correlation between insulin and testosterone, 
30 
Appendix B: Supplementary tables 
 175 
insulin and FSH, testosterone and LH, and LH and FSH  
• significantly reduced reproductive performance, mating 
index, fertility, and libido 
• significantly reduced testis size, which was related to 
loss of interstitial tissue (less compact, increase in 
amorphous material, decrease in the total number of 
Leydig cells per interstitial space (4 ± 1) 
• no disruption in spermatogenesis 
• decreased expression of markers for testicular function 
(phosphorylated tyrosine, GLUT3, IGF-I receptor) 
• no changes in testicular expression of androgen 
receptors 
STZ 
injected 
male 
Sprague-
Dawley 
rats 
• significantly reduced pituitary and plasma LH  
• insulin treatment completely restored these levels 
• significantly decreased cyclic AMP content of 
interstitial cell incubation medium and plasma 
testosterone  
• decreased testicular steroidogenesis in the diabetic rat 
may represent a direct consequence of insulin deficiency 
at the hypothalamic and/or pituitary levels 
34 
STZ 
injected 
male 
Wistar 
albino rats 
• lowering of sexual motivation and mating activity 
• testes were without any traces of oedema, with normal 
blood filling 
• reduction in relative testis weight 
• reduction in spermatozoa 
• changes in spermatogenetic epithelium 
• changes in spermatogenic index, number of 
spermatogonia, tubular epithelium, degenerating 
changes in the testis 
• changes in extracellular matrix proteins 
40 
STZ 
injected 
• significant effects on serum testosterone level, sperm 
DNA integrity and DNA ploidy at 36 days with no 
42 
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Swiss 
albino 
mice 
changes in epididymal sperm concentration or germ cell 
methylation status 
• at the end of 76 days, no significant effects on serum 
testosterone level, sperm DNA integrity and DNA 
ploidy status, but altered epididymal sperm 
concentration and methylation status of 
preleptotene/zygotene cells 
• an attempt to find out the association between the blood 
glucose levels and the abnormalities in hyperglycemic 
group failed to demonstrate any correlation 
STZ 
induced 
male 
Sprague-
Dawley 
rats 
• aromatase expression levels in testis significantly 
decreased in a time dependant manner 
• no difference in aromatase immunoreactivity in vas 
deferens tissues 
• vas deferens smooth muscle responses were altered 
• altered smooth muscle responses did not correlate with 
tissue aromatase levels 
51 
STZ 
injected 
male 
Wistar-
GFT 
strain rats 
• reduction in testis size 
• testicular atrophy and marked oxidative damage 
• enhanced generation of reactive oxygen species, 
hydroperoxide and malondialdehyde levels 
• mitochondrial dysfunctions manifested as reduction in 
the activities of aldehyde dehydrogenase, tricarboxylic 
acid cycle enzymes, enhanced activities of oxidative 
phosphorylation enzymes, perturbations in calcium 
homeostasis and membrane potential 
58 
STZ 
injected 
male 
Sprague-
Dawley 
rats 
• significant decreased intracavernous pressure indicating 
erectile dysfunction 
• this was improved with phosphodiesterase type 5 
(PDE5) inhibitor 
• improved nNOS, endothelial cell, and smooth muscle 
cell staining in diabetic mice after vitamin E plus 
70 
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sildenafil treatment 
• urine nitric oxide increased significantly in diabetic 
animals but was blunted with vitamin E 
• significant increase in positive staining for nitrotyrosine 
after vitamin E plus sildenafil treatment 
STZ 
injected 
male 
Sprague-
Dawley 
rats 
• diabetic animals showed reduced testis weights and 
seminiferous tubule diameter 
• the PCNA (proliferating cell nuclear antigen) index was 
significantly decreased in the diabetic animals 
• total (t)-ERK and phosphor (p)-ERK immunoreactivities 
were significantly decreased  
• t-JNK immunoreactivity was unchanged  
• p-JNK immunoreactivity was significantly increased 
76 
NOD 
mice 
• structural disorganization in the ventral lobe of the 
prostate, which was more intense in the diabetic group  
• increased proliferation and apoptosis rate 
• diabetes disturbed the prostatic secretory activity 
• the association of insulin, testosterone and estrogen was 
crucial for glandular structural restoration 
81 
STZ 
injected 
male 
Wistar 
rats 
• diabetic mice had reduced testicular weight and 
seminiferous tubule diameter 
• GLUT8 immunoreactivity in diabetic rats was mainly 
located associated to the acrosomic system of 
spermatids, and at low levels in Leydig cells 
• no difference in expression levels of GLUT8 
• insulin was diffusely located in the cytoplasm of both 
Leydig cells and early elongated spermatids and 
concentrated in a cytoplasmic compartment in the more 
mature spermatids 
• testicular insulin protein levels were significantly  
reduced in diabetic rats 
• insulin and hyperglycemia do not regulate GLUT8 
92 
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expression 
Alloxan 
injected 
male New 
Zealand 
rabbits 
• nitrotyrosine, a stable end-product of nitrosative stress, 
is unchanged in the testis 
• in the testis, the level of glutathione, glutathione 
peroxidase and catalase, and glutathione reductase 
activities were increased 
97 
STZ 
injected 
male 
Wistar 
rats 
• diabetic animals showed reduced FSH, LH, PRL, and 
GH serum levels  
• insulin injections restored FSH levels  
• reduced testis, seminal vesicle, and epididymis weights 
in diabetic animals were increased by insulin injections 
and testis weights were fully restored 
• higher levels of epididymal ABP activity 
119 
STZ 
induced 
male 
Sprague-
Dawley 
rats 
• significantly reduced testicular weights, as well as 
plasma levels of testosterone, 17-β estradiol, 
progesterone, FSH, and LH 
• reduction in diameter of seminiferous tubules and 
germinal epithelium height 
• oedema in interstitial tissue, germ cell depletion, 
decrease in cellular population and activity with 
disruption of spermatogenesis 
• mitochondrial change and reduction of smooth 
endoplasmic reticulum in Sertoli cells 
• presence of lipid droplets in Leydig cells 
133 
Ins2Akita 
mice 
(C57Bl/6 
Backgrou
nd) and 
STZ 
injected 
B6XSJL 
• no change in expression of SLC2A1, SLC2A3, and 
SLC2A5 in diabetic mice 
• reduced testicular expression of SLC2A8 and SLC2A9b 
• no testicular or sperm expression of SLC2A9a in Akita 
mice 
• significantly decreased expression of 3b-hydroxysteroid 
dehydrogenase (HSD3B) in Leydig cells from diabetic 
mice 
136 
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mice • lower sperm concentration and motility 
• disruption in sperm parameters normalised after insulin 
treatment 
• lower fertilization rates in Akita (17.9%) and STZ-
injected mice (43.6%) 
• lower embryo developmental rates to the blastocyst 
stage 
STZ 
injected 
C57Bl/6 
mice 
• no differences in spermatogenic activity or testicular 
architecture after histological examination 
• changes in the testicular metabolome in T1D mice as 
shown by reduction in carnitine, creatine, and choline 
and increases in lactate, alanine and myo-inositol 
• variations in betain levels depending on the severity of 
the diabetic state 
165 
STZ 
injected 
male 
Syrian 
mice 
• sperm count, rapid and total motilities, morphology and 
viability were significantly different 
• reduced quality and the quantity of sperm nuclear 
chromatin condensation/ DNA fragmentation 
• reduced degree of sperm nuclear DNA susceptibility to 
in-situ acid-induced denaturation 
• no changes in the degree of sperm chromatin 
protamination 
• no sperm chromatin condensation anomalies 
167 
STZ 
injected 
male 
albino rats 
• mean values of malondialdehyde level and caspase 
activity were significantly elevated in diabetic animals 
• SOD and GPx specific activities were significantly 
lower 
• significantly lower testosterone levels 
• 30% of the tubules of diabetic mice showed incomplete 
spermatogenesis with arrest at the secondary 
spermatogenic stage 
• occasional sperm production 
170 
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• apoptotic figures at both primary and secondary 
spermatogenic stage forming small dense nuclei with 
clumped chromatin and fragmentation surrounded by 
clear hallow 
• interstitium was oedematous, vascular and congested 
with normal Leydig cells  
• abnormalities were restored by antioxidant treatment 
STZ 
injected 
Wistar rat 
• major increases in noradrenaline concentration and 
content of the seminal vesicles 
• significant reductions in the concentration and content 
of dopamine  
• small reductions in the content of serotonin and 
adrenaline  
• increased uptake of tritiated noradrenaline  
• release of tritiated noradrenaline was increased in 
response to electrical field stimulation and high 
potassium solutions 
• raising calcium concentration caused increased release 
of tritiated noradrenaline at rest and during electrical 
stimulation 
• increased tyrosine hydroxylase 
• significant changes in the sympathetic innervation of the 
seminal vesicle during the course of STZ diabetes 
171 
STZ 
induced 
male 
Sprague-
Dawley 
rats 
• significant increase in teratozoospermia 
• decrease in serum testosterone, tubular, and testicular 
and epididymal weight 
• decrease in seminal volume and sperm density with no 
change in semen motility 
180 
STZ 
injected 
male 
• CML was observed in the testes, epididymides and 
sperm 
• sperm from DM mice showed strong CML 
189 
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C57Bl/6 
mice; 
Ins2Akita 
mice 
immunolocalization in the acrosomal cap, the equatorial 
region, and cytoplasmic droplets 
• increased CML levels did not reach statistical 
significance 
• RAGE was present on the developing acrosome and 
epididymal sperm of all animals and in discrete regions 
of the epididymides of the diabetic animals 
• epididymal sperm of the Ins2Akita mice had significantly 
increased nDNA damage 
STZ 
injected 
male 
Wistar 
albino rats 
• reduced plasma testosterone levels 
• ejaculatory dysfunction 
• reduction in sexual activity 
• no difference in the sensitivity of the vas deferens to 
norepinephrine 
• increased sensitivity to methoxamine through the α1-
adrenoceptor  
• testosterone supplementation did not restore parameters 
to control values 
• in this experimental model, the lack of testosterone was 
not directly related to the diabetes-induced ejaculatory 
dysfunction 
207 
STZ 
injected 
male 
Wistar 
rats 
• reduction in plasma testosterone (T) concentrations 
• normal dihydrotestosterone (DHT) levels 
• decreased gain in absolute prostatic weight 
• prostatic lobe weight was 100% higher, even at the 
beginning of the experiment 
• anterior lobe showed the highest weight gain in diabetic 
and insulin replacement conditions 
• epithelial cell proliferation was significantly reduced 
• this was recovered by insulin replacement 
• diabetes diminishes prostate growth during puberty 
208 
Alloxan • decrease in prostatic weights 213 
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injected 
male 
Wistar 
rats 
• decrease in testosterone levels 
• high variation in prostate morphology and stereology 
with intense epithelial atrophy, premalignant and 
malignant lesions  
• chronic inflammation, similar to proliferative 
inflammatory atrophy 
• high incidence of prostatitis, adenocarcinoma and 
prostatic intra-epithelial neoplasia  
• samples with adenocarcinoma had poorly differentiated 
acini with high levels of cellular proliferation and 
nuclear atypia 
• invasive feature showed Bcl-2-positive cells and 
interruptions in the basement membrane 
STZ 
injected 
male 
Wistar 
rats 
• testes of diabetic animals showed frequent abnormal 
histology 
• seminiferous epithelium cytoarchitecture appeared 
altered 
• altered occludin distribution pattern 
• high number of damaged tubules, with early onset of 
diabetes 
• changes in spermatogenesis are more severe with early 
onset of diabetes 
• hypertrophic interstitial compartment of the testes  
• fully developed, but abnormally distributed Leydig cells 
• decrease in plasma testosterone levels 
• manganese superoxide dismutase was reduced in 
diabetic animals 
214 
STZ 
injected 
Wistar rat 
• 59 % of animals showed no copulatory behaviour  
• reduced number of animals reaching ejaculation 
• decreased reproductive organ weights 
• diminished sperm counts in the testis and epididymis 
• reduction of plasmatic testosterone levels 
227 
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• decrease in the fertility after natural mating  
• distal cauda epididymal sperm from diabetic rats 
displayed normal fertilization ability using in utero 
insemination 
• no effects of hyperglycaemia on sperm transit time in 
the epididymis and on spermatogenesis 
FVB.B6- 
Ins2Akita 
/MlnJ 
mice 
• Akita homozygous male mice are infertile with reduced 
testis size and abnormal morphology 
• reduction in seminal vesicle weight 
• spermatogonial germ cells are still present but are 
unable to mature into spermatocytes and spermatids 
• significantly lower motile sperm as well as lower 
progressively and rapidly moving sperm 
• display fewer sperm cells in the epididymis 
• sperm cells obtained from the cauda epididymis undergo 
degeneration 
• caudal epididymal sperm display sperm lacking 
acrosomes, some cells with membrane blebbing, and 
numerous detached sperm heads as well as abnormal 
mitochondria 
• decreased levels of serum testosterone and LH 
• These effects were restored by exogenous insulin 
treatment 
• BTB remained intact 
235 
FVB.B6-
Ins2Akita/M
lnJ mice 
• leptin treatment resulted in larger total body size, testes, 
and seminal vesicles 
• Akita mice showed testes with no mature spermatozoa, 
a high degree of vacuolization, and large multinucleated 
cells 
• leptin treatment prevented testicular degeneration and 
rescued sperm  
• leptin-treated mice produced fertile sperm 
236 
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• critical reproductive hormones LH and testosterone 
were only modestly higher in leptin treated mice 
STZ 
injected 
rat 
• decreased reproductive organ weights 
• diminished sperm counts and motility and prostatic acid 
phosphatase 
• increase in seminal fructose  
• significant decrease in serum LH, FSH and testosterone 
• reproductive changes, except for prostatic changes, were 
restored by insulin or testosterone treatment 
• in diabetic animals, there are both pituitary and 
testicular abnormalities 
238 
STZ 
injected 
male 
Wistar 
albino rats 
• reduced spermatogenesis index 
• reduced number of spermatogonia 
• increased levels of epithelium exfoliation 
• increased CYP2E1 expression 
240 
STZ 
injected 
CFT-
Swiss 
mice 
• enhanced lipid peroxidation in testis (cytosol and 
mitochondria) and epididymal sperm (ES) 
• increased ROS production 
• significant perturbations in the activities of antioxidant 
enzymes in testis/ES 
• enhanced protein carbonyl content 
• oxidative damage in both compartments was amenable 
by antioxidative treatments  
• significant increase in testicular DNA damage 
• higher incidence of abnormal sperms  
• mating of STZ treated males resulted in a significant 
increase in the male mediated dominant lethal-type 
mutations 
243 
STZ 
injected 
male 
• significantly reduced epididymal tissue concentrations 
of testosterone, androgen-binding protein, sialic acid, 
glycerylphosphoryl choline, and carnitine 
247 
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Wistar 
rats 
• adverse effects of diabetes on the secretory activity and 
concentrating capacity of epididymal epithelium 
• impaired cauda epididymal sperm motility and fertility 
(in vivo)  
• defective sperm maturation 
• insulin replacement prevented these changes either 
partially or completely 
STZ 
injected 
Wistar rat 
• regression of epididymis, leading to a decrease in the 
absolute weight of caput, corpus, and caudal regions 
• reduction in the size of the tubule and lumen with an 
increase in interstitial stroma 
• tightly packed principal cells with clumping of nuclei 
• reduction in tubular diameter, volume, and surface 
density 
• epididymal lumen was totally devoid of spermatozoa 
• insulin replacement could only prevent some of the 
adverse effects in a region specific manner 
252 
Alloxan 
injected 
male 
Wistar 
rats 
• decreased serum testosterone levels  
• reduced diameter, total area, epithelium area and 
epithelium thickness of seminiferous tubules 
• higher tubular density 
• ultrastructural changes compromising the whole testis 
including germ-, Sertoli-, and Leydig cells, 
mitochondria, and cellular nuclei 
• most frequently vacuolization and/or accumulation of 
lipid droplets and electron dense dark material in cell 
cytoplasm and/or in membranes, cellular degeneration, 
and apoptosis 
270 
STZ 
injected 
male 
Wistar-ST 
• ejaculatory capacity deteriorated with time after the 
onset of diabetes 
• significantly decreased incidence of spontaneous 
seminal emission and the amount of ejaculated seminal 
304 
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strain rats material 
• reduced amount of seminal vesicle fluid 
• insulin replacement, when given before changes 
occurred, completely prevented these changes 
STZ 
injected 
FVB mice 
• diabetes significantly decreased testicular Zn levels 
• significant induction of testicular apoptosis with 
increase in Bax/Bcl-2 ratio as an index of mitochondrial 
cell death pathway 
• diabetes induces ER-Stress via CHOP and caspase-12 
activation 
• diabetic induction of oxidative stress via increased 
oxidative and nitrosative damage and depressed 
antioxidant Nrf2 expression 
• increase in p53 activation and phosphorylation of p38 
MAPK 
309 
 
Table B-8. Association between diabetes and members of the activin family of proteins 
Model Results Referenc
e 
20 T1D 
patients 
with 
nephropa-
thy and 
proteinuria 
and 20 
without 
• expression of the activin antagonist endoglin is increased 
in skin fibroblasts of T1D patients without nephropathy 
• findings suggest a protective role for endoglin in diabetic 
nephropathy 
10 
115 patients  
with acute 
myocardial 
infarction 
(MI) 
• serum levels of activin A were significantly higher in 
those with abnormal glucose regulation (AGR) 
• activin A levels were associated with the presence of 
AGR after 3 months 
• glucose enhanced the release of activin A in endothelial 
15 
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without 
previously 
known 
diabetes 
cells 
• activin A attenuated the release of interleukin (IL)-8 and 
enhanced the mRNA levels of the antioxidant 
metallothionine 
• activin A attenuated the suppressive effect of 
inflammatory cytokines on insulin release in islet cells 
• suggests a protective effect of activin A against 
hyperglycemia 
α-and β-
cell lines, 
sorted 
mouse islet 
were 
treated with 
activin and 
related 
ligands 
• activins A and B suppressed critical α-cell gene 
expression (Arx, glucagone, MafB) in the α-cell line 
• activins A and B enhanced β-cell gene expression in the 
α-cell line 
• activin A induced a significant increase in Pax4 (a fate 
determining β-cell gene) and insulin expression in β-
cells 
• activins suppressed α-cell gene expression and enhanced 
Pax4 in β-cell in isolated islets 
• activin treatment resulted in Smad2 phosphorylation 
• activins A or B significantly inhibited proliferation of α-
cells 
16 
primary 
adult rat 
cardiomyoc
ytes (ARC) 
exposed to 
conditioned 
media 
generated 
from EAT 
biopsies 
(CM-EAT) 
from 
• activin A induces miR-143 in cardiomyocytes and 
therefore inhibits insulin action released from epicardial 
adipose tissue (EAT) of T2D individuals 
• this interaction involves the inhibition of the Akt pathway 
through downregulation of the novel regulator of insulin 
action, ORP8, which regulates glucose uptake by insulin 
• activin A may contribute to the pathophysiology of 
diabetic cardiomyopathy via induction of myocardial 
insulin resistance 
38 
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patients 
with and 
without 
T2D 
human 
pancreas 
and isolated 
islets 
• nodal expression was confirmed on mRNA and protein 
level, with protein expression observed in β and α-cells 
• cripto expression was absent from human islets 
• exogenous Nodal stimulated modest β-cell proliferation 
and inhibited α-cell proliferation with no effect on 
cellular viability, apoptosis, or differentiation 
• nodal stimulated the phosphorylation of Smad2 
• no effect on AKT or MAPK signalling 
• cripto had no effect on human islet cell proliferation, 
differentiation, or viability 
39 
HIP rats, 
MGPtg/wt 
;Ins2Akita/+  
mice, db/db 
mice, 
human 
aortic 
endothelial 
cells 
(HAECs) 
• high glucose augmented expression of BMP-2 and BMP-
4; the BMP inhibitors matrix Gla protein (MGP) and 
Noggin; ALK 1, -2, -3 and -6; the BMP type 2 receptor; 
and the vascular endothelial growth factor in HAECs and 
in the aortic wall of Ins2Akita/+ mice, db/db mice, and HIP 
rats  
• diabetic animals showed a dramatic increase in 
pSMAD1/5/8, which was prevented in transgenic 
Ins2Akita/+ mice with increased aortic BMP inhibition 
43 
Rodent 
islets of 
male 
C57Bl/6J 
mice and 
Lewis rats 
• activin A stimulates GSIS under hyperglycemic 
conditions 
• activin A and B are predominantly expressed in rodent 
islets 
• activins A and B are synthesized in mouse islets, 
primarily in α-cells and to a lesser degree in β-cells 
• non-islet activins were primarily localized in ductal 
epithelium 
48 
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• inhibin α-subunit mRNA and protein was undetectable 
in pancreatic cells 
Human 
islets of 26 
normal and 
7 T2D 
donors 
• Inhba (the gene encoding activin A) was most highly 
expressed in normal, cultured islets 
• Inhba was expressed in both α- and β-cells 
• Inhbb and FSTL3 (activin antagonist follistatin-like-3) 
were primarily in α –cells 
• in cells from T2D donors both activin A and B protein 
expression were undetectable à suggests a functional 
role for these TGF- β superfamily members in islet cells 
• islets from T2D donors had significantly reduced 
expression of Inhba and significantly increased 
expression of TGF-β2 and FSTL3 
• activin A affects GSIS in human islets and restores 
glucose responsiveness in T2D islet cells 
• functional islets responded with increased activin A 
secretion after exposure to high glucose depending on 
functional and diabetic status 
• activin A improves viability of islet cells 
• activin A has a role in modulating several key islet 
functional (Ins, GCG, GLUT2, CACNA1C and 
CACNA1D) and survival genes (HIF1α), as well as, 
self-regulating the expression of Inhba 
49 
78 male 
T2D 
patients 
• no difference in circulating activin A levels between T2D 
men and controls 
• activin A levels were negatively correlated with 
myocardial glucose metabolism, and positively with left 
ventricular mass/volume (LVMV)-ratio in T2D men 
• this suggests activin A has a negative effect in diabetic 
cardiomyopathy 
62 
Mesen-
chymal 
• activin A increases the percentage of differentiation from 
MSCs into insulin producing cells 
67 
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stem cells 
(MSCs) 
human 
pancreatic 
islets 
• activin A did not modify insulin secretion in the absence 
of glucose 
• glucose significantly increased insulin secretion in a dose 
dependent manner 
• in the presence of low glucose (3.3 mM), activin A 
significantly increased insulin secretion 
• in the presence of activin A glucose induced an 
additional effect of the dose-dependent glucose-mediated 
insulin secretion 
85 
Transgenic 
mice 
overexpress
ing activin 
βE subunit 
• overexpression of activin βE in the pancreas decreased 
pancreas size and caused hypoplasia in pancreatic 
exocrine cells 
• activin βE might play a role in suppressing acinar cell 
growth in the pancreas 
105 
cultured 
skin 
fibroblasts 
(SFs) from 
T1D 
patients 
• mRNA levels for TGF-β1, TGF-βRII, and 
thrombospondin-1 were unchanged 
• latent TGF-β binding protein-1 mRNA expression 
correlates with the development of diabetic nephropathy 
117 
272 T1D 
patients 
• susceptibility to diabetic nephropathy is not related to 
suggest common single nucleotide polymorphism (SNP) 
variants in TGFB1, TGFBR1 and TGFBR2 genes 
169 
14 
C57Bl/6J 
mice 
• ALK7 is highly expressed in the pancreas of C57Bl/6J 
mice 
174 
207 
pregnant 
women 
(129 
• significantly lower serum follistatin levels in GDM 
women 
• serum FSTL3 and activin A levels were comparable 
between groups 
175 
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without and 
78 with 
gestational 
diabetes 
mellitus 
(GDM)) 
• serum follistatin concentrations were negatively 
correlated with insulin resistance and the diagnosis of 
gestational diabetes 
Pancreatic 
islets from 
female 
Wistar 
Imamichi 
rats 
• α, βA, and βB subunits of inhibin/activin and follistatin 
mRNAs are expressed in pancreatic islets 
• follistatin was localized only in insulin-producing B cells 
192 
STZ treated 
male Wistar 
rats and 
high 
glucose-
cultured 
HK-2 cells 
• increased production of pSmad2/3 with duration of 
diabetes 
• activin βA was located in tubular epithelial cells, and 
significantly higher in diabetic animals 
• follistatin diminished gradually  
• high glucose facilitates the synthesis of activin bA, TGF-
β, and pSmad2/3 in the human kidney proximal tubular 
epithelial cell line 
211 
Pancreatic 
islets from 
male Wistar 
rats 
• activin A stimulated insulin secretion and reduced 
extracellular Ca2+ in pancreatic islets 
• activin A increased free intracellular Ca2+ concentration 
• this was abolished by the reduction of extracellular Ca2+ 
or the addition of Ca2+ channel blockers 
• activin A did not increase intracellular Ca2+ in the 
presence of diazoxide, an opener of ATP-sensitive K+ 
channels 
• activin A increases insulin secretion by stimulating Ca2+ 
entry 
242 
Human 
islets and 
• activin A decreased the number of mature and increased 
the number of immature β-cells 
260 
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islets from 
C57Bl/6J 
mice, Pdx1 
labelled 
MIN6 cells 
• activin A decreased the expression of insulin and genes 
associated with beta cell maturity (e.g. Pdx1, Mafa, 
Glut2) in primary islets and MIN6 cells 
• activin A upregulated genes (e.g. Mafb) in immature β-
cells  
• activin A reduced insulin secretion 
Pancreatic 
islets from 
male Wistar 
rats 
• activin A stimulated insulin secretion in a dose-dependent 
manner 
• activin A potentiated GSIS 
268 
Pancreatic 
islets from 
male Wistar 
rats 
• TGF-β increased insulin release in a concentration-
dependent manner 
• TGF-β1 and TGF-β2 were equally effective 
• stimulatory action of TGF-β was greater in the presence 
of stimulatory concentration of glucose 
267 
102 patients 
with T2D • serum activin A and the activin A/follistatin ratio were 
increased 
• elevated activin A was associated with the severity of 
coronary atherosclerotic burden 
• no significant association between presence of coronary 
artery disease or extent score and activin A 
272 
Pancreatic 
islets from 
male Wistar 
rats 
• activin A increased insulin and decreased glucagon 
secretion in a concentration dependant manner 
• effect on Ca2+ net uptake 
• activin A elevated Ins(l,4,5)-P 3 content 
• activin A inhibited the closing of K+ channels 
274 
Human 
pancreas 
tissue of 10 
donors 
(mean age 
57 years) 
• activin A strongly immunostained in islets of Langerhans 
• activin A was co-localized with insulin in B cells, but not 
with glucagon in A cells 
277 
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STZ treated 
male 
C57BL/6N
cr mice 
• soluble ACVR2B treatment elevated blood glucose 283 
Primary 
human 
monocytes 
from T2D 
patients 
• systemic activin A levels were not altered in T2D patients 
• activin A is upregulated by adiponectin via the p38 
MAPK pathway 
• this was reversed by the adiponectin inhibitor Metformin 
284 
participants 
(34 males; 
58 females) 
with 
diabetes or 
during an 
oral glucose 
tolerance 
test 
(OGTT) 
• serum levels of activin A, activin B, or follistatin did not 
differ between subjects with normal OGTT, impaired 
glucose tolerance and/or fasting glucose, or T2D 
• activin A and activin B were positively correlated with 
parameters of insulin resistance and T2D (fasting 
glucose, fasting insulin, glycated haemoglobin, and 
homeostasis model assessment of insulin resistance 
(HOMA-IR)) 
• follistatin was positively correlated with HOMA-IR alone 
• activin A, B, or follistatin cannot discriminate risk for 
T2D, but display a positive relationship with clinical 
parameters 
295 
bone 
marrow-
derived 
neutrophil 
precursors 
(BMNPs) 
from male 
C57BL6/J 
mice 
• murine neutrophils are a source of stored activin A 
• activin A release was stimulated by TNF-a 
• LPS stimulated activin A release and production in total 
• activin A secretion was not enhanced by increased 
glucose and insulin 
• insulin pre-treatment blocked the TNF-a induced release 
of activin A 
293 
mice 
lacking 
activin B 
• Inhbb−/− mice displayed elevated serum insulin levels and 
GSIS 
• injection of a soluble activin B antagonist phenocopied 
294 
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(Inhbb−/−), 
pancreatic 
islets 
derived 
from these 
mutants 
these changes in wild-type mice 
• isolated pancreatic islets from Inhbb−/− mice showed 
enhanced GSIS - was rescued by exogenous activin B 
• activin B negatively regulated GSIS and ATP production 
in wild-type islets, activin A displayed the opposite 
effects 
• Smad3 responded preferentially to activin B in pancreatic 
islets and beta cells 
• Smad2 showed a preference for activin A 
• overexpression of Smad3, but not Smad2, decreased 
GSIS in pancreatic islets 
Human 
embryonic 
stem cells 
(hESC) 
• activin A promoted the differentiation of hESCs to a 
mesendoderm fate  
• activin A treatment of hESCs resulted in strong induction 
of primitive-streak and definitive endoderm-associated 
genes (MIXL1, GSC, SOX17, FOXA2) 
• activin A, in combination with other signalling molecules 
(FGF, BMP), determines cell fate of hESCs towards 
pancreatic lineage cells 
296 
IFN-γ 
transgenic 
mice on 
NOD 
background 
• activin βA and βB subunits and activin receptors (type I 
and II) are upregulated in duct epithelial cells during islet 
differentiation 
• βA subunit colocalized with glucagon, but not with 
insulin and only rarely with insulin in the regenerating 
pancreas 
• βB subunit colocalized with insulin and glucagon 
• inhibitors of activin signalling, follistatin and Cripto, were 
found to be augmented 
• activin inhibition significantly enhanced survival and 
expansion of pancreatic epithelial cells but decreased 
numbers of differentiated β-cells 
307 
STZ treated • levels of inhibin βA expression and Smad2 and Smad3 310 
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female 
C57Bl/6J 
mice 
activation were significantly reduced by maternal diabetes 
• activin A treatment significantly increased cell 
proliferation in the myocardium and migration of 
endocardial cells 
• activin A and Smad2/3 signalling system appears to play a 
role in diabetic embryopathy 
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